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Phosphoinositide 3-kinases (PI3Ks) are activated in immune cells downstream of the antigen 
recognition receptors, the signals from which are crucial for the development, differentiation 
and activation of lymphocytes. Engagement of the T cell antigen receptor (TCR) initiates a 
signalling cascade leading to the rapid induction of PI3K activity. The class IA catalytic isoform 
p110δ is known to be the dominant PI3K involved in signal transduction downstream of the TCR. 
However, the mechanism by which the TCR recruits and activates p110δ remains unresolved. 
This study has used a combination of proteomic, biochemical and gene editing approaches to 
identify proteins that are involved in the regulation of p110δ activity during TCR signalling. 
This work has optimised the AviTag affinity purification system for the isolation of endogenous 
p110 isoforms from primary murine lymphocytes. A quantitative proteomics approach was 
subsequently used to identify endogenous proteins that interact with p110δ in primary 
activated CD4+ T cells upon TCR stimulation. This analysis has identified multiple adaptor 
proteins and co-stimulatory receptors that may regulate p110δ activity at the TCR signalosome. 
Intriguingly, the B-cell adaptor for phosphoinositide 3-kinase (BCAP) was found to associate with 
p110δ in a TCR stimulation-dependent manner. Biochemical analyses revealed that BCAP is 
upregulated in activated T cells and rapidly tyrosine phosphorylated upon TCR stimulation. 
Collectively, this work suggests that BCAP is a key adaptor for PI3K downstream of the TCR. 
This study has also developed a CRISPR/Cas9-mediated gene editing approach to disrupt targets 
of interest in primary murine activated T cells via ribonucleoprotein (RNP) nucleofection. This 
system was used to investigate the roles of the p110δ-associated proteins, BCAP and inducible 
T-cell costimulator (ICOS), in TCR-induced PI3K signalling and cytokine production in activated T 
cells. Collectively, this work has demonstrated the potential of proteomic analysis coupled with 
CRISPR/Cas9 gene editing for the identification and interrogation of signalling pathway 
components in primary T lymphocytes. Using this approach, this study has uncovered molecular 
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1.1 The PI3K family 
The phosphoinositide 3-kinases (PI3Ks) are a ubiquitous family of lipid kinases that play essential 
roles in cellular signal transduction. These enzymes phosphorylate the D-3 position of the 
inositol ring in phosphoinositides, generating second messengers vital to many signalling 
pathways involved in responses such as cell survival, proliferation, migration and adhesion 
(Rameh & Cantley, 1999). The PI3K family is divided into three classes based on their structure 
and substrate specificity. 
 
1.1.1 Class I PI3Ks 
Class I PI3Ks phosphorylate PI(4,5)P2 (PIP2) to produce the lipid second messenger PI(3,4,5)P3 
(PIP3). In mammalian cells, four class I catalytic isoforms are expressed – p110α, β, γ and δ 
(Vanhaesebroeck et al, 2010). The p110 catalytic subunits form heterodimers with different 
regulatory subunits, which further separates this class in two. Class IA isoforms, p110α, p110β 
and p110δ, can associate equally with one of five ‘p85’ regulatory subunits: p85α, p55α, p50α 
(splice variants encoded by Pik3r1); p85β (Pik3r2); and p55γ (Pik3r3). The class IB catalytic 
subunit, p110γ, associates with either a p101 (Pik3r5) or p84/87 (Pik3r6) regulatory subunit 
(Stephens et al, 1997; Suire et al, 2005). 
The catalytic and regulatory subunits of class IA PI3Ks are multidomain proteins (Figure 1.1). 
Structurally, the p110 catalytic subunits consist of an adaptor-binding domain (ABD), a Ras-
binding domain (RBD), a C2 domain, a helical domain, and a C-terminal catalytic domain. The 
p85 regulatory subunits all contain a coiled-coil domain known as the inter-SH2 (iSH2), flanked 
by two Src homology 2 domains (SH2), nSH2 and cSH2. In addition, the p85α and p85β subunits 
contain an N-terminal SH3 domain and a breakpoint cluster region homology domain (BH) 
flanked by two proline-rich regions, which are absent in p55α, p50α and p55γ. The ABD of each 
p110 binds with high affinity to the p85 iSH2, which is essential for stabilisation of the catalytic 
subunit (Yu et al, 1998). In contrast, the ABD of the class IB isoform, p110γ, lacks a p85-binding 
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motif, but otherwise p110γ shares the same multidomain organisation as class IA p110 catalytic 
subunits (Amzel et al, 2008). The domain architectures of the p110γ regulatory subunits, p101 
and p84/87, have not yet been defined (Burke & Williams, 2015).  
 
Figure 1.1 Class I PI3Ks 
Domain organisations of the class I catalytic subunits, p110α, p110β, p110γ and p110δ, and the 
class IA p85 regulatory subunits: p85α, p55α, p50α (encoded by Pik3r1); p85β (Pik3r2); and p55γ 
(Pik3r3). ABD, adaptor-binding domain; RBD, Ras-binding domain; SH3, Src homology 3 domain; 
BH, breakpoint cluster region homology domain; nSH2, N-terminal Src homology 2 domain; iSH2, 
inter-SH2; cSH2, C-terminal SH2 domain; proline-rich regions are in grey. Domain architectures of 
the p110γ regulatory subunits, p101 and p84/87 (not shown), are incompletely defined. 
 
A further distinction between the class I PI3Ks lies in their adaption to upstream regulation by 
different cell surface receptors. As cytosolic enzymes, PI3K activation necessitates recruitment 
to their substrate, PIP2, located in lipid membranes. A broad range of receptors couple to 
specific PI3K isoforms, generally receptor tyrosine kinases (RTKs), tyrosine kinase-associated 
receptors and G protein-coupled receptors (GPCRs). 
Class IA PI3Ks are activated downstream of RTKs and tyrosine kinase-associated receptors, 
including antigen, co-stimulatory and cytokine receptors. The p85 SH2 domains facilitate direct 
interaction with receptors or associated adaptor proteins that contain phosphorylated tyrosine 
residues. In contrast, the class IB PI3K, p110γ, is activated by GPCRs, a large family that includes 
the chemokine receptors. Both p110γ regulatory subunits, p101 and p84/87, mediate binding to 
Gβγ subunits of heterotrimeric G proteins. However, this distinction of the classes is not clear 
cut. The p110β heterodimer is unique in that it can be activated by both RTKs and GPCRs. A Gβγ-
binding site located in the linker region between the C2 domain and helical domain of p110β 
enables this isoform to act as a coincidence detector, integrating signals from both RTKs and 
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GPCRs (Guillermet-Guibert et al, 2008; Dbouk et al, 2012; Kulkarni et al, 2011; Houslay et al, 
2016). Similarly, in B lymphocytes and natural killer cells, p110δ can be activated by chemokine 
GPCRs, although the exact mechanism is still unknown (Reif et al, 2004; Saudemont et al, 2009). 
Furthermore, p110γ can be activated downstream of both RTKs and GPCRs in murine 
macrophages (Schmid et al, 2011). Thus, each class I PI3K isoform has a different capacity to 
integrate signals from upstream receptors, and isoform-specific roles of PI3Ks may depend on 
their ability to synergise signals from multiple inputs. 
The class I PI3Ks also demonstrate distinct expression profiles. p110α and p110β are 
ubiquitously expressed, whereas p110γ and p110δ are predominantly expressed in immune 
cells (Vanhaesebroeck et al, 2010). This leukocyte-enriched expression of p110δ may be 
explained by the presence of a conserved transcription factor (TF)-binding cluster located 
upstream of Pik3cd exon 2 that contains at least four leukocyte-related TF-binding sites (Kok et 
al, 2009). 
Common to the class I family is their enzymatic production of PIP3. This lipid second messenger 
regulates the localisation and activity of a multitude of effector proteins that contain a sub-
family of pleckstrin homology (PH) domains. Mammalian cells express over 200 PH-domain 
containing proteins, with an estimated 40 demonstrating selectivity for binding to PIP3 over 
PI(4,5)P2 and PI(3,4)P2 (Lemmon, 2008; Park et al, 2008). The most prominent of these effectors 
is protein kinase B (AKT), but others include Ras superfamily guanine nucleotide exchange 
factors (GEFs), GTPase-activating proteins (GAPs), protein kinases and adaptor proteins. 
Ultimately, class I PI3K effectors initiate a cascade of phosphorylation events and protein-
protein interactions that regulate multiple cellular responses, including cell survival, growth, 
migration, metabolism and differentiation (Rameh & Cantley, 1999). 
 
1.1.2 Class II and class III PI3Ks 
The sole class III PI3K, vacuolar protein sorting-associated protein 34 (VPS34), is unique among 
the family in that it only phosphorylates phosphatidylinositol (PI), forming PI(3)P (Backer, 2008). 
VPS34 thus regulates PI(3)P-dependent processes, such as phagocytosis, autophagy and 
endocytosis (Kihara et al, 2001; Itakura et al, 2008; Jaber & Zong, 2013). VPS34 forms a 
constitutive complex with p150 (VPS15), which is thought to be required for its lipid kinase 
activity and membrane association (Rostislavleva et al, 2015). The class II PI3Ks, PI3KC2α, 
PI3KC2β and PI3KC2γ, produce PI(3)P as well as PI(3,4)P, although PI(3)P is thought to be the 
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main in vivo product, for PI3KC2α at least (Maffucci & Falasca, 2014). Class II PI3Ks are 
monomeric enzymes, distinguished by a C-terminal C2 domain not present in other PI3Ks. As the 
least investigated PI3K class, their mechanisms of action and activation are still unclear, but they 
exhibit disparate, isoform-specific functions in cell migration, intracellular trafficking and 
exocytosis (Falasca & Maffucci, 2012; Mavrommati et al; 2016). 
This study is focused on the class I PI3Ks, specifically the class IA isoform p110δ. 
 
1.2 Regulation of class IA PI3K kinase activity  
Given that class I PI3Ks regulate diverse and essential cellular processes via production of PIP3, 
tight regulation of their kinase activity is essential. PI3K activation requires a combination of 
recruitment to PIP2 within lipid membranes and protein interactions with their regulatory 
subunits that induce conformational changes to the catalytic subunit. Inherently, both could be 
achieved through binding to a single interaction partner. However, class I PI3Ks also receive 
activatory input from Ras-family proteins in an isoform-specific manner (Burke & Williams, 
2015). 
 
1.2.1 The role of class IA regulatory subunits 
Key to the control of class IA lipid kinase activity are the p85 regulatory subunits, which serve a 
dual function by both inhibiting basal p110 activity and facilitating its activation. All class IA p110 
catalytic isoforms are inhibited by interactions with the iSH2 and nSH2 domains of the p85 
regulatory subunit (Figure 1.2; Backer, 2010; Burke et al 2011; Zhang et al, 2011). These 
inhibitory contacts exist between the p85 iSH2 and p110 C2 domain (Wu et al, 2009), as well as 
between the p85 nSH2 and the helical, kinase and C2 domains (Miled et al, 2007; Mandelker et 
al, 2009). However, there are interesting differences in the p85-mediated inhibition of each 
p110 isoform. The iSH2 to C2 contact is partially disrupted in the p110β heterodimer, compared 
to p110α and p110δ (Dbouk et al, 2010). Furthermore, p110β and p110δ make an additional 
inhibitory contact with the cSH2 of p85 via the C-terminal lobe of their kinase domains (Burke & 
Williams, 2013; Burke et al, 2011; Zhang et al, 2011). Thus, it appears that p110β and p110δ 




Figure 1.2 Class IA PI3K inhibitory contacts between the p85 and p110 subunits 
All class IA p110 catalytic subunit isoforms are inhibited by interactions between the p85 iSH2 
domain and the p110 C2 domain, as well as between the p85 nSH2 domain and the p110 C2, 
helical and kinase domains. p110β and p110δ heterodimers contain an additional inhibitory 
contact between the p85 cSH2 domain and the C-terminal lobe of the p110 kinase domain. The 
iSH2:C2 domain contact is partially disrupted in p110β heterodimers. 
 
The critical mode of activation of the class IA PI3Ks involves release of these p85:p110 inhibitory 
contacts upon binding of the p85 SH2 domains to other proteins. SH2 domains are well-
characterised phosphotyrosine-binding modules with distinct specificities for particular peptide 
motifs (Huang et al, 2008). The p85 SH2 domains specifically recognise phosphorylated tyrosines 
located within YxxM motifs (Songyang et al, 1993). Importantly, these interactions compete 
with the p110 subunit for binding to the p85 SH2 domains. In all class IA enzymes, binding to 
phosphotyrosyl YxxM peptides releases the nSH2 to helical domain inhibitory contact. The 
additional cSH2:kinase domain contact present in p110β and p110δ heterodimers is also 
disrupted by phosphotyrosine-peptide binding, with concomitant exposure of the C-lobe of their 
kinase domains (Burke & Williams, 2013). The iSH2:C2 interaction in the p110β heterodimer is 
released in the presence of phosphorylated YxxM peptide, whereas for p110α and p110δ 
heterodimers, subsequent membrane binding is required to achieve the same disruption (Burke 
& Williams, 2013). Thus, there are stereotypical conformational changes upon activation of the 
class IA PI3Ks, but also isoform-specific modes of p85 regulation. 
The importance of p85 inhibitory function is demonstrated by the activating E542K, E545K and 
Q546K helical domain mutants of p110α commonly found in human cancer. These mutations 
mimic the disruption of the nSH2:p110α inhibitory interface that is normally induced by 
phosphotyrosine protein binding to the p85α nSH2 domain (Miled et al, 2007; Burke et al, 
2012). The analogous E525K mutation in p110δ leads to hyperactive enzyme activity and is 
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associated with the human immunodeficiency disease, activated PI3K-delta syndrome (APDS) 
(Dornan et al, 2017). 
Protein-protein interactions involving the p85 regulatory subunit of class IA PI3Ks directly lead 
to activation of their lipid kinase activity. Furthermore, p85α binding to phosphotyrosine 
peptides increases the affinity of the p110δ heterodimer for PIP2-containing membranes, 
possibly by inducing conformational changes that expose regions necessary for lipid interactions 
(Burke et al, 2011). Thus, receptor tyrosine kinases (RTKs) and tyrosine-phosphorylated adaptor 
proteins that bind to the p85 SH2 domains are key regulators of class IA PI3Ks. 
 
1.2.2 The role of Ras-family proteins  
Class IA kinase activity is not only regulated via the p85 regulatory subunit; each p110 subunit 
contains a Ras-binding domain that allows for an additional level of regulation via interaction 
with Ras-family small GTPases. The crystal structure of p110γ in complex with RAS 
demonstrated conformational change in the catalytic domain upon RAS binding, which led to 
the hypothesis that RAS can drive allosteric regulation of PI3K lipid kinase activity (Pacold et al, 
2000). RAS may also act to tether PI3K to the plasma membrane, although the C2 domain may 
be more important for the membrane association of p110δ (Denley et al, 2008). Moreover, the 
binding of membrane-resident HRAS to p110α and p110δ appears to strengthen their 
membrane interactions (Siempelkamp et al, 2017). Interestingly, the oncogenic p110α H1047R 
mutation enhances interaction of the kinase domain with lipid membranes, and this mutant is 
active in the absence of RAS binding (Zhao & Vogt, 2008; Burke et al, 2012).  
The p110 subunits show a high level of sequence divergence within the RBD (Fritsch et al, 2013), 
and so, unsurprisingly, they each interact with different members of the Ras superfamily. The 
RBD of p110α, p110γ, and p110δ can bind to Ras or R-Ras subfamily members (Fritsch et al, 
2013). RAS binding acts synergistically with tyrosine-phosphorylated proteins and Gβγ subunits 
to optimally activate the lipid kinase activity of p110α/p110δ and p110γ, respectively 
(Rodriguez-Viciana et al, 1994, 1996; Pacold et al, 2000; Siempelkamp et al, 2017). In contrast, 
p110β is not activated by the Ras subfamily, but instead by the Rho subfamily GTPases, CDC42 
and RAC1, via its RBD (Fritsch et al, 2013). Interestingly, only RRAS1, RRAS2 (TC21) and HRAS 
have been demonstrated to activate p110δ lipid kinase activity, although p110δ is able to bind 
to NRAS and KRAS (Rodriguez-Viciana et al, 2004; Siempelkamp et al, 2017). It is clear that 
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interaction with Ras superfamily members represents another mode of isoform-specific 
regulation of the PI3Ks.  
The activation of class IA PI3Ks, and subsequent phosphorylation of their substrate PIP2, is 
therefore regulated at two levels; via binding of the regulatory subunit to tyrosine-
phosphorylated proteins and through interaction of the RBD with Ras small GTPases. The former 
also directly influences the localisation of PI3K, ultimately regulating its recruitment to the 
plasma membrane and its substrate PIP2. Due to the role of class IA PI3Ks in fundamental 
cellular signalling processes, decades of work have focused on the molecular mechanisms 
underlying their regulation and dysregulation in many cell types, including those of the immune 
system. 
In lymphocytes, class I PI3Ks are activated downstream of the antigen, cytokine and chemokine 
receptors, the signals from which control the development, differentiation and activation of 
lymphocytes (Okkenhaug & Vanhaesebroeck, 2003). Key studies using gene-targeted mice and 
isoform-selective PI3K inhibitors have demonstrated that the class IA catalytic isoform p110δ is 
the dominant PI3K involved in signal transduction initiated by the T cell antigen receptor (TCR) 
upon antigen recognition (Okkenhaug et al, 2002, 2006; Garçon et al, 2008). However, the 
mechanism by which the TCR recruits and activates p110δ remains unresolved. This body of 
work is focused on the molecular basis of p110δ regulation in T lymphocytes; specifically, 
downstream of the TCR. 
 
1.3 Class IA PI3Ks in T lymphocytes  
T lymphocytes play a central role in adaptive immunity, serving as the effectors of cellular 
immune responses. The protection afforded by the adaptive immune system is dependent on its 
ability to recognise and respond to virtually any foreign antigen. This is mediated by the 
diversity and specificity of the T cell antigen receptor (TCR) and the signalling events it induces 
upon antigen engagement. Given the fundamental role that PI3K signalling plays in cell signal 
transduction, it is no surprise that PI3K is required for the development and activation of T 
lymphocytes.   
T cells differentiate in the thymus from bone marrow-derived precursors and emerge as naïve T 
cells to populate the peripheral lymph nodes and spleen. This tightly controlled process ensures 
development of the TCR repertoire while eliminating cells with high self-reactive potential (Starr 
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et al, 2003). Double negative (CD4-CD8-) thymic precursors undergo rearrangement of the TCRβ 
and TCRα chains by sequential VDJ or VJ recombination, respectively. Productive rearrangement 
of the TCRβ chain allows cells to progress through the ‘β-checkpoint’ to become CD4+CD8+ 
double positive thymocytes, followed by rearrangement of the TCRα chain. Thymocytes 
expressing a recombined TCRβ and TCRα chain are positively selected for low-affinity binding to 
self-antigen presented by major histocompatibility complex (MHC) molecules. However, those 
that bind with high affinity and are likely to be self-reactive are eliminated by clonal deletion 
during negative selection (Hogquist & Jameson, 2014). Two distinct mature T cell lineages 
migrate out of the thymus: MHC class II-restricted CD4+ and MHC class I-restricted CD8+. Mature 
T cells develop in mice that lack both the class IA isoforms p110α and p110δ (Ramadani et al, 
2010). However, the combined loss of p110δ and p110γ causes a near complete block in 
development at the β-checkpoint (Swat et al, 2006; Webb et al, 2005). This was revealed to be 
due to a requirement for signalling through the chemokine receptor CXCR4, a GPCR that 
preferentially activates p110γ, at the β-checkpoint, while the pre-TCR engages p110δ (Janas et 
al, 2010). 
The final stage of T cell differentiation occurs in peripheral lymphoid tissues, where naïve CD4+ 
and CD8+ T cells may encounter antigen on antigen-presenting cells (APCs) and become 
activated via the TCR and co-stimulatory receptors. Upon antigen encounter, naïve CD8+ T cells 
differentiate into effector cytotoxic T lymphocytes (CTLs), which play a fundamental role in anti-
viral and anti-tumour responses. Antigen recognition by naïve CD4+ cells leads to clonal 
expansion and differentiation into effector cells, usually termed T helper (Th) cells due to their 
role in aiding other immune cells, such as B lymphocytes, macrophages and CD8+ T cells, to 
orchestrate a context-dependent immune response (So & Fruman, 2012). PI3K has been shown 
to play a key role in CD4+ T cell antigen-induced clonal expansion, differentiation and cytokine 
production (Okkenhaug et al, 2006; Soond et al, 2010). This can be attributed to the rapid 
activation of PI3K following initiation of the TCR signalling cascade upon peptide-MHC 
engagement (Costello et al, 2002; Harriague & Bismuth, 2002; Garçon et al, 2008). 
 
1.3.1 The TCR signalling pathway 
Engagement of the TCR by an antigenic peptide, bound in the cleft of an MHC class I or II 
molecule, is the critical binding event that ultimately leads to T cell activation, proliferation and 
acquisition of effector functions. Recognition of antigen induces the TCR signalling cascade, 
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dependent first on the activation of several protein tyrosine kinases and subsequently on the 
assembly of scaffolding hubs, which allow the activation of key downstream signalling pathways. 
The molecules and sequence of events that link proximal and distal segments of the TCR 
signalling pathway have been intensely studied, yet the mechanism of PI3K recruitment remains 
unresolved. 
The clonotypic TCR confers antigen binding specificity via the ectodomain of the α and β chain 
heterodimer, TCRαβ, which is non-covalently associated with a multi-subunit CD3 complex, 
comprising invariant CD3γ, δ, ɛ and ζ chains that form γɛ, δɛ and ζζ dimers (Wang & Reinherz, 
2012). None of the proteins within the TCR-CD3 complex contain intrinsic enzymatic activity, 
therefore signal transduction relies on the recruitment of kinases. This is mediated via 
phosphorylated immunoreceptor tyrosine-based activation motifs (ITAMs) present within the 
CD3 cytoplasmic tails. Each CD3γ, δ, and ɛ chain contains one ITAM, of the sequence 
(D/E)xxYxx(L/I)x6-8Yxx(L/I), whereas the ζ chain contains three; thus, the TCR harbours twenty 
potential tyrosine phosphorylation sites (Love & Hayes, 2010). The two tyrosines located within 
ITAM motifs are phosphorylated by the Src-family kinase (SFK) LCK, which is critical for the early 
propagation of TCR signalling. 
LCK is associated with the plasma membrane via N-terminal myristoylated and palmitoylated 
residues, but also interacts with the cytoplasmic tail of CD4 and CD8 co-receptors (Turner et al, 
1990). CD4 and CD8 interact with MHC class II or class I molecules, respectively, on the surface 
of APCs during antigen presentation (König et al, 1992). Consequently, LCK is brought into 
proximity of the TCR complex, where it can phosphorylate the CD3 and ζ chain ITAMs (Holdorf et 
al, 2002). LCK activity is regulated by phosphorylation and dephosphorylation of two conserved 
tyrosine resides, a mechanism common to SFKs. Phosphorylation of Y505 by C-terminal Src 
kinase (CSK) leads to an intramolecular interaction with the LCK SH2 domain, locking the kinase 
in an inactive conformation (Bergman et al, 1992; Xu et al, 1997). In contrast, 
autophosphorylation of Y394 in the enzyme activation loop is thought to stabilise an active 
confirmation (Hardwick & Sefton, 1997). Both residues are dephosphorylated by CD45, a highly 
abundant transmembrane tyrosine phosphatase (D’Oro et al, 1996). Thus, LCK activity can be 
regulated via its recruitment to TCR microclusters and localisation with CD45 and CSK. 
A proportion of LCK is constitutively active at the plasma membrane of resting T cells (Nika et al, 
2010; Stirnweiss et al, 2013). Therefore, an additional level of regulation is required to prevent 
inappropriate phosphorylation of the CD3 ITAMs and to set the threshold of T cell activation 
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(Brownlie & Zamoyska, 2013). It is still unclear precisely how recognition of peptide-MHC allows 
LCK phosphorylation of the CD3 chains. One model proposed for this TCR ‘triggering’ suggests 
that peptide-MHC binding to the TCR induces a conformational change in the CD3ɛ and ζ 
subunits, exposing ITAMs that are usually buried in the lipid bilayer via lipid-interacting basic-
rich stretch (BRS) motifs in the CD3 cytoplasmic domains (Xu et al, 2008; Guo et al, 2017). 
Exposed BRS motifs in the CD3ɛ chain may also directly mediate the recruitment of LCK (Li et al, 
2017). However, triggering upon antigen recognition may also occur via segregation of the TCR 
from the tyrosine phosphatase CD45, which dephosphorylates CD3 ITAMs in resting cells (Varma 
et al, 2006; James & Vale, 2012; Carbone et al, 2017). In this respect, LCK, CSK and CD45 form a 
minimal network that controls the phosphorylation state of the TCR (Hui & Vale, 2014).  
Tyrosine phosphorylated CD3 ITAMs are subsequently able to recruit SH2 domain-containing 
proteins, the most crucial being the Syk-family tyrosine kinase, ζ-chain-associated protein kinase 
of 70 kDa (ZAP-70). Tandem SH2 domains in ZAP-70 bind to doubly phosphorylated ITAMs in the 
CD3 and ζ chains, which is thought to perturb an autoinhibitory conformation and allow access 
to two regulatory tyrosines, Y315 and Y319 (Yan et al, 2013). These residues, as well as Y493 in 
the enzyme activation loop, are phosphorylated by LCK, leading to complete destabilisation of 
the autoinhibited conformation and full activation of ZAP-70 (Au-Yeung et al, 2018). Upon 
recruitment and activation at the TCR, ZAP-70 phosphorylates multiple tyrosine residues in two 
key scaffold proteins: the transmembrane linker for activation of T cells (LAT) and the 
cytoplasmic SH2 domain–containing leukocyte protein of 76 kDa (SLP-76) (Bubeck Wardenburg 
et al, 1996; Zhang et al, 1998). LAT and SLP-76 provide an essential link between the proximal 
tyrosine phosphorylation events of TCR signalling and the activation of distal signalling 
pathways. 
Once phosphorylated, LAT acts as a molecular hub by nucleating multiprotein signalling 
complexes. Phosphotyrosines in LAT are bound by the SH2 domains of PLCγ1, GRB2, and GADS 
(Zhang et al, 2000). SH3 domains in the adaptor protein GRB2 (growth factor receptor–bound 
protein 2) bind to proline-rich regions in the Ras guanine nucleotide exchange factor (GEF) son 
of sevenless (SOS1), recruiting it into the vicinity of its membrane-associated substrate RAS, 
which in turn leads to the activation of extracellular signal-related kinase (ERK) (Quilliam, 2007). 
PLCγ1 (phospholipase Cγ1) catalyses the hydrolysis of PIP2 to the second messengers I(1,4,5)P3 
(IP3) and diacylglycerol (DAG). IP3 causes the release of Ca2+ from intracellular stores and 
promotes Ca2+ influx from the extracellular space, thus elevating intracellular Ca2+ levels, 
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whereas DAG recruits RASGRP and PKCθ to the plasma membrane, initiating the RAS-ERK and 
nuclear factor-κB (NF-κB) pathways, respectively (Spitaler & Cantrell, 2004). As well as binding 
to LAT, GADS (GRB2-related adaptor downstream of Shc) recruits SLP-76, which itself directly 
recruits the Rho-family GEF VAV, the adaptor NCK, and the Tec-family kinase ITK (Koretzky et al, 
2006). Collectively, the protein complexes recruited by tyrosine phosphorylated LAT and SLP-76 
activate the key signalling effectors ERK, PKCθ and calcineurin, which ultimately activate several 
transcription factors, including nuclear factor of activated T cells (NFAT), activator protein 1 
(AP-1) and NF-κB (Gaud et al, 2018; Figure 1.3). Together, these orchestrate antigen-induced 
T cell proliferation, survival, cytokine production and effector functions during T cell 
activation (Foletta et al, 1998; Gerondakis & Siebenlist, 2010; Hermann-Kleiter & Baier, 
2010). 
 
Figure 1.3 The TCR signalosome 
Following TCR engagement, tyrosine phosphorylation of the CD3 and ζ chain ITAMs and ZAP-70 
by LCK, and of the adaptor proteins LAT and SLP-76 by ZAP-70, leads to the recruitment of 
multiprotein signalling complexes. PLCγ1 catalyses production of the second messengers IP3 and 
DAG, leading to increased calcium flux and PKCθ localisation to the plasma membrane, while RAS 
is activated via recruitment of the GEFs, SOS1 and RASGRP. The mechanisms of PI3K recruitment 
and activation at the TCR signalosome are unclear. Collectively, TCR-induced tyrosine 
phosphorylation events and protein-protein interactions activate the RAS-ERK, NF-κB, PI3K and 
calcium signalling pathways, leading to changes in gene regulation orchestrated by the 
transcription factors NF-κB, AP-1, FOXO1 and NFAT.  
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1.3.2 PI3K-AKT signalling downstream of the TCR 
Activation of PI3K is one of the earliest signalling events to occur upon conjugate formation 
between T cells and APCs. The accumulation of PIP3 can be observed rapidly at the plasma 
membrane following formation of the immune synapse (Costello et al, 2002; Harriague & 
Bismuth, 2002).  Furthermore, p85α heterodimers are recruited to the immune synapse from 
the cytosol within a few seconds of antigen recognition (Fabre et al, 2005). PI3K is thus activated 
proximal to the TCR and plays a role in early TCR signal transduction via the production of the 
second messenger PIP3. 
PIP3 at the inner leaflet of the plasma membrane serves as a docking site for proteins that 
contain pleckstrin homology (PH) domains, providing a means of targeting cytosolic proteins to 
the membrane (Fruman et al, 1999). Such proteins include the key TCR signalling effectors 
PLCγ1, SOS, RAS-GAP, VAV, ITK, and TEC (Balagopalan et al, 2010), and the archetypical PI3K 
effector, AKT. PIP3 activates the serine/threonine kinases AKT and 3-phosphoinositide-
dependent kinase 1 (PDK1) via their PH domain-mediated recruitment to the membrane and 
consequent co-localisation. AKT is autoinhibited in the absence of PIP3 by an interaction 
between its PH domain and kinase domain (Lučić et al, 2018).  Binding of the PH domain with 
PIP3 results in a conformational change that allows phosphorylation of residue T308, located in 
the catalytic domain activation loop, by PDK1 (Alessi et al, 1997). PI3K thus regulates AKT by 
producing the PIP3 required for co-localisation with PDK1 and subsequent activation (Stokoe et 
al, 1997). Indeed, mutation of the PDK1 PH domain attenuates AKT T308 phosphorylation in T 
cells (Waugh et al, 2009). AKT is additionally phosphorylated at S473 by mammalian target of 
rapamycin complex 2 (mTORC2) to achieve maximal activation (Sarbassov et al, 2005). 
AKT modulates a number of key signalling pathways via phosphorylation of its substrates (Figure 
1.4). AKT phosphorylates and inhibits TSC1/2, a negative regulator of mTORC1, and thus 
promotes mTORC1 mediated cell growth, protein synthesis and metabolism through activation 
of ribosomal protein S6 kinase beta-1 (S6K1) and inhibition of 4E-BP (Laplante & Sabatini, 2012). 
AKT also inhibits glycogen synthase kinase 3 (GSK3), which leads to increased glycogen synthesis 
and promotes cell cycle progression by preventing GSK3-mediated degradation of BCL1 (Cyclin 
D1), c-JUN and c-MYC (Hers et al, 2011). In addition to these targets, AKT also translocates to 
the nucleus and phosphorylates forkhead box O (FOXO) family transcription factors. This 
promotes the nuclear exclusion and cytosolic sequestration of FOXO, thereby reducing the 
expression of FOXO target genes that are involved in apoptosis and cell cycle arrest, such as Bim 
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and FasL (Hedrick et al, 2012). Indeed, FOXO1, the predominant paralogue expressed in T cells, 
translocates completely from the nucleus in T cells that encounter antigen upon APCs (Fabre et 
al, 2005). Thus, PI3K-AKT signalling induced by antigen recognition promotes cell growth, 




Figure 1.4 PI3K-AKT signalling downstream of the TCR 
Following TCR engagement, PIP3 produced by PI3K acts as a docking site for PDK1 and AKT at the 
plasma membrane. AKT is subsequently activated via phosphorylation at T308 and S473 by PDK1 
and mTORC2, respectively. AKT phosphorylates the effector proteins TSC2, GSK3 and FOXO1, 
resulting in their inhibition and ultimately leading to increased protein synthesis, cell survival and 




1.3.3 PI3K recruitment to the TCR signalosome  
While the molecular details of PI3K-AKT signalling are well understood, it is unclear precisely 
how the mature T cell receptor activates this pathway. Recruitment of PI3K to the TCR 
signalosome and subsequent activation would likely require interaction with proteins containing 
phosphorylated YxxM motifs, which are specifically recognised by the SH2 domains of the p85 
regulatory subunit (Songyang et al, 1993).  
The CD3 cytoplasmic chains and the adaptors LAT and SLP-76 lack such motifs. Nevertheless, the 
adaptor protein SLP-76 has been shown to interact with the nSH2 of p85 using a yeast-2-hybrid 
approach (Shim et al, 2004). SLP-76 contains three non-canonical YE(S/P)P tyrosine 
phosphorylation motifs in its N-terminal region. The SLP-76 association with p85 appears to 
require either p-Y113 or p-Y128, located within YESP motifs (Shim et al, 2004). SLP-76-
deficient Jurkat T cells reconstituted with Y113F or Y128F SLP-76 mutants also exhibit impaired 
AKT activation upon TCR-stimulation (Shim et al, 2011). However, these residues are also 
required for the recruitment of VAV and NCK to the TCR signalosome (Raab et al, 1997; 
Wunderlich et al, 1999). Therefore, it is not clear which of these molecules could be involved 
in PI3K activation, or whether p85 associates with SLP-76 in primary T cells. It has also been 
suggested that the p85 SH2 domains interact with non-canonical phosphotyrosine motifs in 
LAT and ZAP-70. An association between p85 and LAT occurs in Jurkat T cells (Zhang et al, 
1998) and p85 demonstrates direct binding to LAT residues Y171 and Y191 in vitro, both of 
which are located within YVNV motifs (Paz et al, 2001). Similarly, ZAP-70 has been shown to 
interact with the cSH2 of p85 in vitro (Moon et al, 2005). Whether these interactions occur in a 
physiological context upon TCR antigen engagement is yet to be shown.  
The transmembrane adaptor TCR-interacting molecule (TRIM) has been proposed to act as a 
PI3K docking site in activated T cells, due to the presence of a YxxM motif in its cytoplasmic 
domain that is phosphorylated by ZAP-70 (Bruyns et al, 1998). However, TRIM-deficient primary 
CD4+ T cells do not exhibit impaired TCR-dependent activation of AKT, suggesting that this 
adaptor is not required for PI3K signalling in this context (Kölsch et al, 2006).  
Aside from phosphotyrosine-mediated recruitment mechanisms, p85 could also form 
interactions with TCR-associated proteins via its SH3 domain, proline-rich regions and Ras-
binding domain. Indeed, Src-family kinases LYN and FYN can interact via their SH3 domains with 
p85 in vitro (Prasad et al, 1993; Pleiman et al, 1994). Ras-family proteins are thought to activate 
PI3K lipid kinase activity, synergistically with tyrosine-phosphorylated proteins, through binding 
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to the catalytic subunit RBD, and may tether the enzyme to the membrane. Additionally, they 
could recruit PI3K to receptor signalosomes, a role that is illustrated by the Ras GTPase TC21. 
TC21 can bind to the RBD of p110δ and activate its lipid kinase activity (Rodriguez-Viciana et al, 
2004). Interestingly, TC21 is constitutively associated with non-phosphorylated ITAMs of the 
CD3 chains (Delgado et al, 2009).  TC21-deficient T cells exhibit reduced levels of basal AKT 
phosphorylation and reduced p85α association with the TCR (Delgado et al, 2009). TC21 is 
therefore hypothesised to be involved in ‘tonic’ TCR signalling via the PI3K-AKT pathway for T 
cell homeostasis. However, TC21-deficient T cells also exhibit reduced AKT phosphorylation 
upon TCR stimulation in vitro (Delgado et al, 2009). Whether TC21 is involved in p110δ 
recruitment to the TCR upon antigen engagement, or solely serves to activate p110δ kinase 
activity in co-operation with a phosphotyrosine-mediated mechanism, is currently unresolved. 
Another protein proposed to recruit and activate PI3K upon TCR stimulation is the co-
stimulatory receptor, CD28. Its role in this context, however, has been much debated.  
 
1.3.4 The role of the CD28 co-stimulatory receptor in TCR-PI3K signalling 
Recognition of antigenic peptides presented by MHC molecules induces the TCR signalling 
pathway, but the outcome on T cell function and fate is also determined by co-stimulatory and 
co-inhibitory receptors, which are engaged upon the interaction with APCs (Chen & Flies, 2013). 
This two-signal model of T cell activation, in which both TCR and co-stimulatory signalling are 
required for full T cell activation, is illustrated by the CD28 co-receptor (June et al, 1987). CD28 
is constitutively expressed on naïve T cells and provides signals for cell growth and survival upon 
ligation by its ligand B7-1 (CD80) or B7-2 (CD86), present on the surface of antigen-presenting 
cells (Esensten et al, 2016). CD28 ligation alone fails to activate T cells, but without CD28 co-
ligation the TCR can induce an anergic state or cell death (Jenkins et al, 1988; Mueller et al, 
1989). 
Clustering of the TCR and CD28 is induced in the early stages of peptide-MHC recognition and is 
dependent on CD28 ligation by its ligand on the surface of APCs (Yokosuka et al, 2008). The 
cytoplasmic tail of CD28 contains a YMNM motif, which upon tyrosine phosphorylation can bind 
to p85 (Prasad et al, 1994). The importance of this CD28-PI3K interaction in the context of TCR 
signalling has been a subject of much debate (Rudd & Schneider, 2003). CD28 engagement by its 
ligand CD80 transiently enhances PI3K recruitment to TCR-CD28 microclusters during initial TCR 
activation (Yokosuka et al, 2008). In addition, PIP3 accumulation at the immune synapse is 
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reduced in antigen-specific CD28−/− T cells activated by peptide-MHC on APCs, although AKT 
activation is unimpaired in CD28−/− T cells upon TCR stimulation (Garçon et al, 2008). Thus, CD28 
contributes to sustaining PIP3 production at the immune synapse. However, studies using T cells 
expressing the CD28Y170F YMNM mutant demonstrated that direct interaction between PI3K and 
CD28 via the YMNM motif is not required for PIP3 production at the immune synapse (Garçon et 
al, 2008). Thus, it is thought that CD28 maintains PI3K activity via other means. Indeed, CD28 co-
stimulation has been shown to sustain LCK activity at the immune synapse, via an interaction 
involving the C-terminal PYAP motif in the cytoplasmic domain of CD28 (Holdorf et al, 2002; 
Dobbins et al, 2016). LCK binds first to clusters of basic residues in CD28 and then 
phosphorylates Y207 of the PYAP motif, such that this motif becomes a binding site for the LCK 
SH2 domain. The ability of CD28 to sustain LCK activity is a plausible mechanism for how CD28 
maintains PI3K signalling, given that LCK may phosphorylate other docking sites for p85 at the 
immune synapse. Thus, there may be a more general role for CD28 in enhancing TCR signalling 
rather than specifically regulating PI3K activation. Furthermore, CD28 forms a stable complex 
with PKCθ at the immunological synapse, which is hypothesised to be the specific mediator of 
CD28 co-stimulatory signalling (Coudronniere et al, 2000; Yokosuka et al, 2008). Indeed, CD28 
associates with RLTPR, a scaffolding protein that is required for CD28 co-stimulation and the 
localisation of PKCθ and CARMA1 to the immune synapse (Liang et al, 2013; Roncagalli et al, 
2016). Consequently, a crucial function of CD28 co-stimulation during T cell activation is 
induction of the NF-κB signalling pathway via RLTPR, PKCθ and CARMA1 (Liang et al, 2013). 
The mechanism of PI3K recruitment to the TCR signalosome clearly remains unresolved. 
However, it has become clear over the past two decades that the class IA isoform p110δ 
appears to be preferentially recruited or activated upon TCR signalling  
 
1.3.5 p110δ is the dominant PI3K isoform in mature T cells 
T lymphocytes express all class I catalytic subunits, albeit p110δ and p110γ are highly enriched 
compared to p110α and p110β (Okkenhaug et al, 2002). The generation of knock-in mice that 
express PI3K isoforms with loss-of-function point mutations has allowed the precise study of the 
unique and redundant roles of class I catalytic isoforms in T lymphocytes, while avoiding the 
compensatory effects associated with deletion of individual isoforms (So & Fruman, 2012). 
Furthermore, crystal structures of their catalytic ATP-binding pockets led to the development of 
compounds with selectivity for specific class I isoforms (Vadas et al, 2011). Using gene-targeted 
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mice with an inactivating D910A mutation in the p110δ catalytic domain, p110δ has been shown 
to play a dominant role in TCR signalling (Okkenhaug et al, 2002). 
T cells from mice expressing kinase-inactive p110δD910A fail to activate AKT phosphorylation 
upon TCR and CD28 co-stimulation, and do not produce PIP3 above basal levels (Okkenhaug et 
al, 2002; Stark et al, 2018). Equally, wild type T cells treated with a p110δ-selective inhibitor 
demonstrate the same impairment in TCR-induced PIP3 production and AKT activation. (Stark et 
al, 2018). Furthermore, antigen-specific p110δD910A/D910A T cells exhibit greatly reduced PIP3 
accumulation at the immune synapse formed with antigen-presenting cells, equivalent to T cells 
treated with a p110δ-selective inhibitor (Garçon et al, 2008). These studies have clearly 
demonstrated that p110δ is the dominant PI3K isoform activated by the TCR in mature T cells, 
responsible for the majority of the PIP3 produced and essential for subsequent AKT activation. 
Additional studies have revealed that mature CD4+ T cell differentiation and effector cytokine 
production is under the control of p110δ (Okkenhaug et al, 2006; Soond et al, 2010). 
p110δD910A/D910A CD4+ T cells exhibit reduced proliferation and production of effector cytokines, 
IFNγ and IL-4, in response to antigen presentation and co-stimulation both in vitro and in vivo 
(Okkenhaug et al, 2006). Differentiation along the Th1 and Th2 lineages is also impaired in 
p110δD910A/D910A T cells. Similar defects are evident in both naïve and effector/memory CD4+ T 
cells treated with a p110δ-selective inhibitor, which exhibit supressed proliferation and strongly 
reduced production of IFNγ and TNFα in vitro following TCR stimulation (Soond et al, 2010). 
These studies indicate that p110δ plays an important role in the TCR-induced effector 
functions of both naïve and previously activated CD4+ T cells (Okkenhaug & Fruman, 2010). 
 
Given the importance and dominance of p110δ activity in T cell activation and function, there 
is a clear rationale to understand its regulation downstream of TCR engagement. This is only 
emphasised by the potential of p110δ as a therapeutic target in autoimmune and 
inflammatory diseases and cancer (So & Fruman, 2012). Despite this interest, the 
mechanisms that regulate p110δ activity in T cells, and determine isoform-specificity, are still 
unclear. Therefore, using a combination of proteomic, biochemical and gene editing 
approaches, this body of work has investigated the molecular basis of p110δ regulation in T 
lymphocytes. Specifically, with the aim to identify and characterise proteins involved in the 
recruitment and activation of p110δ downstream of the TCR. 
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Chapter 2        
 
Optimisation of AviTag affinity purification 
for the study of p110δ interaction partners 
in primary lymphocytes 
 
2.1 Introduction 
A key aim of this study was to identify proteins involved in the recruitment and activation of 
p110δ at the TCR signalosome. The motivation for this was two-fold. First, despite extensive 
study of the major components involved in TCR-mediated signalling, the precise mechanisms of 
PI3K recruitment to the TCR are still unclear. Second, while previous genetic and biochemical 
studies have demonstrated that p110δ is the dominant class IA PI3K isoform in TCR signalling, 
the reason for this is unknown. One hypothesis is that isoform specificity may be mediated via 
preferential recruitment or activation of p110δ over p110α. Thus, in both respects, the current 
understanding of PI3K regulation in T lymphocytes would be advanced by the identification of 
proteins that specifically interact with the p110δ heterodimer downstream of TCR engagement. 
To identify physiologically relevant p110δ interactors, this work aimed to study endogenously 
expressed proteins in primary lymphocytes. Therefore, a system was required for the isolation 
of specific PI3K p110 isoforms from primary T cells, and the subsequent analysis of associated 
proteins. 
Affinity purification coupled with mass spectrometry (AP-MS) was chosen for this purpose, as it 
enables unbiased identification of protein-protein interactions under physiological conditions 
(Gingras et al, 2007). AP-MS relies on a method to efficiently isolate protein complexes from 
cells. A widely used approach involves the introduction of an epitope tag at an endogenous gene 
locus, leading to expression of a tagged bait protein that can be purified using an affinity matrix 
specific for the epitope (Dunham et al, 2012). In this manner, mice have recently been 
generated that express the class IA PI3K isoforms fused to the AviTag biotinylation consensus 
sequence (T. Chessa, unpublished work). The AviTag sequence is inserted at the C-terminus of 
the mouse Pik3cd or Pik3ca gene, such that p110δ or p110α are expressed under the control of 
their endogenous promoters with a 15-amino acid AviTag (Figure 2.1A). This tag is specifically 
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recognised and biotinylated by the E. coli biotin ligase BirA, which can be expressed in 
transgenic mice (Beckett et al, 1999; de Boer et al, 2003; Figure 2.1B). Therefore, in parallel with 
p110-AviTag mice, transgenic mice have also been generated that constitutively express BirA 
under the control of the endogenous ROSA26 promoter (T. Chessa, unpublished work). Thus, 
AviTagged p110 isoforms can be biotinylated in vivo following co-expression of BirA. The 
obvious advantage of this system is that AviTagged p110 subunits, and their binding partners, 
can be purified in a single step from cell lysates using streptavidin-conjugated magnetic beads. 
Furthermore, the high affinity of the biotin-streptavidin interaction allows for high stringency 
during purification, without the risk of eluting the tagged protein. Importantly, this system 
allows for the specific purification of either p110δ or p110α. Naturally biotinylated or biotin-
associated proteins, such as biotin-dependent carboxylases (Tong, 2013), would also be 
captured by streptavidin-conjugated beads. However, by comparison with control purifications 
from cells expressing BirA alone, it should be possible to exclude these irrelevant proteins from 
downstream analysis.  
Thus, the PI3K-AviTag system was chosen for the study of endogenous p110δ protein-protein 
interactions in primary T lymphocytes. In this approach, primary T cells would be isolated from 
mice expressing AviTagged-p110δ and BirA (p110δAvi/AviBirA+/-) or mice expressing BirA alone 
(BirA+/-) and stimulated in vitro via the TCR (Figure 2.1C). Cells would then be lysed and their 
lysates subjected to affinity purification using streptavidin-conjugated magnetic beads. The 
proteins isolated using this technique could then be analysed by immunoblotting and identified 
by mass spectrometry. This work therefore aimed to validate and optimise the AviTag system 






Figure 2.1 The AviTag affinity purification system for the study of p110δ in primary 
lymphocytes.  
A. The C-terminal amino acid sequence of murine AviTagged-p110δ, comprising the kinase domain 
(775-1028, yellow), C-terminal tail (1029-1043), 2-amino acid linker (grey) and AviTag sequence (red). 
B. AviTagged-p110δ (or p110α) is expressed under the control of its endogenous promoter with a C-
terminal 15-amino acid AviTag (GLNDIFEAQKIEWHE). This tag acts as a substrate mimic for the E. coli 
biotin ligase, BirA, which specifically recognises and biotinylates the AviTag sequence. 
C. Strategy for the purification of p110δ from primary T lymphocytes. Lymphocytes are isolated from 
the lymph nodes of mice expressing AviTagged-p110δ and BirA (p110δAvi/AviBirA+/-) or control mice 
expressing BirA alone (BirA+/-) and stimulated in vitro. Cells are lysed and p110δ is purified from lysates 
by incubation with streptavidin-conjugated magnetic beads. Protein complexes are eluted from the 
beads and subjected to immunoblotting or LC-MS/MS analysis. Non-specific interactors are 
distinguished from p110δ-specific interactors by comparison of p110δ affinity purifications (APs) with 




















2.2.1 Validation of the AviTag system for the study of specific PI3K p110 
isoforms in primary lymphocytes 
It was first determined whether AviTagged p110δ protein was successfully expressed at 
endogenous levels in primary lymphocytes. To this end, naïve T and B lymphocytes were 
isolated from the lymph nodes and spleens, respectively, of p110δAvi/Avi mice homozygous for 
AviTagged-p110δ. Immunoblotting of cell lysates with antibodies specific for p110δ or the 
AviTag peptide sequence confirmed that AviTagged-p110δ was expressed in both T and B 
lymphocytes at an equivalent level to wild type p110δ (Figure 2.2). 
 
Figure 2.2 AviTagged p110δ is expressed at endogenous levels in primary naïve T and B 
lymphocytes from p110δAvi/Avi mice. 
Immunoblot analysis of cell lysates from wild type and p110δAvi/Avi naïve T and B lymphocytes. 
Naïve T and B cells were isolated from the lymph nodes and spleens, respectively, of wild type 
(WT) and p110δAvi/Avi mice and 2 million cells of each genotype were lysed. Whole cell lysates were 
then separated by SDS-PAGE in duplicate. Each half of the immunoblot was probed with anti-
p110δ or anti-AviTag and then anti-β-actin.  
 
p110δAvi/Avi mice were then crossed with BirA+/+ mice expressing the biotin ligase BirA to 
generate p110δAvi/AviBirA+/- animals. Previous studies have demonstrated that heterozygous 
expression of BirA is sufficient to biotinylate AviTagged PI3K isoforms in vivo (T. Chessa, 
unpublished work). Experiments were performed to assess whether p110δ was biotinylated in 
p110δAvi/AviBirA+/- primary naïve T cells and could thus be purified from cell lysates using 
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streptavidin-conjugated magnetic beads. Cells were stimulated by crosslinking of CD3 and CD28 
and their lysates were incubated with 50 μl streptavidin-conjugated magnetic beads for one 
hour. Affinity-purified proteins were eluted from the beads by boiling in denaturing LDS gel 
loading buffer and then analysed by immunoblotting (Figure 2.3). Strikingly, p110δ was 
completely depleted from cell lysates, and was detected at high abundance in the bead eluate. 
Furthermore, the p85 regulatory subunit was co-purified with p110δ, as detected using a pan-
p85 antibody that recognises all p85 isoforms (Deane et al, 2004), indicating successful isolation 
of the PI3K heterodimer. The presence of the TCR-associated adaptor proteins GRB2 and NCK1 
was also investigated but neither could be detected in p110δ affinity purifications by 
immunoblotting.  
 
Figure 2.3 Efficient affinity purification of p110δ and co-purification of p85 from naïve T 
cells. 
Immunoblot analysis of cell lysates and affinity purifications from p110δAvi/AviBirA+/- naïve T cells. 
Fifty-two million naïve T cells were isolated from the lymph nodes of 3 mice and stimulated with 
1 μg/ml anti-CD3 and 5 μg/ml anti-CD28 for 3 minutes. Cells were lysed and lysates containing 
0.318 mg total protein were subjected to affinity purification with 50 μl streptavidin-conjugated 
magnetic beads for 1 hour at 4 °C. Equal proportions of lysates from before (Pre-AP) and after 
(Post-AP) bead purification, equivalent to 1.5 million cells, were separated by SDS-PAGE 
alongside 2
7
 of the bead eluate (AP). Immunoblots were probed with anti-p110δ, anti-pan-p85 
(which detects all p85 isoforms; Deane et al, 2004), anti-GRB2, anti-NCK1 and anti-β-actin. The 
immunoblot shown is representative of two independent experiments. 
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It was clear from this analysis that not all cellular p85 was depleted from lysates upon p110δ 
affinity purification. This observation was replicated in further experiments, which 
demonstrated near complete purification of p110δ from naïve CD4+ T cell lysates but not of the 
p85 isoforms p85α/β, p55α and p50α (Figure 2.4). Lysates from control BirA+/- naïve CD4+ T cells 
were also subjected to affinity purification. As expected, no depletion of p110δ, p85α/β, p55α 
or p50α was observed in these lysates, confirming the specificity of the streptavidin-mediated 
bead purification. Quantification and normalisation of the p85 detected in cell lysates before 
and after p110δ affinity purification, in two independent experiments, revealed that an average 
of 17 %, 13 % and 14 % of p85α/β, p55α and p50α, respectively, remained following p110δ 
purification. To investigate this further, naïve CD4+ T cells were isolated from the lymph nodes 
of p110αAvi/WTBirA+/- mice, which heterozygously express AviTagged-p110α and BirA. Cell lysates 
were subjected to affinity purification with streptavidin-conjugated magnetic beads and bead 
eluates were analysed by immunoblotting for p110α and p85 isoforms (Figure 2.5). AviTagged-
p110α, accounting for half of the total p110α expressed, was efficiently purified from lysates. 
The p85α/β and p50α regulatory subunits were also co-purified with p110α, but p55α could not 
be detected in bead eluates by immunoblotting. Taken together, this demonstrated that 
p110α:p85 heterodimers were present in naïve CD4+ T cells and that they likely accounted for a 
proportion of the residual p85 that remained following affinity purification of p110δ from naïve 
CD4+ T cell lysates. These experiments also indicated that p110δ forms heterodimers with all 
p85 isoforms in naïve T cells, while p110α forms heterodimers with p85α/β and p50α, at least. It 







Figure 2.4 Efficient affinity purification of p110δ from naïve CD4+ T cells. 
Immunoblot analysis of cell lysates from BirA+/- and p110δAvi/AviBirA+/- naive CD4+ T cells before 
and after streptavidin-mediated affinity purification. Naïve CD4+ T cells were isolated from the 
lymph nodes of 3 to 5 mice of each genotype. Lysates from 34, 38 and 25 million cells of each 
genotype (containing 0.202, 0.143, and 0.133 mg total protein, respectively) were then subjected 
to affinity purification by incubation with 50 μl streptavidin-conjugated magnetic beads for 1 hr 
at 4 °C. Equal proportions of lysates from before (Pre) and after (Post) each bead purification were 
separated by SDS-PAGE and immunoblots were probed for p110δ, p85 (pan-p85) and β-actin. The 
signal detected for p85α/β, p55α and p50α in post-AP lysates was quantified using Image Studio 
and normalised to the signal for β-actin in the same lane, and then calculated as a percentage of 








Figure 2.5 Co-purification of p85 with p110α from naïve CD4+ T cells. 
Immunoblot analysis of cell lysates and affinity purifications from p110αAvi/WTBirA+/- naïve CD4+ T 
cells. Twenty-five million cells isolated from the lymph nodes of 2 mice were stimulated with 1 
μg/ml anti-CD3 and 2 μg/ml anti-CD28 for 2 minutes, lysed and cell lysates were subjected to 
affinity purification with 50 μl streptavidin-conjugated magnetic beads for 1 hour at 4 °C. Equal 
proportions of lysates from before (Pre-AP) and after (Post-AP) bead purification were separated 
by SDS-PAGE alongside 2
7
 of the p110α affinity purification (AP). Immunoblots were probed for 
p110α and p85 (pan-p85). AviTagged-p110α appears as a higher molecular weight species to wild 
type p110α in heterozygous Pre-AP lysates, indicated with a black arrow. The blot shown is 
representative of two independent experiments. 
 
These initial experiments demonstrated that the AviTag affinity purification system was an 
efficient method for isolating endogenous p110δ from primary naïve lymphocytes. The aim of 
this study was to use this approach to purify p110δ-associated proteins from primary T cells for 
subsequent MS identification. This technique, affinity purification coupled with mass 
spectrometry (AP-MS), requires a high amount of starting material (total cellular protein) to 
enable detection of low abundance interactors and transient protein-protein interactions 
(Morris et al, 2014). Accordingly, recent studies using AP-MS to study TCR-associated proteins in 
primary T cells have used 1 × 108 activated and expanded CD4+ T cells for each affinity 
purification (Roncagalli at al, 2014; Voisinne et al, 2016). In the experiments presented here 
thus far, only 0.133 – 0.318 mg of total protein was obtained for each purification from 25 – 52 
million naïve T cells, which were isolated from up to five mice. Indeed, preliminary qualitative 
LC-MS/MS analyses of these p110δ purifications did not identify any proteins at a level of 
abundance that would enable their designation as specific p110δ interactors with any 
confidence. In addition, the majority of the proteins identified were present in purifications 
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from both BirA+/- and p110δAvi/AviBirA+/- cells. These outcomes were likely due to the low amount 
of starting material and a high abundance of non-specific background interactors. 
Consequently, the AviTag-AP approach was modified in two respects. First, the technique was 
adapted to purify p110δ from in vitro activated and expanded primary T cell blasts. Second, the 
affinity purification protocol was optimised in an effort to reduce non-specifically interacting 
proteins while maintaining interactions with low affinity or transient binding partners. 
 
2.2.2 Validation and optimisation of p110δ AviTag-mediated affinity 
purification from primary T blasts 
To increase the amount of protein subjected to affinity purification, subsequent experiments 
aimed to purify p110δ from primary T blasts, as blasted lymphocytes are larger in size than naïve 
T cells and can be expanded to high numbers in vitro. For this purpose, cells were isolated from 
the lymph nodes of p110δAvi/AviBirA+/- mice and activated for 48 hours with soluble anti-CD3, 
followed by expansion for 5 days in the presence of IL-2 to generate T blasts. Total T blasts were 
then purified, rested without IL-2 for 75 minutes, and stimulated by crosslinking of CD3 and 
CD28 for 2 minutes. The efficiency of the AviTag-AP approach for the isolation of AviTagged-
p110δ from more than 1 × 108 T blasts was then investigated. 
To this end, lysates from 1.42 × 108 stimulated T blasts were subjected to affinity purification 
using streptavidin-conjugated magnetic beads. Two durations of bead incubation were tested in 
parallel: 1 hour, as used previously, and 30 minutes. This shorter time was chosen with the 
intention to minimise both the loss of transient interactions with p110δ and the extent of non-
specific binding to the magnetic beads. In addition, following bead incubation, three stringent, 
timed wash steps were performed at 4°C. Cell lysates from before and after bead purification 
were then analysed by immunoblotting (Figure 2.6). This revealed that a 30-minute bead 




Figure 2.6 Thirty-minutes bead incubation is sufficient to efficiently isolate p110δ from T 
blasts. 
Immunoblot analysis of cell lysates and affinity purifications from p110δAvi/AviBirA+/- T blasts. 
Lysates from 142 million total T blasts that had been stimulated with 1 μg/ml anti-CD3 and 2 
μg/ml anti-CD28 were subjected to affinity purification by incubation with 80 μl streptavidin-
conjugated magnetic beads for either 30 minutes or 60 minutes at 4°C. Lysates equivalent to 4 
million cells from before (Pre-AP) and after (Post-AP) bead purification were separated by SDS-
PAGE alongside 1
5
 of each p110δ affinity purification (AP). Immunoblots were probed for p110δ, 
p85 (pan-p85) and AKT1. The signal detected for p110δ in Post-AP lysates was quantified using 
Image Studio and normalised to the signal for β-actin in the same lane, and then calculated as a 
percentage of p110δ in Pre-AP lysate. 
 
Affinity purifications using this protocol were then performed on lysates from 1 × 108 BirA+/-, 
p110δAvi/AviBirA+/- and p110αAvi/WTBirA+/- CD4+ T blasts, each containing 1.7 mg total protein 
(Figure 2.7). Thus, the amount of protein subjected to affinity purification was approximately 3-
fold that which could be obtained from an equal number of naïve T cells. Immunoblotting of the 
bead eluates demonstrated successful isolation of p110δ and all p85 regulatory subunits from 
p110δAvi/AviBirA+/- T blasts, following 30 minutes incubation with 60 μl streptavidin-conjugated 
magnetic beads and strict wash steps (Figure 2.7). Importantly, the purification of p110δ was 
specific; neither p110δ nor p85α could be detected by immunoblotting in bead eluates from 
BirA+/- control purifications. Equally, p110δ could not be detected in p110αAvi/WTBirA+/- 
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purifications. Immunoblotting of lysates from the same experiment also confirmed that p110δ 
was expressed at equivalent levels in BirA+/-, p110δAvi/AviBirA+/- and p110αAvi/WTBirA+/- CD4+ T 
blasts. 
 
Figure 2.7 Co-purification of p85 with p110δ and p110α from CD4+ T blasts. 
Immunoblot analysis of cell lysates and affinity purifications from p110δAvi/AviBirA+/-, 
p110αAvi/WTBirA+/- and BirA+/- (Control) CD4+ T blasts. Lysates from 1 × 108 cells of each genotype, 
containing 1.685 ± 0.144 mg (mean ± SD, n=4) total protein were subjected to affinity purification 
by incubation with 60 μl streptavidin-conjugated magnetic beads for 30 min at 4 °C. Lysates 
equivalent to 2 million cells from before bead purification were separated by SDS-PAGE alongside 
2
7
 of each control, p110δ and p110α affinity purification (AP). Immunoblots were probed for p110δ 
and p85 (pan-p85). 
 
Collectively, this work demonstrated that AviTagged-p110δ could be purified efficiently and 
specifically from primary CD4+ T blasts following a 30-minute one-step incubation with 
streptavidin-conjugated magnetic beads. 
 
2.2.3 Optimisation of in vitro TCR stimulation of CD4+ T blasts 
This study intended to use the AviTag-AP approach to isolate proteins that associate with p110δ 
upon TCR stimulation. Engagement of the TCR induces extensive tyrosine phosphorylation of 
multiple proteins at the TCR signalosome (Guy & Vignali, 2009), and these phosphorylation 
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events are likely to be important for transient p85-SH2 domain-mediated interactions that lead 
to the recruitment and activation of p110δ. Earlier optimisation of the AviTag-AP protocol 
shortened the bead incubation time and performed all wash steps at 0 - 4°C in an effort to 
maintain transient interactions with p110δ. Nevertheless, it was also important to preserve TCR-
induced phosphorylation events during bead purification by inhibiting protein phosphatases 
released upon cell membrane disruption. Therefore, the lysis buffer composition was examined.  
The standard lymphocyte lysis buffer used in previous experiments contained sodium fluoride, 
which acts as an inhibitor of serine/threonine phosphatases. This recipe was improved further 
by the addition of the serine/threonine phosphatase inhibitors β-glycerophosphate and sodium 
pyrophosphate. Most importantly, the tyrosine phosphatase inhibitor sodium orthovanadate 
was also supplemented. The efficacy of the two lysis buffers was then compared by investigating 
the level of total cellular protein tyrosine phosphorylation in lysates from CD3+CD28 stimulated 
T cells (Figure 2.8). Immunoblotting of cell lysates showed that the modified lysis buffer 
preserved a greater number of stimulation-induced protein tyrosine phosphorylation events. 
However, this experiment also revealed that the extent of protein tyrosine phosphorylation 
induced by CD3 and CD28 crosslinking was noticeably low. This prompted work to optimise the 
conditions for TCR stimulation of CD4+ T blasts. For this, the magnitude of cellular protein 
tyrosine phosphorylation upon TCR crosslinking was taken as a proxy for the extent of successful 
TCR signalosome activation. It was theorised that maximising TCR activation would induce the 
greatest number of interactions at TCR signalosomes, including those involved in the 
recruitment and activation of PI3K. Thus, it would be more likely that TCR stimulation-




Figure 2.8 Improved lysis buffer composition preserves total cellular protein tyrosine 
phosphorylation.  
Immunoblot analysis of cell lysates from p110δAvi/AviBirA+/- primary naïve total T cells. Ten million 
cells per condition were incubated on ice for 30 minutes with 1 μg/ml anti-CD3 plus 2 μg/ml anti-
CD28 (CD3+CD28) followed by crosslinking with anti-hamster IgG for 2 minutes at 37°C, or left 
unstimulated (Unstim) for 2 minutes at 37°C. Cells were lysed for 10 minutes on ice with either 
standard (Std) lysis buffer (1 % IGEPAL CA-630, 50 mM HEPES, 150 mM NaCl, 5 mM EDTA, 10 mM 
NaF, 10 mM Iodoacetamide, 5 mM protease inhibitor cocktail) or a modified (Mod) lysis buffer (1 
% IGEPAL CA-630, 50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 25 mM NaF, 10 mM 
Iodoacetamide, 2.5 mM sodium pyrophosphate, 5 mM β-glycerophosphate, 5 mM sodium 
orthovandate, 5 mM protease inhibitor cocktail). Lysates equivalent to 0.3 × 106 cells were 
separated by SDS-PAGE and immunoblots were probed for phosphorylated tyrosine residues 
(pTyr) and β-actin.  
 
The experiments presented thus far stimulated T cells by crosslinking antibodies targeted to CD3 
and CD28 on the cell surface. This aimed to mimic the clustering of the TCR and CD28 co-
stimulatory receptor that is induced in the early stages of MHC-presented peptide recognition 
by the TCR, which is dependent on CD28 ligation by its ligand B7-1 or B7-2 on antigen-
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presenting cells (Yokosuka et al, 2008). Nevertheless, the co-receptor CD4 also interacts with 
antigen-presenting MHC class II (König et al, 1992). This proximity to the TCR complex allows 
LCK associated with the CD4 cytoplasmic tail to phosphorylate CD3 ITAMs, leading to the 
initiation and amplification of the TCR signalling cascade (Barber et al, 1989; Holdorf et al, 2002; 
Wang et al, 2010).  
Therefore, combinations of CD3, CD28 and CD4 crosslinking were investigated for their ability to 
induce protein tyrosine phosphorylation (pTyr) in p110δAvi/AviBirA+/- CD4+ T blasts (Figure 2.9). 
Doubling of the anti-CD3 and anti-CD28 antibody concentrations used in previous experiments 
had little effect on induced pTyr. In contrast, addition of anti-CD4 greatly increased the level of 
pTyr induced upon crosslinking. Furthermore, absence of anti-CD28 did not reduce this level of 
pTyr. Therefore, crosslinking of CD3 and CD4 appeared to induce the greatest extent of protein 
tyrosine phosphorylation, while successfully activating AKT, and was thus used in subsequent 




Figure 2.9 Greatest cellular protein tyrosine phosphorylation in CD4+ T blasts is achieved 
by CD3 and CD4 crosslinking.  
Immunoblot analysis of cell lysates from p110δAvi/AviBirA+/- CD4+ T blasts. Thirty-million CD4+ T 
blasts per condition were incubated on ice for 30 minutes with anti-CD3 plus anti-CD28 or anti-
CD4 in the combinations and concentrations indicated, followed by crosslinking with 13 μg/ml 
anti-hamster IgG for 2 minutes at 37°C, or were left unstimulated or stimulated with 100 μM 
pervanadate (PV) for 2 minutes at 37°C. Lysates equivalent to 1.5 million cells were separated by 
SDS-PAGE and immunoblots were probed for phosphorylated tyrosine residues (pTyr), 




The optimal time point for TCR stimulation-induced protein tyrosine phosphorylation was also 
investigated. p110δAvi/AviBirA+/- CD4+ T blasts were stimulated by crosslinking of anti-CD3 and 
anti-CD4 for between 30 seconds and 3 minutes and lysates were analysed by immunoblotting 
(Figure 2.10). This revealed that the greatest levels of total cellular pTyr were induced between 
1 – 2 minutes of crosslinking. Cell lysates were also subjected to affinity purification with 
streptavidin-magnetic beads to isolate p110δ, and the bead eluates were then analysed by 
immunoblotting for pTyr and p110δ. Intriguingly, multiple tyrosine-phosphorylated proteins 
were co-purified with p110δ from stimulated cells (Figure 2.10). These associations appeared to 
peak at 1 minute of crosslinking. Based on these observations, TCR stimulation via anti-CD3 and 
anti-CD4 crosslinking for 1 minute was used in subsequent experiments. It was also apparent 
from these experiments that p110δ was constitutively tyrosine phosphorylated in CD4+ T blasts. 
Moreover, a prominently tyrosine-phosphorylated protein of 115 kDa appeared to associate 




Figure 2.10 Investigating the optimal timepoint for TCR stimulation to induce maximal 
cellular protein tyrosine phosphorylation in CD4+ T blasts. 
Immunoblot analysis of cell lysates and affinity purifications from p110δAvi/AviBirA+/- CD4+ T blasts. 
Fifty-three million CD4+ T blasts per condition were incubated on ice for 30 minutes with 2 μg/ml 
anti-CD3 plus anti-CD4 followed by crosslinking at 37°C with 13 μg/ml anti-hamster IgG for the 
times indicated, or left unstimulated (-) for 3 minutes at 37°C. Cell lysates were then subjected to 
affinity purification using 60 μl streptavidin-conjugated magnetic beads. Lysates equivalent to 1.3 
million cells from before bead purification were separated by SDS-PAGE alongside 2
7
 of each p110δ 
affinity purification (AP). Immunoblots were probed for phosphorylated tyrosine residues (pTyr) 
and p110δ. The immunoblot shown is representative of two independent experiments. The red 
arrow indicates the position of p110δ. The black arrow highlights a prominently tyrosine-





It was next investigated whether doubling the anti-CD3 and anti-CD4 concentrations used for 
TCR stimulation would further increase total cellular pTyr or the number of pTyr proteins 
associated with p110δ. There was a noticeable increase in the tyrosine phosphorylation of 
higher molecular weight proteins in whole cell lysates from cells stimulated with the higher anti-
CD3 and anti-CD4 antibody concentration (Figure 2.11).  The tyrosine phosphorylation status of 
LAT (linker for activation of T cells) was also examined. LAT is phosphorylated by the tyrosine 
kinase ZAP-70 upon TCR activation and acts as an adaptor for multiple SH2 domain-containing 
proteins involved in the amplification of TCR signalling (Zhang et al, 1998). Tyrosine 
phosphorylation of a protein that migrated by SDS-PAGE according to the position of LAT was 
enhanced using the higher concentration of anti-CD3 and anti-CD4 (Figure 2.11). 
p110δAvi/AviBirA+/- cell lysates from this experiment were also subjected to affinity purification 
with streptavidin-magnetic beads to isolate p110δ, and the bead eluates were analysed by 
immunoblotting. There were slightly more pTyr proteins co-purified with p110δ following 
stimulation with the doubled concentration of anti-CD3 and anti-CD4. These pTyr bands were 
also more pronounced, suggesting that the phosphorylated proteins were purified at higher 
abundance. Strikingly, tyrosine-phosphorylated proteins were not detected by immunoblotting 
in control purifications from BirA+/- cells. This indicated that the tyrosine-phosphorylated 




Figure 2.11 Increased antibody concentrations for TCR crosslinking induce maximal cellular 
protein tyrosine phosphorylation and tyrosine phosphorylation of LAT in CD4+ T blasts. 
Immunoblot analysis of cell lysates and affinity purifications from p110δAvi/AviBirA+/- (p110δAvi/Avi) 
and BirA+/- (Control) CD4+ T blasts. Fifty million CD4+ T blasts per condition were incubated on ice 
for 30 minutes with 2 μg/ml or 4 μg/ml anti-CD3 and anti-CD4 (αCD3+αCD4), followed by 
crosslinking at 37°C with 13 μg/ml anti-hamster IgG for 1 minute, or left unstimulated (-) at 37°C 
for 1 minute. Cell lysates were subjected to affinity purification by incubation with 30 μl 
streptavidin-conjugated magnetic beads for 30 min at 4 °C. Lysates equivalent to 1.2 million cells 
from before bead purification were separated by SDS-PAGE alongside half of each control and 
p110δ affinity purification (AP). Immunoblots were probed for phosphorylated tyrosine residues 
(pTyr) and LAT. The signals detected for pTyr and LAT are overlaid in the fourth panel in green and 




Collectively, these experiments led to an optimised protocol for the efficient and specific 
purification of p110δ and associated proteins from CD4+ T blasts (Figure 2.12). TCR stimulation 
of CD4+ T blasts with 4 μg/ml anti-CD3 and anti-CD4 for 1 minute induced robust cellular 
tyrosine phosphorylation. p110δ protein could be efficiently purified from the lysates of 1 × 108 
CD4+ T blasts by incubation for only 30 minutes with 60 μl streptavidin-conjugated magnetic 
beads, followed by strict wash steps. Intriguingly, tyrosine-phosphorylated proteins could be co-
purified specifically with p110δ in a TCR-stimulation dependent manner, including a prominently 









Figure 2.12 An optimised protocol for efficient and specific AviTag-mediated affinity 
purification of p110δ from CD4+ T blasts. 
Immunoblot analysis of cell lysates and affinity purifications from p110δAvi/AviBirA+/- (p110δAvi/Avi) 
and BirA+/- (Control) CD4+ T blasts. One-hundred million CD4+ T blasts per condition were 
stimulated by crosslinking 4 μg/ml CD3+CD4 for 1 minute (+), or were left unstimulated (-), and 
cell lysates were subjected to affinity purification with 60 μl streptavidin-conjugated magnetic 
beads for 30 min at 4°C. Lysates equivalent to 2.5 million cells from before (Pre-AP) and after 
(Post-AP) bead purification and 1
5
 of each control and p110δ affinity purification (AP) were 
separated by SDS-PAGE in parallel. Immunoblots were probed for phosphorylated tyrosine 








This work has demonstrated that the AviTag system is a valuable tool for the study of 
endogenous PI3K in primary lymphocytes. The isoforms p110δ and p110α could be purified 
efficiently and specifically from both naïve and blasted primary T cells that expressed AviTagged 
proteins and the biotin ligase BirA. The advantages of this approach for the investigation of PI3K 
protein-protein interaction are numerous. Firstly, the tagged isoforms were shown to be 
expressed at endogenous levels. Alternative systems that stably or transiently express tagged 
proteins often result in overexpression at non-physiological levels. This would likely lead to 
artefacts in interatomic studies, as the tagged proteins may associate with proteins that they do 
not normally bind (Aebersold & Mann, 2003). Conversely, lower than physiological expression 
levels may have the opposite effect. Secondly, AviTagged p110δ and p110α are expressed in 
primary cells, thus allowing their study in a physiological environment where protein 
localisation, post-translational modification and signalling-induced interactions should closely 
reflect those in the in vivo situation. This would not be possible using cell lines expressing tagged 
p110δ. For example, immortalised Jurkat T cells, which are commonly used in proteomics 
studies to investigate TCR signalling (Nguyen et al, 2009; Cao et al, 2012; Salek et al, 2013; Helou 
& Salomon, 2015), lack expression of the lipid phosphatases PTEN and SHIP1 that regulate PI3K 
signalling by dephosphorylating PIP3 (Gioia et al, 2018). The use of primary T lymphocytes to 
study PI3K is therefore a better model of the physiological situation, as all endogenously 
expressed proteins should be present. 
Consequently, the AviTag system offers a unique approach to isolate and identify physiologically 
relevant, TCR-induced protein-protein interactions involving PI3K. However, the potential of this 
system can only be realised if such interactions are captured and preserved, in sufficient 
abundance, upon purification of p110δ. Activated and expanded T blasts were therefore used to 
increase the quantity of protein subjected to affinity purification, as in previous studies 
(Roncagalli at al, 2014; Voisinne et al, 2016). This had two purposes; to compensate for the loss 
of protein during washing, and to increase the probability that low abundance interactors would 
be detected in downstream MS analyses.  
It was of equal importance to maintain transient phosphorylation-dependent associations with 
p110δ during purification. Thus, further optimisation of the technique implemented short bead 
incubations with extensive inhibition of protein phosphatases. The conditions for TCR 
stimulation itself were also optimised to induce robust tyrosine phosphorylation in CD4+ T 
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blasts. This process revealed that CD3 plus CD4 crosslinking induced high levels of protein 
tyrosine phosphorylation in CD4+ T blasts, independently of CD28 crosslinking. This was not 
surprising, considering that CD4 has been shown to facilitate the rapid recruitment of the 
protein tyrosine kinase LCK to the TCR signalosome and subsequent LCK autophosphorylation, 
whereas CD28 is only thought to sustain LCK autophosphorylation (Holdorf et al, 2002; Dobbins 
et al, 2016). LCK is then able to phosphorylate immunoreceptor tyrosine-based activation motifs 
(ITAMs) within the TCR-CD3 complex, which subsequently recruit the cytosolic protein tyrosine 
kinase ZAP-70 (Wang et al, 2010). ZAP-70 in turn phosphorylates proteins including LAT and SLP-
76. Thus, CD4 recruitment of LCK amplifies the TCR-induced protein tyrosine phosphorylation-
mediated signalling cascade. This was evident in immunoblotting experiments of CD4+ T blast 
lysates following CD3 plus CD4 crosslinking. The T cell stimulation strategy used in this study was 
therefore an appropriate in vitro model of peptide-bound MHC class II engagement of both the 
TCR and CD4 co-receptor. Inducing robust protein tyrosine phosphorylation in this manner 
would be expected to increase the number of signalling events at activated TCR signalosomes, 
and thus lead to robust recruitment and activation of PI3K. The interaction partners involved in 
PI3K regulation could then be captured by p110δ affinity purification.   
When optimising the AviTag-AP protocol for downstream MS analysis, a balance had to be 
found between maintaining p110δ interactions with low affinity or transient binding partners 
and reducing non-specifically interacting proteins. It is widely accepted that affinity purifications 
of protein complexes also contain a vast number of non-relevant background proteins (Yang et 
al, 2008). Thus, modifications were made in an effort to reduce this. For example, implementing 
strict wash steps and a shorter bead incubation. Nevertheless, the one-step nature of the 
AviTag-AP technique, and the fact that proteins were crudely eluted from magnetic beads by 
boiling, meant that a high background was inevitable. However, given that the aim of this study 
was to discover p110δ interaction partners, it was preferable to retain a high background than 
to lose relevant interactions by using excessively stringent purification techniques. This view was 
supported by the increased tolerance for background contaminants afforded by modern MS 
analyses of affinity purifications; considerable advances in quantitative MS approaches, 
combined with improved statistical analyses, have allowed biologically relevant interactors to be 
distinguished from irrelevant background contaminants, and have thus reduced the number of 
false positives (Ong et al, 2005; Dunham et al, 2012; Li et al, 2012; Morris et al, 2014).  
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The AviTag system is highly suited for this differential MS approach, as two affinity purifications 
can be performed: one from p110δAvi/AviBirA+/- lysates containing the tagged bait protein p110δ, 
and one using lysates from cells expressing BirA. It is expected that non-specific proteins 
interacting with the magnetic beads, or endogenously biotinylated proteins captured by 
streptavidin, would appear at a 1:1 ratio in each AP, whereas specific interactors would be 
enriched in bait purifications (Blagoev et al, 2003). This would then enable the differentiation of 
p110δ-associated proteins. Indeed, in the experiments presented herein, tyrosine-
phosphorylated proteins were specifically co-purified with p110δ but were not detected in 
control affinity purifications from BirA+/- cells. Given that these proteins were detectable by 
immunoblotting, it was expected that they could be identified by LC-MS/MS analysis. Thus, 
subsequent experiments planned to analyse affinity purifications from p110δAvi/AviBirA+/- and 
BirA+/- CD4+ T blasts by LC-MS/MS analysis, with the aim to identify p110δ interaction partners 







Chapter 3        
 
Proteomic analysis of p110δ interactors 
downstream of TCR engagement in 
primary murine CD4+ T lymphocytes 
 
3.1 Introduction  
Earlier work extensively optimised the AviTag-affinity purification technique for the isolation of 
endogenous p110δ complexes from primary activated CD4+ T lymphocytes. This presented a 
unique approach to study proteins that specifically associate with p110δ in a physiological 
context. Moreover, it could be used to compare purified p110δ signalling complexes prior to 
and following TCR stimulation, thus allowing the identification of proteins that may regulate 
PI3K localisation and activity upon receptor engagement. The composition of such protein 
complexes can be determined though the coupling of affinity purification with mass 
spectrometry (Gingras et al, 2007; Yang et al, 2008).  
Modern MS platforms are increasingly sensitive in characterising complex protein mixtures, 
such as those isolated by affinity purification (Morris et al, 2014). They therefore represent a 
powerful tool for identifying proteins that may be present in low abundance, either due to their 
expression level or due to the transient nature of their interaction with the bait. These types of 
interaction, possibly dependent on tyrosine phosphorylation events, are likely to be present in 
p110δ complexes. However, the high sensitivity of MS analysis means that non-specifically 
interacting proteins within p110δ purifications will also be detected. These irrelevant, 
background contaminants could obscure the identification of true interactions. One way to 
reduce this risk is to use stringent purification protocols. For example, the strict wash steps and 
short bead incubation times implemented in the current study. Unfortunately, increasing wash 
steps may exclude interactions that are transient, low affinity, or that occur with low abundance 
proteins. The AviTag-AP system is advantageous in this respect, as the single-step purification 
with magnetic beads minimises the amount of protein lost, and also increases the speed of 
purification so that transient interactions are more likely to be captured (Kean et al, 2012). 
Nevertheless, this increases the recovery of both specific and non-specific proteins (Chen & 
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Gingras, 2007). Therefore, even with a highly optimised AviTag affinity purification protocol, the 
sensitivity of downstream MS analysis necessitated a method to differentiate true p110δ 
protein interactions from non-specific background. This validation required two components: a 
reliable method to quantitate proteins, and a statistical analysis.  
The current study therefore used a quantitative proteomics approach to analyse affinity-purified 
p110δ signalling complexes. The most widely used quantitative MS technologies are label-based 
(Ong & Mann, 2005). Isobaric labelling of peptide samples with tandem mass tags (TMTs) is one 
such technique, allowing multiple protein samples to be chemically labelled in parallel and then 
combined for LC-MS/MS analysis (Thompson et al, 2003). Isobaric TMTs are isotopic variants 
that generate reporter ions of different masses only upon fragmentation during tandem MS. 
The detected intensity of these distinct reporter ions allows accurate quantification of the 
relative abundance of any identified peptide in each original sample (Rauniyar & Yates, 2014). 
The advantage of TMT-based labelling is that up to ten samples can be analysed simultaneously 
using ten isobaric tag variants. This facilitates the analysis of biological replicates in one MS 
analysis, therefore providing greater statistical validation by removing inter-run variability. 
Furthermore, by combining identical peptides from multiple samples, the sensitivity of 
detection is improved for low abundance proteins (Li et al, 2012).  
For its recognised advantages, the TMT isobaric labelling strategy was chosen for the 
quantitative MS analysis of p110δ affinity purification samples. Following TMT-based 
quantification, the relative abundance of identified proteins could be compared in bait-specific 
and control purifications and their enrichment determined using statistical analyses. As 
described previously, the AviTag system enables purifications from BirA+/- cell lysates to be used 
as background controls to exclude irrelevant proteins that are biotinylated or bind non-
specifically to the magnetic beads. Following this approach, AviTag-AP coupled with quantitative 
TMT-based MS analysis was used to identify p110δ interaction partners in TCR-stimulated and 
unstimulated primary mouse CD4+ T blasts.  
 
3.2 Results 
3.2.1 MS identification of a tyrosine-phosphorylated protein associated with 
p110δ in a TCR stimulation-dependent manner 
Earlier experiments detected a prominently tyrosine-phosphorylated protein of 115 kDa that 
appeared to associate with p110δ upon TCR-stimulation. Before conducting a high-throughput 
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quantitative MS analysis of p110δ affinity purifications, a small-scale mass spectrometry 
approach was used to investigate the identity of this protein.  
Using the optimised AviTag affinity purification (AP) protocol, p110δ was isolated from the cell 
lysates of unstimulated and TCR-stimulated p110δAvi/AviBirA+/- CD4+ T blasts. A control 
purification was also performed on lysates from TCR-stimulated BirA+/- CD4+ T blasts. For each 
purification, the same number of cells were lysed and thus the same amount of total protein 
was subjected to streptavidin-mediated purification, as confirmed by measuring the protein 
concentration of the lysates. A proportion of the bead eluates from each AP was first analysed 
by immunoblotting, alongside the corresponding cell lysates, to confirm both successful TCR-
stimulation and co-purification of tyrosine-phosphorylated proteins (Figure 3.1). As observed 
previously, a tyrosine-phosphorylated protein of 115 kDa was detected only in the TCR-
stimulated p110δ AP. Subsequently, the remaining bead eluates were separated by SDS-PAGE. 
The region corresponding to 110 - 120 kDa was isolated from the polyacrylamide gel for each 
p110δ and control AP, and proteins that migrated within this molecular weight range were then 




Figure 3.1 Identifying a tyrosine-phosphorylated p110δ-associated protein of 115 kDa. 
Immunoblot analysis of cell lysates and affinity purifications from p110δAvi/AviBirA+/- (p110δAvi/Avi) 
and BirA+/- (control) CD4+ T blasts. One-hundred million CD4+ T blasts per condition were 
stimulated with 4 μg/ml CD3+CD4 for 1 minute (+), or left unstimulated (-), and cell lysates 
were subjected to affinity purification using streptavidin-conjugated magnetic beads. Lysates 
equivalent to 2.16 million cells from before (pre) and after (post) bead purification were separated 
by SDS-PAGE, alongside 𝟐
𝟕
 of each control (Ctrl) and p110δ affinity purification (AP). Immunoblots 
were probed for phosphorylated tyrosine residues (pTyr). In parallel, the remainder of the same 
AP samples were separated by SDS-PAGE, and the region 110 - 120 kDa for each AP lane (indicated 
with red brackets on the immunoblot) was excised from the polyacrylamide gel and subjected to 
LC-MS/MS analysis.  
 
A total of 241 high-confidence proteins were identified across all three samples. The fold 
enrichment for each protein was calculated as the ratio of its abundance in the stimulated 
p110δ AP to the stimulated control AP. The proteins were then ranked by their fold enrichment 
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in the stimulated p110δ purification. Only 26 proteins exhibited a 1.5-fold or greater enrichment 
in the p110δ purification or were absent in the control purification (Table 3.1). p110δ was the 
most abundant of these proteins and was not detected in the control purification. The PI3K 
regulatory subunit p85α was also identified in the stimulated and unstimulated p110δ 
purifications, at a higher abundance than in the control purification. It was noted that both PI3K 
subunits were detected with a higher abundance in the unstimulated p110δ purification than in 
the stimulated sample. Given that the total amount of protein subjected to streptavidin-
mediated purification was the same for both, this could reflect a difference in the amount of 
PI3K protein that was recovered by the SDS-PAGE ‘gel slice’ strategy. Indeed, the small region 
analysed was cut along the 120 kDa band of p110δ protein, which was visible following 
Coomassie staining, and thus a difference in the slice area would affect the amount of p110δ 
recovered. Nevertheless, this analysis was most interested in proteins identified in the 
stimulated p110δ purification and not in the stimulated control purification. Thus, it was 
intriguing that one such protein had functional relevance to PI3K signalling: B-cell adaptor for 
phosphoinositide 3-kinase, BCAP. BCAP was identified from two unique peptides that were 
detected only in the TCR-stimulated p110δ affinity purification. The failure to detect BCAP in the 
unstimulated and control purification did not necessarily indicate that it was absent, as it may 
have been below the threshold of detection. Nevertheless, this qualitative MS analysis 
suggested that BCAP associated with p110δ in a TCR stimulation-dependent manner. The 
remaining p110δ-enriched proteins were determined to be non-relevant contaminants, based 
on their Gene Ontology (GO) annotation for molecular function and cellular component, as well 




Table 3.1 Proteins identified by LC-MS/MS as enriched by p110δ affinity purification from 
CD4+ T cells.  
Affinity purifications (AP) as described in Figure 3.1 were separated by SDS-PAGE and proteins 
that migrated in the region 110 - 120 kDa were extracted from the polyacrylamide gel and 
analysed by LC-MS/MS. For proteins identified with high-confidence, quantified protein 
abundance values were calculated within Proteome Discoverer 1.4 using the average of the peak 
areas for the three most abundant peptides per protein. The fold enrichment for each protein 
was calculated as the ratio of its abundance in the stimulated p110δ AP to the stimulated control 
AP. Identified proteins with a 1.5-fold or greater enrichment in stimulated p110δ purifications 
compared with control purifications, or those that were absent in the control purification but 





BCAP is an adaptor protein expressed as two isoforms with observed molecular weights of 70 – 
100 kDa (Okada et al, 2000). BCAP has been shown to associate with PI3K in mouse splenic B 
cells upon BCR crosslinking. Moreover, BCAP is tyrosine phosphorylated in B cells upon BCR 
activation, and associates with p85 in a BCR stimulation-dependent manner (Okada et al, 2000). 
It was therefore possible that BCAP was the tyrosine-phosphorylated protein of 115 kDa that 
associated with p110δ in a TCR stimulation-dependent manner.  
 
3.2.2 A quantitative AP-MS approach to identify p110δ-specific interactors in 
CD4+ T blasts 
The main aim of the present study was to identify proteins that interact with p110δ upon TCR 
engagement in primary CD4+ T cells using AviTag-affinity purification in combination with 
quantitative mass spectrometry (AP-MS). To this end, using the earlier optimised protocol, 
p110δAvi/AviBirA+/- CD4+ T blasts were stimulated by CD3 and CD4 crosslinking for 1 minute and 
lysed. Endogenous p110δ protein was then purified from cell lysates using streptavidin-
conjugated magnetic beads. To be able to distinguish p110δ-specific interactors from non-
specific background contaminants in downstream analysis, control purifications were also 
performed on lysates of stimulated BirA+/- CD4+ T blasts. For each purification, the same number 
of cells were used, resulting in the same amount of total protein subjected to streptavidin-
mediated purification, as confirmed by measuring the protein concentration of the lysates. 
Three biologically independent experiments were carried out, and the quality and 
reproducibility of TCR stimulation across all three was assessed by immunoblotting (Figure 3.2). 
As seen previously, TCR-stimulation via CD3 and CD4 crosslinking induced strong and consistent 
tyrosine phosphorylation in all experiments. Furthermore, multiple tyrosine-phosphorylated 
proteins were isolated with p110δ from stimulated cells, with few visible in corresponding 
unstimulated samples. In contrast, tyrosine-phosphorylated proteins could not be detected by 




Figure 3.2 p110δ and control affinity purifications from CD4+ T blasts for TMT labelling-
based MS analysis.  
Immunoblot analysis of cell lysates and affinity purifications (AP) from CD4+ T blasts. One-hundred 
million p110δAvi/AviBirA+/- (δAvi/Avi) or BirA+/- (Ctrl) CD4 + T blasts were stimulated for each AP with 4 
μg/ml CD3+CD4 for 1 minute (+), or left unstimulated (-), and their cell lysates were subjected 
to affinity purification using streptavidin-conjugated magnetic beads. Lysates (equivalent to 2.16 




 of each affinity purification and immunoblotted for phosphorylated tyrosine residues 
(pTyr). Blots shown are from three independent experiments (labelled Expt 1, 2 and 3).  
 
Ten affinity purification samples from the three independent experiments, representing 
unstimulated and stimulated control and p110δ purifications, were then digested and the 
peptide samples were labelled in parallel with one of ten isobaric Tandem Mass Tags (TMT) 
(Figure 3.3). Unfortunately, one unstimulated p110δ AP sample from experiment 1 was voided 
due to a faulty TMT reagent. The remaining nine labelled peptide samples were combined and 




Figure 3.3 p110δ and control affinity purification samples analysed by TMT-labelling based 
LC-MS/MS. 
Ten streptavidin-mediated affinity purifications (AP) from unstimulated and stimulated 
p110δAvi/AviBirA+/- (p110δ) or BirA+/- (control) CD4 + T blasts were denatured, reduced, alkylated 
and digested to generate peptide samples. The ten peptide samples were then labelled in parallel 
with one of ten isobaric tandem mass tags (10plex TMTs) and combined for LC-MS/MS analysis. 
*One sample (number 5) was not analysed due to a faulty TMT label. 
 
 
3.2.3 Proteins specifically associated with p110δ in CD4+ T blasts 
LC-MS/MS analysis identified 3,473 proteins with high confidence in the nine affinity purification 
samples, which were quantified and normalised in each sample based on their associated 
reporter ion intensities. To determine whether an identified protein was specifically associated 
with p110δ, or whether it was a background contaminant, the log2-transformed abundance for 
each protein was compared in stimulated p110δ purifications and stimulated control 
purifications, using the Perseus computational platform (Tyanova et al, 2016; Tyanova & Cox, 
2018). The mean log2-fold change calculated for each protein was used to select those with a 
mean 1.5-fold or greater enrichment in stimulated p110δ purifications (Table 3.2). A statistical 
analysis was also performed for all proteins to determine those that were significantly 
differentially abundant in p110δ and control purifications, using a two-tailed Student’s t-test 
that was corrected for multiple hypothesis testing using a permutation-based false discovery 
rate (FDR) threshold. The FDR threshold chosen defines the maximum acceptable proportion of 
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expected false positives among the set of proteins that are determined to be significantly 
differentially abundant (Burger, 2018). With a stringent FDR threshold of 0.05, 53 of 3,473 
tested proteins were deemed to be significantly differentially abundant, whereas 175 proteins 
were significantly differentially abundant with an FDR of ≤0.20. The conservative FDR threshold 
was therefore chosen to consider a higher number of potential true interactors, with the 
acknowledged risk of selecting potential false positives (Giai Gianetto et al, 2014). Combining 
this differential analysis with a fold change threshold of 1.5 revealed 30 proteins that were 
significantly enriched in p110δ purifications as compared to controls (FDR≤0.20; Table 3.2). 
Seven proteins were enriched more than 1.5-fold but did not reach significance with an FDR less 
than or equal to 0.20.  
A bioinformatic analysis was subsequently performed using Gene Ontology (GO) annotation to 
determine the main molecular and biological functions of the identified p110δ-associated 
proteins (Table 3.2). Based on this analysis, five additional MS identified proteins with an 
enrichment of between 1.25- and 1.44-fold were selected for further consideration. These were 
the TCR co-receptors CD4 and CD28, the TCR complex CD3γ chain, and two signalling adaptor 
proteins, CRK and NCK1. CRK and NCK1 were selected as proteins of interest as they are both 
recruited to the TCR signalosome upon TCR stimulation (Gil et al, 2002; Dong et al, 2017). 






Table 3.2 Proteins identified by LC-MS/MS as specifically associated with p110δ in CD4+ T 
blasts. 
Proteins identified by LC-MS/MS as enriched in p110δ affinity purifications. Quantified and 
normalised protein abundance values were analysed using Perseus. Values were log2-transformed 
and the mean abundance in stimulated p110δ purifications was compared with the mean 
abundance in stimulated control purifications from 3 independent experiments. Statistical 
significance for the difference of the means for all identified proteins was determined using a two-
tailed Student’s t-test and corrected for multiple testing using a permutation-based false 
discovery rate (FDR) with a threshold of 0.05 in the first instance, and 0.20 in a second test. 
Proteins with a mean fold enrichment of 1.5 or greater in p110δ purifications were selected. Five 
proteins enriched less than 1.5-fold with a known role in TCR signal transduction were also 
selected, as shown below the broken line in the table. 
Significantly differentially abundant proteins are indicated with a black + (FDR≤0.05) or red + 
(FDR≤0.20). Molecular and biological functions for each protein were determined based on their 
Gene Ontology (GO) annotations. 
 
All 3,473 identified proteins were then plotted as a volcano scatter plot to allow visualisation of 
their differential abundance and associated statistical significance. The 31 significantly enriched 
p110δ-associated proteins appeared as clear outliers in the upper right quadrant of the plot 
(Figure 3.4; red scatter points). The validity of the analysis performed, and the specificity of the 
affinity purifications, was confirmed by the significant enrichment of p110δ, p85α and p85β in 
p110δ purifications. These PI3K subunits exhibited a high mean fold enrichment of 6.80, 8.16 




Figure 3.4 Proteins specifically associated with p110δ in CD4+ T blasts. 
Volcano plot of proteins identified by LC-MS/MS in p110δ and control affinity purifications. 
Quantified and normalised protein abundance values were analysed using Perseus. Values were 
log2-transformed and the mean abundance in stimulated p110δ purifications was compared with 
the mean abundance in stimulated control purifications from 3 independent experiments. 
Statistical significance for the difference of the means for each protein was determined using a 
two-tailed Student’s t-test and corrected for multiple testing using a permutation-based false 
discovery rate (FDR) with a threshold of 0.20. The –log10 p value for each protein was plotted 
against its mean log2(fold change) in p110δ purifications compared with control purifications (Log2 
(p110δ/Control)). Significantly differentially abundant proteins are labelled and highlighted in red 
(FDR≤0.20) on the scatter plot. Proteins enriched greater than 1.5-fold but not reaching 
significance with an FDR≤0.20 are labelled and highlighted in blue. Proteins of interest with an 
enrichment of 1.25-1.44-fold are labelled in black. The vertical dotted line indicates a mean 1.5-
fold enrichment in the stimulated p110δ purifications. Proteins TOMM20, FSD1L, SOD2 and LARS2 
are labeled with an asterisk (*), dagger (†), double dagger (‡) and section (§), respectively, for 
clarity. 
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Combining the results of these analyses, it was remarkable that the majority of proteins 
significantly enriched with p110δ were involved in signal transduction, and specifically TCR 
signalling. Ten adaptor proteins were enriched (GAB2, GAB3, IRS2, BCAP, GRB2, CRKL, SH3KBP1, 
CD2AP, CRK, NCK1) along with five TCR co-receptor or co-stimulator membrane proteins (ICOS, 
CD5, CD4, CD3γ, CD28). In addition, two protein tyrosine phosphatases (SHP-2, STS-2) and an E3 
ubiquitin-protein ligase (CBL) were significantly enriched, representing proteins that 
downregulate the propagation of TCR-induced signals. Interestingly, many of these proteins 
have been shown to have the capacity to bind to p85, and could therefore be involved in the 
recruitment, localisation or activation of PI3K at the TCR signalosome.  
At this stage, removed from further analyses were proteins localised to the nucleus or 
mitochondria (BICRA, TOMM20, TFAP4, STAT1, SOD2, LARS2, SSBP4, MRPL44, TTF2, RUNX1) and 
those not known to be involved in signal transduction (NUDCD2, TMEM199, WASHC1, FSD1L, 
PLP2). Of the remaining 27 enriched proteins of interest, 21 were significantly differentially 
abundant with an expected FDR of 0.20 or less. The minimum expected FDR that could be 
attained when calling the other proteins significantly differentially abundant was 0.32 (BCAP), 
0.22 (GRK2), 0.43 (CD4), 0.27 (CD3γ), 0.24 (CRK), and 0.34 (CD28). These FDRs were close to the 
imposed FDR threshold of 0.20; while these proteins were therefore not classed as significant, 
their biological relevance justified their inclusion as proteins of interest. The abundance of all 27 
proteins of interest (including p110δ) was then compared in all nine unstimulated and 
stimulated affinity purifications to investigate the context of their association with p110δ upon 
TCR stimulation.   
 
3.2.4 Proteins specifically associated with p110δ in a TCR-stimulation 
dependent manner in CD4+ T blasts 
The relative abundance levels of p110δ-associated proteins of interest were subsequently 
analysed across all nine affinity purification samples. This was to determine if their association 
with p110δ was dependent on TCR stimulation, and to examine the variation between biological 
replicates. To this end, the quantified abundance of each protein in all nine affinity purifications 
was normalised using Z-score transformation. Hierarchical clustering was then performed to 
group proteins with similar patterns of abundance across the samples, and this analysis was 





Figure 3.5 Proteins specifically associated with p110δ in a TCR stimulation-dependent or 
stimulation-independent manner in CD4+ T blasts. 
Heat map with hierarchical clustering, visualising the relative abundance of p110δ-associated 
proteins in affinity purifications (APs) from unstimulated (Un) and TCR-stimulated (Stim) 
p110δAvi/AviBirA+/- (p110δ) and BirA+/- (control) CD4+ T blasts. Quantified abundance values for each 
protein were log2-transformed and normalised across all nine affinity purifications using Z-score 
transformation in Perseus. Hierarchical clustering was then performed using Euclidean distance 
and average linkage. Clustering is represented as a dendrogram. Z-scores are represented by a 
colour scale from black (low) to yellow (high).  
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Strikingly, hierarchical clustering revealed that there were two main groups of p110δ-enriched 
proteins - those that were associated with p110δ in a TCR stimulation-dependent manner, and 
those that appeared to be associated independently of stimulation. The p85α and p85β 
regulatory subunits were constitutively associated with p110δ, as expected. The proteins CRKL, 
AKT2, SH3KBP1 and NCK1 demonstrated a similar stimulation-independent pattern of 
abundance, indicating that they may also constitutively associate with p110δ. Nine enriched 
proteins (ISG15, IRS2, CD2AP, CRK, MALT1, IQGAP3, GRK2, CD3γ and JAML) exhibited noticeable 
variation in their relative abundance across both unstimulated and stimulated biological 
replicates of p110δ purifications. Nevertheless, among these proteins, MALT1 exhibited 
increased p110δ-association upon stimulation, whereas JAML, CRK, CD2AP, IRS2 and ISG15 were 
slightly more enriched in all unstimulated p110δ purifications compared to the corresponding 
stimulated p110δ purifications.  
In contrast, eleven proteins (BCAP, ICOS, GAB3, CD28, CD5, GRB2, STS-2, CBL, SHP-2, GAB2 and 
CD4) demonstrated distinct TCR-stimulation dependent association with p110δ. This was clear 
for SHP-2 and GAB2, which both showed a consistent level of abundance and enrichment in 
stimulated purifications. The relative abundance of the other eight stimulation-dependent 
interactors was more variable across the three stimulated p110δ purifications. BCAP, ICOS, 
GAB3 and CD28 were detected with highest abundance in experiment 1, whereas CD5, GRB2, 
STS-2 and CBL were more abundant in experiment 2. Nevertheless, this analysis revealed that 
these proteins interacted specifically with p110δ upon TCR-stimulation, with low relative 
abundance in unstimulated p110δ purifications equivalent to that detected in control samples. 
CD4, CD28, CRK and CD3γ were selected as proteins of interest based on their known functions, 
even though their enrichment in p110δ purifications was less than 1.5-fold, and this was not 
statistically significant. Their low enrichment in each p110δ purification, compared to its 
corresponding control, was evident by heatmap visualisation, as was the inconsistency of their 
enrichment. In experiment 1, CD4 was identified at a higher abundance in the control 
purification than its corresponding stimulated p110δ sample. Therefore, there was lower 
confidence associated with identifying these proteins as true interactors based on this MS data 
alone. However, their low enrichment may represent transient or low affinity binding to p110δ, 
or tertiary interaction via intermediate proteins. In contrast, the adaptor protein NCK1 was 
enriched by only 1.28-fold, yet the heatmap visualisation and statistical analysis revealed that 
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this enrichment was consistent and significant across all purifications. This justified the use of 
less stringent fold change and FDR thresholds to avoid excluding potential true interactors. 
 
3.3 Discussion 
This study aimed to identify p110δ interaction partners in CD4+ T blasts downstream of TCR 
engagement. Use of a quantitative AP-MS approach led to the identification of 24 proteins that 
specifically associated with endogenous p110δ and had biologically relevant functions. 
Moreover, eleven of the proteins associated with p110δ in a TCR stimulation-dependent 
manner, highlighting their involvement in TCR-PI3K signalling.  
Over 3,000 proteins were identified in total by LC-MS/MS in the affinity purifications that were 
analysed. This raises two important points. First, the use of TMT labelling and the consequent 
pooling of nine AP samples into one MS experiment enabled a much deeper analysis than that 
afforded by earlier label-free analyses. Secondly, the inclusion of control purifications and 
subsequent comparison of accurately quantified protein abundance between samples was 
clearly crucial to enable true interactors to be distinguished from the vast number of non-
specific background interactors. TMT labelling also provided a high level of confidence in the 
relative quantification of the identified proteins in each sample, since run-to-run variation was 
eliminated. It was clear in the heatmap analysis of relative protein abundance that, instead, 
biological variability was the main source of variation. Therefore, it proved advantageous that it 
had been possible to analyse three independent biological replicates using the 10-plex TMT 
approach. 
Differential abundance analysis was used to distinguish proteins that were significantly enriched 
in p110δ purifications. Firstly, proteins of interest were selected based on their fold enrichment. 
Secondly, the false discovery rate (FDR) threshold for determining significance was intentionally 
optimised to reduce the number of potentially true interactors rejected, while estimating the 
proportion of false positives that may be included, as recommended in the field of discovery 
proteomics (Giai Gianetto et al, 2016; Burger, 2018). This approach was justified in the current 
analysis, for example, by inclusion of the biologically relevant protein NCK1, which was not 
highly enriched, but was consistently found at a higher abundance in p110δ purifications and 
was therefore statistically significant. Using heatmapping to visualise relative abundance across 
the samples also proved valuable for examining potential interactors. For example, the 
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inconsistency in the enrichment of CD4 in p110δ purifications was clear by inspecting the 
heatmap. Furthermore, comparing the relative abundance of each protein across unstimulated 
and stimulated affinity purifications revealed the context of their association with p110δ. It is 
worth noting that, had an unstimulated p110δ AP sample not been voided during sample 
preparation, a statistical analysis could have been performed comparing stimulated p110δ 
purifications with unstimulated p110δ purifications. Nevertheless, meaningful insight was 
gained using heatmapping and hierarchical clustering. It was striking that 11 proteins were 
distinctly enriched in p110δ purifications from TCR-stimulated cells, compared with 
unstimulated cells. These proteins are of great interest, as they are most likely to be involved in 
the regulation of PI3K activity upon TCR engagement in CD4+ T blasts. Alternatively, they may be 
involved in the effector functions of PI3K following TCR activation.  
 
3.3.1 TCR stimulation-dependent p110δ-associated proteins 
BCAP was identified as a p110δ-specific interactor in CD4+ T blasts via two different MS 
approaches. First, using a small-scale MS analysis of proteins purified with p110δ that migrated 
by SDS-PAGE with an estimated molecular weight of 115 kDa. This qualitative MS analysis 
suggested that BCAP associated with p110δ in a TCR stimulation-dependent manner. Based on a 
previous study demonstrating that BCAP is tyrosine phosphorylated upon antigen receptor 
crosslinking in B cells (Okada et al, 2000), it seemed likely that BCAP may have been the 
prominent pTyr-staining protein of 115 kDa detected by immunoblotting in earlier AP 
experiments. This protein also associated specifically with p110δ only in TCR-stimulated CD4+ T 
blasts. Subsequently, BCAP was identified as a p110δ interactor using a quantitative MS analysis 
of three biologically independent AP experiments. BCAP was enriched greater than 2-fold in 
p110δ affinity purifications compared to control purifications. Strikingly, BCAP associated with 
p110δ in a TCR stimulation-dependent manner, with consistently low relative abundance in 
control and unstimulated p110δ purifications. Nevertheless, statistical analysis only deemed 
BCAP to be significantly differentially abundant with an FDR of 0.32. This could be explained by 
the fact that BCAP was highly enriched with p110δ in one experiment, but to a lesser extent in 
the other two replicates. Thus, taking into account its mean fold enrichment, stimulation-
dependent association, and identification by two different approaches, BCAP was considered 
likely to be a true p110δ interactor with biological relevance. This was supported by its known 
capacity to bind p85 (Okada et al, 2000). The variability in the detection of BCAP suggests that it 
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may interact with PI3K with low affinity or transiently. The most intriguing aspect of the 
identification of BCAP was that BCAP is believed to be predominantly expressed in B cells and 
macrophages, and not in T cells (Okada et al, 2000; Yamazaki et al, 2002). The expression and 
function of BCAP in activated T cells had not been studied. Therefore, BCAP was selected for 
subsequent biochemical analysis in CD4+ T blasts.  
Inducible T-cell costimulator (ICOS) demonstrated the same stimulation-dependent pattern of 
interaction with p110δ as BCAP, with a higher and statistically significant enrichment of 3.24-
fold in p110δ purifications. ICOS is a co-receptor that plays an important role in the positive 
regulation of CD4+ T cell activation and proliferation (Wikenheiser & Stumhofer, 2016). ICOS is 
not expressed on resting T cells but is rapidly induced following TCR crosslinking (Hutloff et al, 
1999). ICOS ligation alone or in combination with CD3 crosslinking potently stimulates PI3K-AKT 
signalling in activated CD4+ T cells (Arimura et al, 2002; Fos et al, 2008; Gigoux et al, 2009). This 
has been shown to be mediated by ICOS recruitment of the p85α regulatory subunits, via a 
YMFM motif in the ICOS cytoplasmic tail (Fos et al, 2008; Gigoux et al, 2009). Interestingly, ICOS 
appears to be responsible for the recruitment of the p50α regulatory subunit to the immune 
synapse in activated T cells, an isoform that is not recruited to the immune synapse in resting 
cells (Fos et al, 2008). In the present study, ICOS was identified as a p110δ-associated protein in 
CD4+ T blasts upon CD3+CD4 crosslinking alone, in the absence of professional antigen-
presenting cells that express its natural ligand ICOS-L. This is similar to a recently reported 
observation that p85α associates with ICOS in primary mouse CD4+ T cells upon CD3 crosslinking 
alone (Pedros et al, 2016). This raises the possibility that ICOS may act as an adaptor for PI3K 
recruitment to the TCR independently of ICOS engagement. This could be investigated by 
examining the induction of phosphorylated AKT in ICOS-deficient CD4+ T blasts upon CD3+CD4 
crosslinking. Therefore, subsequent experiments aimed to study PI3K-AKT signalling in ICOS-
deficient CD4+ T blasts. 
In addition to BCAP and ICOS, the proteins GRB2, GAB2, GAB3 and SHP-2 were identified as TCR 
stimulation-dependent p110δ-associated proteins, with a mean fold enrichment of 2.09, 5.11, 
4.31 and 3.12, respectively. GRB2 is a ubiquitously expressed adaptor protein, comprising an 
SH2 domain and two SH3 domains, that plays a central role in regulating signal transduction 
downstream of the TCR (Samelson, 2002). The GRB2 SH2 domain binds to phosphorylated YxNx 
motifs in the scaffolding protein LAT (Zhang et al, 2000), while the GRB2 SH3 domains recruit 
the RAS GEF SOS1 to the membrane (Houtman et al, 2006). Together, this is thought to facilitate 
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the formation of LAT microclusters upon TCR stimulation, which is required for subsequent 
PLCγ1 phosphorylation and cytokine production (Bilal & Houtman, 2015). Moreover, the GRB2 
SH3 domains have the capacity to bind to proline-rich regions in p85 (Wang et al, 1995; Weinger 
et al, 2008).  
GRB2 also recruits members of the Grb2-associated binding (Gab) family to the TCR signalosome 
(Yamasaki et al, 2003). Interestingly, two Gab-family proteins were identified in the current 
study as stimulation-dependent p110δ associated proteins; GAB2 and GAB3. These proteins act 
as scaffolds, containing multiple binding motifs and domains for the assembly of signalling 
complexes, including a PH domain that localises them to PIP3 in the membrane, and a proline-
rich domain that allows binding to GRB2 (Adams et al, 2012). GRB2 is thought to recruit GAB2 to 
LAT upon TCR ligation (Yamasaki et al, 2003). GAB2 is tyrosine phosphorylated by ZAP-70 and 
has been shown to associate with p85 and the SH2 domain-containing tyrosine phosphatase 
(SHP-2) in a TCR stimulation dependent manner in Jurkat T cells (Nishida et al, 1999). The 
interaction with p85 is most likely mediated via three YxxM motifs, which are present in both 
GAB2 and GAB3 (Sármay et al, 2006). Similarly, phosphorylated YxxL and YxxV motifs in GAB2 
and GAB3 engage tandem SH2 domains in SHP-2 (Gu et al, 1998), which activates the enzyme 
via conformational change (Barford & Neel, 1998). It is possible that SHP-2 dephosphorylates 
the p85 binding motif within GAB2 and GAB3; this mechanism has been observed in the case of 
GAB1 in epidermal growth factor (EGF)-stimulated mouse embryonic fibroblasts (Zhang et al, 
2002) and BCR-FcγRIIb co-stimulated B cells (Koncz et al, 2001). Thus, GAB2 and GAB3 could 
participate in both positive and negative feedback loops in T cells with respect to PI3K 
regulation: the former via recruitment of PI3K to the TCR signalosome, which could be sustained 
by further GAB accumulation at the membrane through binding to PIP3 via its PH domain; the 
latter by binding to SHP-2, which may induce release of PI3K from the complex to terminate 
PI3K signalling or prevent hyperactivation of the PI3K pathway. Interestingly, mature T cells 
from Gab2−/− mice exhibit slightly enhanced proliferation in response to TCR stimulation 
(Yamasaki et al, 2003), suggesting that an inhibitory role for GAB2 dominates in T cells, perhaps 
through recruitment of SHP-2 to the TCR signalosome. Taken as a whole, it is intriguing that 
GRB2, GAB2, GAB3 and SHP-2 were all identified in the present study as TCR stimulation-
dependent p110δ interactors. It is therefore possible that these proteins were isolated as a 
single complex with p110δ. Indeed, GAB2 and SHP-2 demonstrated a highly similar pattern of 
abundance across p110δ affinity purifications.  
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It was interesting that several proteins identified as p110δ stimulation-dependent interactors 
have known roles in the negative regulation of TCR signalling. Specifically, CBL, STS-2 and CD5. 
These proteins were identified in p110δ purifications with a mean enrichment of 2.47, 2.54 and 
1.93-fold, respectively.  
The E3 ubiquitin-protein ligase CBL (c-CBL) is an important negative regulator of TCR signalling in 
thymocytes, involved in downmodulation of the TCR upon receptor engagement (Naramura et 
al, 1998, 2002). This is thought to be mediated via CBL-promoted ubiquitination of the CD3ζ 
chain, with ZAP-70 acting as an adaptor in this process to form a CD3ζ:ZAP-70:CBL complex 
(Wang et al, 2001). In addition, CBL has been shown to associate with LCK and target its 
ubiquitination and degradation upon CD3+CD4 stimulation in a human CD4+ T cell line (Rao et 
al, 2002). However, CBL-deficient mature CD4+ T cells exhibit reduced proliferation and ERK 
activation in response to anti-CD3 stimulation (Naramura et al, 2002). Interestingly, CBL is 
able to bind to the PI3K p85 SH2 domain via a YxxM motif that is phosphorylated by Src-
family kinases (Hunter et al, 1999). This interaction leads to the ubiquitination of p85 in some 
cell types (Dufour et al, 2008; Bulut et al, 2013), but the mechanism of CBL-mediated PI3K 
regulation in primary mature T cells is unclear. It has been suggested that, aside from its E3 
ubiquitin-protein ligase activity, CBL may act as a multivalent adaptor, given that it also 
comprises a proline-rich region, an SH2-containing tyrosine kinase binding (TKB) domain, and 
several phosphorylated tyrosine residues (Lee & Tsygankov, 2013). Thus, CBL could bind to 
several proteins at the plasma membrane, including PI3K via its phosphorylated YxxM motif. 
CBL demonstrated the same pattern of interaction with p110δ across stimulated affinity 
purifications as the proteins STS-2, CD5 and GRB2. This is particularly interesting as all three 
proteins can bind directly to CBL; GRB2 can interact via its SH3 and SH2 domains with CBL upon 
TCR crosslinking, and this is thought to form a distinct complex to the GRB2:SOS1 complex 
(Meisner et al, 1995). STS-2 (suppressor of TCR signalling 2; UBASH3A) contains a ubiquitin 
binding UBA domain and an SH3 domain, which facilitates binding to the proline-rich region of 
CBL (Feshchenko et al, 2004). STS-2 is a protein tyrosine phosphatase involved in the 
downregulation of TCR signalling, which is thought to be mediated via its dephosphorylation of 
ZAP-70 (Carpino et al, 2004; San Luis et al, 2011). Interestingly, STS-2 has been shown to form a 
complex with ZAP-70 and the E3 ubiquitin ligase NRDP1 in primary CD8+ T cells (Yang et al, 
2015). It is thought that polyubiquitination of ZAP-70 by NRDP1 leads to its interaction with and 
dephosphorylation by STS-2, or the related protein STS-1. This is an interesting example of dual 
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E3 ubiquitin ligase-phosphatase-mediated termination of TCR signalling. The identification of 
STS-2 and CBL in the present AP-MS study suggests that p110δ may interact with an STS-2:CBL 
complex at the early stages of TCR stimulation.  
The transmembrane co-receptor CD5 also plays a role in attenuating antigen-induced TCR 
signalling (Lozano et al, 2000). The CD5 cytoplasmic domain is rapidly tyrosine phosphorylated 
upon TCR stimulation and this leads to the recruitment of proteins that exert a negative 
regulatory function, including the tyrosine phosphatase SHP-1, which dephosphorylates ZAP-70 
(Plas et al, 1996). LCK also binds to CD5 upon CD5 ligation in Jurkat T cells and phosphorylates 
the Src-family kinase FYN at an inhibitory tyrosine, which decreases FYN activity and 
consequently leads to a reduction in ZAP-70 phosphorylation (Bamberger et al, 2011). However, 
none of the phosphotyrosines in CD5 are located within YxxM motifs. Nevertheless, p85α has 
been shown to associate with CD5 via non-canonical motifs in vitro, although this has only been 
confirmed by immunoprecipitation in pervanadate-stimulated thymocytes (Dennehy et al, 
1997). Interestingly, CD5 interacts directly with CBL (Dennehy et al 1998; Demydenko, 2010). 
Moreover, a recent study found that CBL associates with CD5 upon CD3+CD4 crosslinking in 
primary murine activated CD4+ T cells (Voisinne et al, 2016). Additionally, in CD5-/- T cells, 
drastically fewer ubiquitinated proteins were found to be associated with CBL upon TCR 
stimulation. Thus, it has been suggested that CD5 recruits CBL to the plasma membrane upon 
TCR stimulation, where it mediates ubiquitination of substrates. Given that the present study 
identified both CD5 and CBL as p110δ interactors under similar physiological conditions as those 
used by Voisinne et al, it is not unreasonable to speculate that p110δ associates indirectly with 
CD5 via CBL.  
The aforementioned study used an AP-MS approach to investigate the CBL signalosome after 
TCR stimulation of primary murine activated CD4+ T cells (Voisinne et al, 2016). Intriguingly, 
among the proteins selected as specific CBL-interactors were p110δ, p85α, p85β, STS-2, CD5, 
GRB2, CRK, CRKL, CD2AP and SH3KBP1. These proteins were also identified in the current study 
as p110δ interactors. This shared interactome suggests that p110δ and CBL form a stable 
complex upon TCR stimulation. It also indicates that these proteins could associate directly or 
indirectly with either p110δ or CBL. In the current study, CRK, CRKL, CD2AP and SH3KBP1 
associated constitutively with p110δ, whereas CBL was clearly associated with p110δ in a TCR-
stimulation dependent manner. Thus, is it likely that CRK, CRKL, CD2AP and SH3KBP1 interact 
directly with p110δ. In contrast, STS-2 and CD5, which lack obvious p85-binding motifs, 
65 
 
associated with p110δ in a TCR stimulation-dependent manner and with a similar fold 
enrichment and pattern of abundance to CBL. Therefore, it is possible that STS-2 and CD5 were 
isolated via CBL. Ultimately, it appears that p110δ forms a complex with CBL, STS-2 and CD5 
upon TCR stimulation in activated CD4+ T cells. 
The co-receptors CD4 and CD28 were also isolated with p110δ in a TCR-stimulation dependent 
manner. It was observed, however, that their enrichment in p110δ purifications compared with 
control purifications was low and inconsistent. One explanation for this is that they may interact 
with p110δ transiently, with low affinity, or indirectly. In support of the latter, a direct 
interaction between CD4 and PI3K has not been reported, and the CD4 cytoplasmic tail lacks 
p85-specific YxxM motifs (Wittlich et al, 2007). In contrast, CD28 is a well-characterised p85 
interactor, with a YxxM motif that is tyrosine phosphorylated by Src-family kinases upon TCR 
engagement (Rudd & Schneider, 2003). However, it is interesting that an association of p110δ 
with CD28 occurred upon CD3+CD4 crosslinking alone, in the absence of CD28 co-stimulation or 
APCs expressing the CD28 ligands B7-1/B7-2. Only low levels of p85 association with CD28 are 
induced upon CD3 crosslinking alone (Alcázar et al, 2009). It is possible that crosslinking of both 
CD3 and CD4 at the cell surface brings CD28 into proximity with the TCR signalosome, facilitating 
CD28 tyrosine phosphorylation by LCK and subsequent p85:p110δ recruitment. Surprisingly, and 
in contrast to the co-receptors CD4 and CD28, the CD3γ chain was enriched in p110δ 
purifications independently of TCR stimulation. Albeit, as observed for CD4 and CD28, this 
enrichment was inconsistent across samples. Since CD3γ does not possess p85-binding motifs, it 
could be that CD3γ was isolated indirectly with another p110δ associated protein. Nevertheless, 
a proportion of p110δ may reside in proximity to the CD3 complex in resting CD4+ T blasts. 
 
3.3.2 TCR stimulation-independent p110δ-associated proteins 
As previously mentioned, CRK, CRKL, CD2AP and SH3KBP1 were found to be associated with 
p110δ independently of TCR stimulation and can also interact with CBL. Intriguingly, the Crk-
family members CRK and CRKL are thought to stabilise the binding of p85 to CBL (Gelkop et al, 
2001). Upon TCR stimulation, the CRK SH2 domain recognises phosphorylated YxxP motifs in CBL 
(Reedquist et al, 1996). In addition, the N-terminal SH3 domain of CRK is able to interact with 
proline-rich regions of p85, which has been proposed to stabilise the interaction of p85 with the 
same CBL molecule (Gelkop et al, 2001). It has also been demonstrated in Jurkat T cells that CRK 
and CRKL rapidly associate with the phosphorylated CD3ζ chain upon TCR crosslinking (Dong et 
66 
 
al, 2017). Interestingly, the adaptor GAB2, which was also identified in the present study by AP-
MS, contains multiple YxxP motifs that can bind to CRK, although GAB3 lacks such motifs 
(Sármay et al, 2006). Thus, the CRK SH2 domain can mediate interactions with CBL, CD3ζ and 
GAB2 upon their tyrosine phosphorylation. CRK and CRKL were found to be constitutively 
associated with p110δ. Therefore, the binding of CRK/CRKL to CBL, CD3ζ or GAB2 upon TCR 
stimulation may facilitate the recruitment of p110δ to the TCR signalosome.   
CD2-associated protein (CD2AP) and SH3-domain kinase binding protein 1 (SH3KBP1) are 
members of the CMS/CIN85 family of adaptor proteins, which interact with CBL via their SH3 
domains and are involved in the degradation of receptor tyrosine kinases via clathrin-mediated 
endocytosis (Dikic, 2002). CD2AP is required for the termination of TCR signalling and TCR 
downregulation (Lee et al, 2003). T cells from CD2AP-/- mice do not form an immune synapse 
upon peptide-MHC presentation by APCs and exhibit prolonged tyrosine-phosphorylation of 
ZAP-70 and CD3ζ. The CD2AP SH3 domains have been shown to interact with p85, but this 
association has not been demonstrated in T cells (Huber et al, 2003). In contrast, a proline-rich 
region in the rat homologue of SH3KBP1 has been shown to interact with the SH3 domain of p85 
(Gout et al, 2000). Interestingly, human SH3KBP1 can form complexes with CRK, CBL and p85 in 
resting and EGF-stimulated HEK293 cells (Watanabe et al, 2000). The MS identification of 
CD2AP, SH3KBP1, CRK and CRKL as constitutive p110δ interactors in the present study suggests 
that p110δ may be part of a pre-formed complex with these proteins in resting CD4+ T blasts. In 
support of this, CRKL and SH3KBP1 exhibited a highly similar pattern of abundance as p110δ 
across all p110δ affinity purifications that were analysed. This proposed pre-formed complex 
could be recruited to the plasma membrane via CBL upon TCR stimulation.  
Several other proteins were constitutively associated with p110δ in CD4+ T blasts. Of these 
proteins, NCK1 was considered of particular interest as it has been shown to interact with BCAP 
in B lymphocytes (Castello et al, 2013). NCK1 is one of two members in the Nck family of 
adaptor proteins, comprising one SH2 domain and three SH3 domains (Lettau et al, 2009). In T 
cells, NCK proteins are thought to be recruited to the TCR signalosome via two mechanisms. The 
first SH3 domain of NCK binds to a proline-rich region in the CD3ɛ chain that is exposed rapidly 
upon TCR antigen recognition, before tyrosine phosphorylation of the CD3ζ ITAMs (Gil et al, 
2002). NCK is also recruited through binding of its SH2 domain to phosphorylated tyrosines in 
the scaffolding protein SLP-76 (Koretzky et al, 2006). SLP-76-associated NCK is thought to 
regulate actin remodelling upon TCR stimulation though recruitment of Wiskott-Aldrich 
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syndrome protein (WASP) to the immune synapse (Zeng et al, 2003). However, NCK-deficient 
primary T cells exhibit normal TCR aggregation and internalization, which are dependent on 
actin remodelling. Interestingly, NCK-deficient T cells demonstrate greatly reduced TCR-induced 
proliferation (Roy et al, 2010). An association between NCK proteins and PI3K has not yet been 
demonstrated in T cells; NCK1 lacks YxxM motifs but could mediate interactions with the p85 
proline-rich regions via its SH3 domains.  
Nevertheless, in B cells, NCK is thought to facilitate the recruitment of PI3K to the BCR 
signalosome via BCAP (Castello et al, 2013). NCK interacts with the second proline-rich region of 
BCAP via its three SH3 domains and is required for BCAP localisation to the BCR signalosome. 
This is mediated via the interaction of NCK with the immunoglobulin-α tail (Castello et al, 2013). 
Given that BCAP interacts with PI3K in B cells (Okada et al, 2000), NCK may recruit PI3K to the 
BCR. In support of this, AKT and FOXO1 phosphorylation are reduced in NCK1-deficient B cells 
(Castello et al, 2013). In the proteomics study herein, NCK was found to be constitutively 
associated with p110δ in CD4+ T blasts, whereas the interaction of p110δ with BCAP was clearly 
TCR stimulation-dependent. It is possible that NCK facilitates the interaction between PI3K and 
BCAP upon TCR stimulation. Subsequently, NCK could recruit this complex to the TCR via binding 
to the CD3ɛ chain or SLP-76. This hypothesis requires biochemical examination of BCAP and NCK 
in CD4+ T blasts.  
Another protein of particular interest was insulin receptor substrate 2 (IRS2). IRS2 is a member 
of the IRS family of cytosolic scaffolding proteins and contains eight YxxM motifs (Sun et al, 
1995). In the canonical IRS activation pathway, IRS proteins undergo insulin-dependent tyrosine 
phosphorylation by the insulin receptor kinase (IRK) and subsequently associate with p85 via 
their YxxM motifs (Balbis et al, 2000). Nevertheless, IRS proteins also signal downstream of 
integrin, cytokine and growth hormone receptors (Waters & Pessin, 1996). In mature T cells, 
IRS2 has been shown to associate with p85 downstream of IL-4 receptor activation (Wurster et 
al, 2002). Identification of IRS2 in the present study suggests that the TCR signalosome recruits 
IRS2 as an adaptor molecule for PI3K. Interestingly, tyrosine phosphorylation sites in the IRS2 
homologue IRS1 can bind to GRB2, SHP2, NCK and CRK (Lee et al, 1993; Skolnik et al, 1993; 
Beitner-Johnson et al, 1996; Myers et al, 1998). It is therefore possible that IRS2 could act as a 
docking site for multiple p110δ-associated proteins that were identified in this study. 
Interestingly, IRS2 did not demonstrate TCR stimulation-dependent association with p110δ, 
suggesting that they could be constitutively associated in activated T cells. Further biochemical 
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analyses would be required to examine the tyrosine phosphorylation status of IRS2 in 
unstimulated T blasts, and to determine whether IRS2 forms TCR stimulation-dependent 
interactions with GRB2, SHP2, NCK or CRK.  
The transmembrane receptor JAML (junctional adhesion molecule-like) was also identified as a 
stimulation-independent p110δ interactor. JAML promotes the adhesion of leukocytes to 
endothelial cells via binding to the coxsackievirus and adenovirus receptor (CAR) (Luissint et al, 
2008). Intriguingly, JAML is upregulated on activated CD8+ T cells and has also been shown to act 
as a co-stimulatory receptor specifically in a subset of epithelial γδ T cells (Witherden et al, 
2010). In these cells, co-ligation of the TCR and JAML potentiates the proliferation and cytokine 
production induced by TCR stimulation alone (Witherden et al, 2010). Ligation of JAML alone 
also leads to the phosphorylation of AKT in this subset of T cells. This has been attributed to the 
interaction of p85 with JAML; CAR-mediated clustering of JAML on γδ T cells rapidly recruits 
PI3K to a YxxM motif in the JAML cytoplasmic tail (Verdino et al, 2010). PI3K was also found to 
be associated with JAML in resting cells, albeit at lower levels. In the present study, JAML was 
identified as a p110δ-associated protein in unstimulated and stimulated CD4+ T blasts. This 
raises the possibility that PI3K may be constitutively associated with JAML in activated CD4+ T 
cells, independently of TCR or JAML engagement. Thus, JAML may act as an adaptor for PI3K 
localisation at the plasma membrane in activated T cells. Furthermore, if an interaction with p85 
occurs via the YxxM motif of JAML, this would require basal tyrosine phosphorylation of JAML in 
resting cells. The phosphorylation status of JAML and interaction with PI3K in CD4+ T blasts 
warrants further biochemical analyses.  
Surprisingly, the PI3K effector AKT2 was also identified as associated with p110δ in both 
unstimulated and stimulated CD4+ T blasts. There are three mammalian AKT isoforms, AKT1, 
AKT2 and AKT3, which are highly homologous, and their functional redundancy appears to be 
tissue and context dependent (Vanhaesebroeck & Alessi, 2000; Manning & Toker, 2017). 
Nevertheless, all three isoforms are expressed in murine T cells (Juntilla et al, 2007). PI3K 
regulates AKT by producing the PIP3 required for its co-localisation with PDK1 and subsequent 
activation at the plasma membrane (Stokoe et al, 1997). Interestingly, AKT2 is also activated by 
PI(3,4)P2 located both in the plasma membrane and early endosomes (Liu et al, 2018). However, 
direct interaction between AKT and PI3K has not been reported. The TCR stimulation-
independent association of AKT2 and p110δ in CD4+ T blasts suggests that PI3K and AKT2 are co-
localised in activated T cells before and after TCR engagement.  
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Another serine/threonine kinase, GRK2, was associated with p110δ in unstimulated and 
stimulated CD4+ T blasts. GRK2 (β-adrenergic receptor kinase 1) is a ubiquitous member of the 
GPCR kinase (GRK) family, which, despite its name, phosphorylates a vast variety of receptors 
and cytosolic proteins (Penela et al, 2010). GRK2 contains a PH domain and binding to PIP2 
activates the enzyme, in combination with protein-protein interactions (DebBurman et al 1996). 
GRK2 has recently been shown to be involved in the transactivation of the chemokine receptor 
CXCR4 following TCR stimulation, which involves TCR-induced tyrosine phosphorylation of GRK2 
by a Src-family kinase or ZAP-70 (Dinkel et al, 2018). While this suggests that GRK2 is localised to 
the TCR signalosome, it is unclear whether GRK2 interacts directly with PI3K. Interestingly, GRK2 
has been reported to interact directly with AKT and to inhibit AKT kinase activity (Liu et al, 
2005). Both GRK2 and AKT2 were identified by AP-MS as constitutively associated with p110δ. 
Thus, it is possible that this complex forms in activated CD4+ T cells. 
It is also unclear how IQGAP3 may be associated with p110δ in activated CD4+ T cells. The 
IQGAP family of proteins are multimodular scaffolds that have been linked to the regulation 
of both microtubule and actin cytoskeletal reorganisation (Hedman et al, 2015). Indeed, 
IQGAP1 has been shown to negatively regulate TCR stimulation, partly via modulating F -actin 
dynamics (Gorman et al, 2012). However, the role of IQGAP3 in lymphocytes has not yet 
been studied. IQGAP3 is able to interact with the GTP-bound active form of RAS, as well as 
CDC42 and RAC1, and is thought to activate RAS by inhibiting its intrinsic GTPase activity 
(Nojima et al, 2008). It is unclear whether IQGAP3 could play a role in the activation or 
localisation of PI3K. Interestingly, inspection of the IQGAP3 amino acid sequence reveals the 
presence of two YxxM motifs. However, IQGAP3 was found to associate with p110δ 
independently of TCR stimulation in this study. The tyrosine phosphorylation status of IQGAP3 
has not yet been studied; biochemical analyses of IQGAP3 in primary T cells would be required 
to investigate both its post-translational regulation and putative association with p85. 
Similarly, an association of MALT1 with PI3K has not been previously reported, although its role 
in T cells is well-studied. Mucosa-associated lymphoid tissue lymphoma translocation gene 1 
(MALT1) is a cysteine protease that forms a complex with CARMA1 and B-cell lymphoma 10 
(BCL10) upon TCR stimulation, triggered by PKCθ phosphorylation of CARMA1. This CARMA1-
BCL10-MALT1 (CBM) complex connects TCR signalling to the canonical NF-κB signalling pathway 
via activation of the IκB kinase (IKK) complex, which subsequently phosphorylates inhibitors of 
NF-κB and leads to nuclear translocation of NF-κB (Schulze-Luehrmann & Ghosh, 2006). MALT1 
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serves as both an adaptor and a protease, required for optimal NF-κB activation via proteolytic 
cleavage of several substrates, including A20, a deubiquitinase that negatively regulates NF-κB 
activation (Coornaert et al, 2008; Rebeaud et al, 2008). In addition to this role, the CARMA1-
MALT1 complex, independently of IKK, is required for the optimal activation of mTORC1 in TCR-
CD28 co-stimulated CD4+ T cells (Hamilton et al, 2014). A direct association between the CBM 
complex and PI3K has not been demonstrated, thus it is unclear how p110δ may be associated 
with MALT1. It is possible that they share interaction partners or are co-localised at the TCR 
signalosome. Nevertheless, this putative link between the PI3K and NF-κB pathways warrants 
further investigation. 
Lastly, the ubiquitin-like modifier ISG15 (interferon stimulated gene 15) was identified as a TCR 
stimulation-independent p110δ associated protein. ISG15 conjugation (ISGylation) of proteins 
may promote their degradation through the lysosome (Villarroya-Beltri et al, 2016). The 
physiological relevance of ISGylation in T cells remains to be elucidated (Friend et al, 2014). It is 
possible that p110δ-associated proteins identified in this study could be regulated by 
ISGylation. 
3.3.3 Previously proposed p110δ interactors downstream of TCR engagement 
It was noteworthy that proteins previously proposed to bind and recruit PI3K during TCR 
signalling were not identified by MS as p110δ interactors; for example, SLP-76, LAT, ZAP-70 and 
TC21. There are two possible interpretations of this observation: either these proteins do not 
interact with PI3K at the TCR signalosome in activated T cells, or, they do interact but were not 
detected by AP-MS. Previous studies demonstrated the capacity for SLP-76, LAT and ZAP-70 to 
bind to p85 in vitro (Paz et al, 2001; Shim et al, 2004; Moon et al, 2005). However, these 
interactions may not occur in the physiological environment of the cell. Associations with PI3K 
have also been reported in the immortalised Jurkat T cell line, in the case of LAT and SLP-76 
(Zhang et al, 1998; Shim et al, 2004), and in naïve lymph node cells, in the case of TC21 (Delgado 
et al, 2009). However, the same interactions may not occur in activated CD4+ T cells; the 
recruitment of PI3K to the TCR may rely on different adaptors in immortalised and naïve T cells 
compared to activated T cells.  
Alternatively, interactions with these proteins may be of low affinity or occur with fast kinetics, 
and therefore could have been lost during the affinity purification procedure. Indeed, the 
interaction of p110γ with NRAS via its RBD is both low affinity and transient (Pacold et al, 2000), 
and thus it is likely that interactions of p110δ with Ras GTPases, such as TC21, may not be 
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preserved during affinity purification. Furthermore, p85 has been predicted to bind to SLP-76 
and LAT via the non-canonical phosphotyrosine motifs YESP and YVNV, respectively (Paz et al, 
2001; Shim et al, 2004). These interactions may be of low affinity, given that the p85 SH2 
domains preferentially bind to phosphotyrosine motifs containing methionine at the +3 position 
and bind optimally to bidentate YxxM motifs that can engage both SH2 domains simultaneously 
(Songyang et al, 1993; Burke et al, 2011).  
A further explanation is that p85 may interact only indirectly with LAT and SLP-76 in activated T 
cells, and consequently their association may not have been detected by affinity purification. In 
the present study, the adaptors GRB2 and NCK1 were identified by MS as p110δ-associated 
proteins, and these proteins are known to interact with phosphotyrosines in LAT and SLP-76, 
respectively (Zhang et al, 2000; Koretzky et al, 2006). Therefore, a multiprotein complex may 
form at the TCR signalosome whereby PI3K is recruited to LAT and SLP-76 via GRB2 and NCK1. 
This could explain the observations of previous studies that isolated p85 with LAT and SLP-76 by 
co-immunoprecipitation (Zhang et al, 1998; Shim et al, 2004). 
 
Collectively, the quantitative AP-MS approach identified proteins that specifically associate with 
endogenous p110δ in CD4+ T blasts. It was remarkable that the majority of proteins identified 
were known to be involved in TCR signal transduction, and, moreover, that most are able to 
interact directly with p85. Thus, it is possible to speculate on the molecular organisation of the 
p110δ interactome that was identified herein, based on previously reported protein-protein 
interactions (Figure 3.6). From the 24 selected proteins of interest, the first protein chosen for 
biochemical validation and analysis was BCAP. This was for two intriguing reasons. First, BCAP is 
proposed to act as an adaptor for PI3K recruitment to the B cell antigen receptor, and thus may 
play an analogous role in T cells. Secondly, BCAP was not thought to be expressed in T 
lymphocytes. Therefore, subsequent experiments aimed to investigate the expression and 




Figure 3.6 The p110δ interactome in CD4+ T blasts.  
A model for the protein-protein interactions involved in p110δ recruitment and activation at the 
TCR signalosome, based on proteins identified by a quantitative proteomic analysis of p110δ 
affinity purifications from primary CD4+ T blasts.  Proteins that associated with p110δ in a TCR 
stimulation-dependent manner are drawn in red (unfilled). TCR stimulation-independent 
interactors are in black (unfilled). SLP-76, LAT, and the TCR-CD3 complex are included but were 
not identified by AP-MS. Amino acid motifs and protein domains involved in previously reported 
interactions between proteins are annotated in grey. See section 3.3 text for detailed descriptions 
of the proteins shown.  
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Chapter 4        
 
A new role for BCAP in TCR-PI3K 
signalling in activated T cells 
 
4.1 Introduction  
BCAP was first identified in chicken DT40 B cells by affinity purification using the N-terminal SH2 
domain of p85 (Okada et al, 2000). It was concluded that BCAP is expressed predominantly in B 
cells and macrophages, based on the absence of BCAP mRNA in the T cell lines EL-4 and BW5147 
(Okada et al, 2000) and the lack of BCAP protein detected in naïve mouse splenic CD3+ T cells 
(Yamazaki et al, 2002). Two BCAP transcripts are generated by alternative initiation or splicing of 
the Pik3ap1 gene and encode two isoforms in mouse B cells, with observed molecular weights 
of 70 and 72 kDa (short isoform) and 98 and 100 kDa (long isoform) (Okada et al, 2000).  
BCAP is tyrosine phosphorylated in mouse B cells upon BCR crosslinking and associates with PI3K 
p85 in a BCR stimulation-dependent manner, which correlates with BCAP phosphorylation 
(Okada et al, 2000). Tyrosine phosphorylation of BCAP and its association with p85 is also 
induced by CD19 crosslinking alone (Inabe & Kurosaki, 2002). Furthermore, BCR-dependent 
tyrosine phosphorylation of long-isoform BCAP is reduced in DT40 cells in the absence of NCK, 
an adaptor protein that binds to immunoglobulin-α of the BCR complex (Castello et al, 2013). 
BCAP recruitment to the BCR signalosome is also impaired in these NCK-deficient cells. 
Collectively, these studies have elucidated the role of BCAP as an adaptor for PI3K recruitment 
to the BCR upon receptor engagement.  
The identification of BCAP as a p110δ-associated protein in the present study suggests a new 
role for BCAP in CD4+ activated T cells. The fact that this association was TCR stimulation-
dependent indicates that BCAP may be involved in the recruitment and activation of PI3K upon 
TCR engagement. Experiments were therefore undertaken to investigate the expression and 





4.2.1 BCAP is expressed in primary CD4+ T blasts 
Lysates from activated CD4+ T cells (T blasts) were analysed by immunoblotting for BCAP protein 
expression (Figure 4.1A). In the absence of BCAP-/- cells as a negative control, T blast lysates 
were compared with those from naïve splenic B cells and previous reports probing murine B 
cells using the same anti-BCAP antibody (Okada et al, 2000; Yamazaki et al, 2002; Inabe & 
Kurosaki, 2002). Several protein species were detected within the expected molecular weight 
ranges for long and short BCAP isoforms in both cell types. In naïve B cells, the relative 
abundances of these species differed in unstimulated and BCR-stimulated cells, possibly 
reflecting an increase in phosphorylated BCAP upon stimulation that migrates more slowly by 
SDS-PAGE. This was not as pronounced in CD4+ T blasts, and BCAP protein levels appeared lower 
than in naïve B cells. Analysis of BCAP in whole cell lysates was complicated somewhat by the 
high number of potentially non-specific proteins detected by immunoblotting using the anti-
BCAP antibody. 
To more clearly study the BCAP isoforms present in CD4+ T blasts, immunoprecipitation was 
performed to specifically enrich BCAP protein for immunoblot analysis. This revealed the 




Figure 4.1 BCAP is expressed in CD4+ T blasts. 
A. Immunoblot analysis of BCAP protein in naïve splenic B cells and CD4+ T blasts. Naïve B cells 
were stimulated with 50 μg/ml anti-mouse IgM (Fab’)2 for 2.5 minutes and CD4+ T blasts were 
stimulated with 4 μg/ml CD3+CD4 for 1 minute. Cell lysates equivalent to 1.33 million 
unstimulated (-) or stimulated (+) cells were separated by SDS-PAGE and immunoblotted for BCAP 
and p110δ. Brackets indicate the expected BCAP protein species.  
B. Immunoprecipitation of BCAP protein from CD4+ T blasts. Twenty-million CD4+ T blasts were 
stimulated with 4 μg/ml CD3+CD4, or left unstimulated, for 1 minute and cell lysates were 
immunoprecipitated with anti-mouse BCAP antibody or IgG isotype control (IC). Cell lysates 
equivalent to 1.33 million cells were separated by SDS-PAGE alongside 
3
10
 of each 
immunoprecipitation (IP) and immunoblotted for BCAP. 
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To compare the BCAP isoforms detected in CD4+ T blasts with those expressed in B cells, BCAP 
was also immunoprecipitated from naïve splenic B cells. B cells were stimulated by BCR 
crosslinking for various times and purified BCAP was analysed by immunoblotting (Figure 4.2). 
Similar to previous reports, B cells expressed five BCAP species, four of which were tyrosine 
phosphorylated upon BCR activation. Notably, there was an increase in the abundance of 
species 5, and a concomitant decrease in species 4, upon BCR stimulation, with both species 
inducibly tyrosine phosphorylated. This suggests that species 5 could be a highly phosphorylated 
form of species 4. A similar pattern was observed for species 1 and 2. Interestingly, this shift in 
BCAP species was not seen in CD4+ T blasts upon TCR stimulation (Figure 4.1B). 
Tyrosine phosphorylation of BCAP in B cells peaked at 2.5 minutes and returned to basal levels 
at 10 minutes, although the abundances of species 2 and 5 were still elevated at this time point 
compared with unstimulated levels (Figure 4.2). The PI3K regulatory subunit p85 co-
immunoprecipitated at low abundance with BCAP from both unstimulated and stimulated cells. 
This could reflect the basal tyrosine phosphorylation of BCAP seen in these experiments, and 
not in previous reports (Okada et al, 2000). A slight increase in p85 association with BCAP was 
observed at 2.5 minutes following BCR-stimulation, correlating with the peak of 
phosphorylation. Unfortunately, an isotype control IP could not be included in this experiment, 
due to low cell numbers, to confirm the specificity of the p85 co-immunoprecipitation.  
Overall, these experiments indicate that long and short isoforms of BCAP are expressed in both 
naïve B cells and CD4+ T blasts, but their post-translational regulation downstream of the BCR 




Figure 4.2 Tyrosine phosphorylation of BCAP upon BCR stimulation in naïve B cells.  
Immunoprecipitation of BCAP protein from naïve splenic B cells. Ten-million cells per condition 
were stimulated with 50 μg/ml anti-mouse IgM (Fab’)2 (IgM), or left unstimulated, for the times 
indicated and cell lysates were immunoprecipitated with anti-mouse BCAP antibody. Two-fifths 
of each IP and lysates equivalent to 1 million cells were separated by SDS-PAGE and 
immunoblotted for phosphotyrosine (pTyr), BCAP and p85 (pan-p85). The signals detected for 
pTyr and BCAP are overlaid in the third panel in green and red, respectively. Red arrows indicate 









4.2.2 BCAP is phosphorylated upon TCR stimulation and associates with 
PI3K in primary CD4+ T blasts 
To investigate whether BCAP is post-translationally modified upon TCR engagement, BCAP was 
immunoprecipitated from CD4+ T blasts that had been stimulated by CD3 and CD4 crosslinking 
for various times (Figure 4.3). As in B cells, CD4+ T blasts expressed five BCAP species, but there 
was no increase in the abundance of species 2 or 5 upon stimulation. Strikingly, there was a 
rapid induction of BCAP tyrosine phosphorylation upon TCR stimulation, and this was greatest 
for the long-isoform species, 4 and 5. Species 5 had the lowest abundance of the five, yet 
exhibited strong tyrosine phosphorylation, suggesting that it may contain multiple 
phosphorylated tyrosine residues. This phosphorylation dissipated completely within 2 minutes 
of TCR crosslinking. In contrast, the strong tyrosine phosphorylation of species 4 decreased over 
5 minutes but did not return to basal levels in the time studied. Tyrosine phosphorylation of 
short-isoform species 1 and 2 was considerably lower than that observed for the long isoforms 




Figure 4.3 BCAP is tyrosine phosphorylated upon TCR stimulation in CD4+ T blasts. 
Immunoprecipitation of BCAP protein from CD4+ T blasts. Twenty-million CD4+ T blasts per 
condition were stimulated with 4 μg/ml CD3+CD4 for the indicated times and cell lysates were 
immunoprecipitated with anti-mouse BCAP antibody or IgG isotype control (IC). One-third of each 
IP and lysates equivalent to 1 million cells were separated by SDS-PAGE and immunoblotted for 
phosphotyrosine (pTyr) and BCAP. The signals detected for pTyr and BCAP are overlaid in the third 
panel in green and red, respectively. Arrows indicate BCAP species 1, 2, 3, 4 and 5. Blots shown 
are representative of 3 independent experiments.  
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It was next examined whether BCAP associates with PI3K in CD4+ T blasts. Immunoblot analysis 
revealed that low levels of p85 co-immunoprecipitated with BCAP and this appeared to be from 
TCR-stimulated cells only (Figure 4.4). p85 association with BCAP appeared to be almost absent 
after 5 minutes stimulation. The low abundance of p85 associated with BCAP could reflect that 
their interaction is transient or of low affinity.  
 
Figure 4.4 BCAP associates with p85 at low levels in CD4+ T blasts. 
Immunoprecipitation of BCAP and co-immunoprecipitation of p85 from CD4+ T blasts. Twenty-
million CD4+ T blasts per condition were stimulated with 4 μg/ml CD3+CD4 for the indicated 
times and cell lysates were immunoprecipitated with anti-mouse BCAP antibody or IgG isotype 
control (IC). One-third of each IP and lysates equivalent to 1 million cells were separated by SDS-
PAGE and immunoblotted for p85 (pan-p85), phosphotyrosine (pTyr) and BCAP. Red arrows 
indicate BCAP species 1, 2, 3, 4 and 5. Yellow arrows represent p85α/β detected in the previous 
immunoblot. Blots shown are representative of 3 independent experiments.  
 
Collectively, these results demonstrate that BCAP is rapidly phosphorylated upon TCR 
engagement in activated CD4+ T cells and suggest that BCAP associates with PI3K in a TCR 
stimulation-dependent manner. Based on the previously identified role of BCAP in BCR-PI3K 





4.2.3 BCAP is upregulated in activated T cells 
BCAP was identified in the present study as a p110δ-associated protein in activated CD4+ T cells 
and was found to be tyrosine phosphorylated in these cells upon TCR stimulation. It remained 
unanswered whether BCAP was also expressed in naïve CD4+ T cells, and if it was similarly 
regulated in naïve cells. Therefore, immunoprecipitations using anti-BCAP antibody were 
performed on lysates from primary mouse naïve CD4+ T cells (Figure 4.5). The BCAP protein 
species 1, 2, 4 and 5 were not detected in naïve T cells. The low-abundance non-tyrosine 
phosphorylated BCAP species 3, found in CD4+ T blasts and naïve B cells, was detected by 
immunoblotting in naïve CD4+ T cells. However, the identity of this species cannot be confirmed 
as BCAP protein without further experiments using BCAP-/- cells. Nevertheless, these results 
indicate that BCAP protein is expressed in activated CD4+ T cells at markedly higher levels than in 






Figure 4.5 BCAP is not expressed in naïve CD4+ T cells. 
Immunoprecipitation of BCAP protein from naïve CD4+ T cells and naïve splenic B cells. Naïve CD4+ 
T cells were stimulated with 4 μg/ml CD3+CD4 for 30 seconds and naïve B cells were stimulated 
with 50 μg/ml anti-mouse IgM (Fab’)2 for 2.5 minutes. Cell lysates from 10-million unstimulated 
(-) or stimulated (+) cells were immunoprecipitated with anti-mouse BCAP antibody or IgG isotype 
control (IC). One-half of each IP was separated by SDS-PAGE and immunoblotted for 
phosphotyrosine (pTyr) and BCAP. The signals detected for pTyr and BCAP are overlaid in the third 
panel in green and red, respectively. Red arrows indicate BCAP species 1, 2, 3, 4 and 5. 
 
The observations made in CD4+ T cells raised the question of whether naïve and activated CD8+ 
T cells also exhibited distinct differences in BCAP expression. To this end, in vivo RNA sequencing 
data from naïve and antigen-specific effector murine CD8+ T cells were analysed for expression 
of Pik3ap1, which encodes BCAP (Figure 4.6). The normalised transcript abundance detected for 
the gene Lyn was used as a threshold for expression, as LYN is not expressed in primary T 
lymphocytes (Yamanashi et al, 1989; Beavitt et al, 2005; Tsantikos et al, 2009). Strikingly, 
Pik3ap1 was not expressed in naïve CD8+ T cells, but it was expressed in effector CD8+ T cells.  
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For comparison, the expression of four genes associated with the differentiation of naïve CD8+ 
cells into effector CD8+ cells, Cd44, Sell, Foxo1 and Bach2, were also examined. The cell adhesion 
molecule CD44 is an early indicator for T cell activation that is upregulated upon TCR stimulation 
and is likely to be important for effector T cell migration (DeGrendele et al, 1997). In contrast, L-
selectin (CD62L; encoded by Sell) is downregulated upon T cell activation, which is thought to 
allow homing of effector cells to sites of infection (Andersson et al, 1994). The transcription 
factor Foxo1 is also downregulated by TCR signals upon T cell activation (Stittrich et al, 2010; 
Bothur et al, 2015; Ban et al, 2017), as is Bach2, a transcriptional repressor that maintains the 
naïve T cell state (Tsukumo et al, 2013). In line with previous studies, RNA sequencing analysis 
from this study showed an upregulation of Cd44 and downregulation of Sell, Foxo1 and Bach2 in 
effector CD8+ T cells compared with naïve CD8+ T cells (Figure 4.6). The fact that BCAP-encoding 
Pik3ap1 was distinctly upregulated in parallel with these transcriptional changes strengthens the 




Figure 4.6 BCAP is upregulated in effector CD8+ T cells. 
Expression levels of selected genes in naïve and effector CD8+ T cells as determined by RNA 
sequencing. Naïve (CD44-CD62Lhi) CD8+ T cells were purified by flow cytometric sorting from 
splenic cells of wild type mice. Effector (CD44+CD62LloH-2Kb-SIINFEKL+ antigen-specific) CD8+ T 
cells were purified by flow cytometric sorting from splenic cells of wild type mice on day 7 post-
infection with ΔActA-Lm-Ova. Normalised transcript abundances for each gene are reported as 
Reads Per Kilobase of transcript per Million mapped reads (RPKM). Bars represent the mean of 3 
(naïve) or 4 (effector) biological replicates, each from one mouse. Error bars show SEM. The 
dotted line drawn at log2(RPKM)=0.25 indicates the threshold used for expression. Genes 
downregulated in effector cells are highlighted in grey; genes upregulated in effector cells are 
highlighted in red. Pik3ap1, encoding BCAP, is highlighted in yellow. 
This experiment was performed by Hicham Bouabe and the data were re-analysed for the current 
study. 
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Earlier AP-MS analyses identified BCAP as a TCR stimulation-dependent p110δ-associated 
protein in activated CD4+ T cells. Subsequent experiments have shown that BCAP is rapidly 
tyrosine phosphorylated upon TCR engagement (Figure 4.3) and concurrently associates with 
p85 (Figure 4.4). Together, these results suggest that BCAP may serve as an adaptor protein in 
activated T cells, involved in PI3K recruitment to the TCR and plasma membrane.   
Tyrosine phosphorylation of BCAP upon TCR stimulation could provide binding sites to the p85 
PI3K regulatory subunit. Murine BCAP contains three YxxM motifs (Okada et al, 2000). The p85 
subunit contains two SH2 domains that bind with high affinity to phosphorylated tyrosines 
located within YxxM motifs (Songyang et al, 1993). The p85 SH2:pYxxM interaction is important 
not only for recruitment of PI3K to the plasma membrane, through interaction with YxxM-
containing proteins, but also for increasing PI3K activity via release of SH2 domain inhibitory 
contacts with p110 upon binding (Burke & Williams, 2013). Indeed, BCAP was first isolated from 
chicken DT40 B cells using the N-terminal SH2 domain of p85 (Okada et al, 2000). Furthermore, 
a mutant long-isoform chicken BCAP protein in which four YxxM motifs are mutated to FxxM 
does not associate with p85 in DT40 B cells upon BCR stimulation or CD19-crosslinking (Okada et 
al, 2000; Inabe & Kurosaki, 2002). In addition, this FxxM mutant does not restore the decreased 
activation of AKT observed in BCAP-deficient DT40 cells, as measured by in vitro kinase assays. 
Immunoprecipitation studies have also shown that BCAP-deficient DT40 cells expressing the 
FxxM BCAP mutant do not exhibit the highest molecular weight tyrosine phosphorylated BCAP 
species that are seen in wild type cells (Okada et al, 2000). However, tyrosine phosphorylation 
of BCAP is still observed in these cells. This suggests that high-molecular weight BCAP species 
(species 5 in this study) represent the long isoform phosphorylated at one or more YxxM motifs, 
but that additional tyrosine phosphorylation sites are also present. Indeed, long-isoform murine 
BCAP contains 23 potential phosphotyrosine residues. Collectively, these studies demonstrate 
that in B cells, BCAP is likely to bind to the SH2 domains of p85 via its YxxM motifs.  
In the present study, long-isoform BCAP species 5 was strongly tyrosine phosphorylated upon 
TCR-stimulation, despite having lower abundance than the other species present (Figure 4.3). 
Therefore, this species may contain multiple phosphorylated tyrosine residues, which could be 
located within YxxM motifs. Interestingly, p85 still co-immunoprecipitated with BCAP at time 
points following BCR stimulation when phosphorylation of species 5 could no longer be 
detected, while species 1 and 4 remained tyrosine phosphorylated (Figure 4.4). Taken together, 
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these results suggest that p85 could associate with phosphorylated tyrosines in either the long 
or short isoform or BCAP, or it may bind via other protein domains. BCAP also contains three 
proline-rich regions, and it is not known if these interact with the SH3 domain of p85. Both 
isoforms of BCAP contain three YxxM motifs (at Y420, Y445 and Y460) and differ only by the 
absence of residues 1-179, which form a Toll/interleukin-1 receptor (TIR) domain (Halabi et al, 
2017).  
Unlike in BCR-stimulated naïve B cells, where all BCAP species were tyrosine phosphorylated 
similarly, the TCR-induced tyrosine phosphorylation of BCAP was predominantly of the long-
isoform species 4 and 5 (Figure 4.3). This could indicate a dominant role for the long isoform in 
activated T cells. It may also reflect the difference in available tyrosine kinases with specificity 
for BCAP in T blasts, compared with those in naïve B cells. Studies using LYN-, SYK- and BTK-
deficient DT40 B cells have suggested that SYK and BTK initiate and sustain BCR-mediated BCAP 
tyrosine phosphorylation, respectively, whereas LYN negatively regulates this phosphorylation 
(Okada et al, 2000). In the absence of LYN, higher molecular weight forms of BCAP appear more 
phosphorylated (Okada et al, 2000). In contrast, CD19-mediated BCAP tyrosine phosphorylation 
appears to require LYN in DT40 B cells that express exogenous CD19 (Inabe & Kurosaki, 2002). 
Interestingly, recruitment of NCK, an adaptor for BCAP, to BCR signalosomes is impaired in LYN-
deficient DT40 cells (Castello et al, 2013). Furthermore, long-isoform BCAP can be 
phosphorylated by LYN in vitro, and can associate with both SYK and LYN (Halabi et al, 2017). 
Whether LYN directly phosphorylates BCAP, or regulates SYK activity in this role, is unclear. The 
interpretation of these studies must also consider that chicken DT40 cells do not express CD19; 
in mouse B cells, where CD19 is expressed, BCAP recruitment and phosphorylation may differ.  
In CD4+ T blasts, the rapid tyrosine phosphorylation of BCAP upon TCR crosslinking suggests that 
BCAP is regulated by kinases in close proximity to the TCR signalosome. The main Src-family 
tyrosine kinases involved in the early stages of TCR activation are LCK and FYN (Palacios & 
Weiss, 2004). LCK is associated with the CD4 and CD8 coreceptors (Turner et al, 1990), while 
FYN interacts with the TCR-CD3 complex (Timson Gauen et al, 1992), and both LCK and FYN 
contain SH2 and SH3 domains. LCK phosphorylates immunoreceptor tyrosine-based activation 
motifs (ITAMs) located within the CD3ζ chain, which then recruit the SYK-family tyrosine kinase 
ZAP-70 via its tandem SH2 domains (Wang et al, 2010). LCK, FYN and ZAP-70 are potential 
candidates that could be responsible for the tyrosine phosphorylation of BCAP in activated T 
cells, which would require further investigation using specific kinase-deficient T cells.  
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While BCAP is thought to recruit PI3K to the BCR, BCAP itself is not a membrane-associated 
protein. In B cells, BCAP is found mainly in the cytoplasmic fraction (Okada et al, 2000). The 
adaptor protein NCK has been shown to recruit BCAP to the BCR signalosome (Castello et al, 
2013). NCK associates with the BCR via a region of the immunoglobulin-α tail containing the 
non-ITAM phosphorylated residue Y204, which is dependent on the expression of LYN. NCK 
interacts with the second proline-rich region of BCAP via its three SH3 domains. The NCK family 
proteins NCK1 and NCK2 are both expressed in activated mouse CD4+ T cells (Figure 4.6). 
Moreover, NCK, via its first SH3 domain, binds to a proline-rich region in the CD3ɛ chain, which 
is exposed upon TCR antigen recognition and occurs before tyrosine phosphorylation of the 
CD3ζ ITAMs (Gil et al, 2002). It is therefore possible that NCK could recruit BCAP to the TCR 
signalosome in activated T cells. Interestingly, NCK1 was identified by AP-MS in the present 
study as a TCR stimulation-independent p110δ-associated protein. This suggests that NCK1 is 
constitutively associated with PI3K; upon TCR stimulation, NCK could stabilise an interaction 
between BCAP and PI3K and facilitate PI3K recruitment to the TCR signalosome. This 
hypothesis warrants further study. 
Aside from 3 YxxM motifs and 3 proline-rich regions, murine BCAP also contains a YxNx (Y375-
PNT) and a YxxV (Y513-HIV) motif. These tyrosine phosphorylated sequences are well 
characterised as consensus binding motifs for the SH2 domains of GRB2 and SHP-2, respectively 
(Songyang et al, 1993, 1994). Intriguingly, GRB2 and SHP-2 were both identified by AP-MS as 
TCR-stimulation dependent p110δ-associated proteins in the present study. While interaction 
between BCAP and these proteins has not yet been demonstrated, it is possible that they may 
associate in a TCR-proximal complex involving PI3K. It has been shown that BCAP is able to form 
dimers, mediated by its N terminal Dof/BANK/BCAP (DBB) domain (Halabi et al, 2017). This 
raises the possibility that dimerised BCAP could bind to multiple proteins simultaneously at the 
TCR signalosome.  
It remains unanswered how BCAP affects PI3K activation and subsequent signalling downstream 
of the TCR. In BCAP-deficient DT40 B cells, PIP3 production upon BCR-stimulation is decreased by 
50%, while AKT activation, measured by in vitro kinase assay, is also reduced (Okada et al, 2000). 
As previously discussed, DT40 cells do not express CD19, thus BCAP may play a more essential 
role in these cells. Indeed, activation of PI3K and AKT, measured by their kinase activity in vitro, 
appears to be unaffected in BCAP-/- mouse splenic B cells, in which CD19 may substitute as the 
main PI3K adaptor (Yamazaki et al, 2002). Nevertheless, the residual PIP3 production observed 
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in DT40 cells indicates that there are BCAP-independent mechanisms of PI3K activation in these 
B cells. If BCAP is assumed to perform an analogous role in T cells, it may serve to activate the 
PI3K-AKT pathway upon TCR engagement. Due to the observations that BCAP is expressed 
predominantly in B cells and macrophages, and not in naïve T cells, previous studies using BCAP-
/- mice have not examined the functional impact on PI3K signalling in effector T cells. These 
studies revealed that BCAP-/- mice exhibit normal thymic development, with only marginally 
decreased numbers of CD3+ T cells in the spleen (Yamazaki et al, 2002). To uncover the role of 
BCAP in PI3K signalling downstream of the TCR, BCAP-deficient activated T cells would be 
required.  
The current study revealed that BCAP is not expressed in naïve CD4+ T cells but is upregulated in 
activated CD4+ and CD8+ T cells. This intriguing observation raises the question of whether BCAP 
becomes a critical adaptor for PI3K upon expression in activated T cells, or if it plays a redundant 
role with other constitutively expressed proteins. It also suggests that there could be a rewiring 
of TCR-induced signalling upon differentiation of effector T cells, which may alter the regulation 
of PI3K activity. 
The biochemical study of BCAP in activated CD4+ T cells demonstrated that tyrosine 
phosphorylation of BCAP and its association with PI3K are induced by TCR crosslinking. 
Subsequent experiments aimed to investigate the role of BCAP in TCR-PI3K signalling by 
interrogating BCAP-deficient CD4+ T blasts.  
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Chapter 5        
 
Interrogating TCR-PI3K signalling using 
CRISPR/Cas9 gene editing in primary 
murine T cells 
 
5.1 Introduction  
The identification of p110δ-associated proteins in activated T cells prompted work to investigate 
their functions as potential regulators of PI3K signalling downstream of TCR engagement. This 
called for a system of intervention to disrupt candidate proteins and analyse downstream 
perturbations in the pathway. In order to interrogate their function in the same physiological 
scenario in which they were identified by mass spectrometry, this assay required application to 
primary murine T blasts expanded by in vitro culture. This necessity was reinforced by the 
observation that two proteins of interest, BCAP and ICOS, are expressed only in activated, and 
not naïve, T cells. In the absence of specific small-molecule inhibitors against the candidate 
proteins, their study necessitated genetic knock out, or knock in loss-of-function. Due to the 
number of proteins that could be investigated, and the availability of such models, transgenic 
mice were not a suitable option for this purpose. Therefore an in vitro gene editing approach 
was required.  
Commonly used strategies for gene knock down in primary T cells involve RNA interference via 
viral-based transduction of vectors encoding siRNA/shRNA or direct transfection of siRNA 
(Freeley & Long, 2013). These methods are often time consuming, labour intensive and low-
efficiency. Following the emergence of CRISPR/Cas9 technology as a powerful tool for genome 
engineering across many cell types (Doudna & Charpentier, 2014), considerable efforts have 
been made to advance Cas9-mediated gene editing techniques in primary T cells for therapeutic 
and research applications. This has driven the development of various approaches to express or 
directly deliver Cas9 nuclease and short guide RNA (gRNA) in human T cells, with variable editing 
efficiencies (Mandal et al, 2014; Wang et al, 2014; Li et al, 2015; Su et al, 2016). The delivery of 
in vitro-assembled Cas9:gRNA ribonucleoproteins (Cas9 RNPs) has been demonstrated as a rapid 
and efficient method for gene editing in primary activated human CD4+ T cells (Hendel et al, 
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2015; Schumann et al, 2015). Electroporation of Cas9 RNP complexes targeting CXCR4 led to 
efficient knock out of the cell surface receptor CXCR4 in activated human CD4+ T cells 
(Schumann et al, 2015). Following this pioneering work, RNP nucleofection has been successfully 
used for the CRISPR/Cas9-mediated knock out of CCR5 (Hendel et al, 2015), CD7 (Gomes-Silva 
et al, 2017), CD3 (Ren et al, 2017) and PD-1 (Rupp et al, 2017) in primary activated human T 
cells. 
The RNP-based delivery method is advantageous for CRISPR/Cas9 editing of primary murine 
cells in vitro as it does not require mice expressing transgenic Cas9. Given that RNPs also exhibit 
rapid turnover in cells within 24 hours (Kim et al, 2014), the RNP-based method therefore avoids 
the increased frequency off-target cleavage that may be associated with Cas9 expressed by a 
constitutive transgene, or even a long-persisting plasmid (Schumann et al, 2015; Kornete et al, 
2018). Furthermore, RNP delivery has been shown to be less toxic to human T cells than the 
nucleofection of plasmid DNA (Hendel et al, 2015).  
Recently, in the first reported use of RNP delivery for CRISPR/Cas9 editing in mouse primary T 
cells, Seki & Rutz (2018) have demonstrated high efficiency knock out of CD90, CTLA-4 and PD1 
in purified murine CD8+ T cells. These cells had been activated with anti-CD3, anti-CD28 and IL-2 
for 3 days prior to nucleofection using a Lonza 4D nucleofection system. In parallel, Kornete et al 
(2018) have achieved high efficiency knock out of CD90 in purified murine CD4+ T cells following 
24-hour activation with anti-CD3, anti-CD28 and IL-2, using the Neon transfection system.  
The current study set out to adapt the RNP nucleofection method to enable CRISPR/Cas9-
mediated gene editing in primary murine total T cells that had been activated with anti-CD3 for 
two days in the same manner as previous experiments (Figure 5.1A). This was with the aim to 
knock out MS-identified p110δ-associated proteins to interrogate their potential functions as 




Figure 5.1 Experimental workflow for CRISPR/Cas9 gene editing via RNP nucleofection in 
primary activated murine T cells.  
A. in vitro culture of primary activated murine T cells. Cells are isolated from mouse lymph nodes 
and activated for 48 hours with 1 μg/ml soluble anti-CD3. Activated cells are then cultured for a 
further 5 days in 20 ng/ml rhIL-2. Cells are re-stimulated on day 7 for biochemical and flow 
cytometric analysis.  
B. Schematic representation of CRISPR guide crRNA sequences (pink) designed to edit exon 2 of 
the mouse Thy1 gene. The protospacer adjacent motif (PAM) is recognised by Cas9 nuclease. 
Arrows indicate the predicted Cas9 cleavage sites, separated by 43 bp. 
C. Strategy for RNP nucleofection. Recombinant Cas9 protein is complexed with tracrRNA:crRNA 
duplex to form the Cas9 RNP, which is then delivered by electroporation into primary mouse total 
T cells that have been activated for 48 h with anti-CD3. Insertions/deletions (indels) generated via 
Cas9 cleavage-induced non-homologous end joining (NHEJ) are analysed by Sanger sequencing of 
PCR amplicons spanning the target locus. Protein loss and functional impact is determined by flow 




5.2.1 Generation of knock out primary activated murine T cells via Cas9:gRNA 
RNP nucleofection 
To test the feasibility and efficacy of RNP delivery for CRISPR/Cas9 gene editing in activated 
mouse T cells, the highly expressed, glycosyl phosphatidylinositol (GPI)-anchored T cell surface 
glycoprotein CD90, encoded by the gene Thy1, was chosen as a target for knock out. CD90 
expression can be easily assessed by flow cytometry, and Thy1 has been successfully edited by 
CRISPR/Cas9 in primary mouse T cells in previous reports (Kornete et al, 2018; Seki & Rutz, 
2018). 
Two CRISPR RNA (crRNA) guide sequences were designed to recognise Thy1 exon 2, with their 
Cas9 cleavage sites separated by 43 bp (Figure 5.1B). Both guides had no predicted off-target 
sites in coding regions. The synthetic Thy1-specific crRNAs were then annealed with trans-
activating crRNA (tracrRNA), which possesses complementarity to the Cas9 nuclease, to form a 
single guide RNA (gRNA) (Figure 5.1C). Recombinant Cas9 protein was complexed with either 
Thy1 gRNA 1, Thy1 gRNA 2, or equimolar amounts of both gRNAs, at a molar ratio shown to be 
effective for gene editing in human CD8+ T cells (unpublished work). Total T cells that had been 
activated for 48 hours with anti-CD3 were nucleofected with Thy1 Cas9 ribonucleoproteins 
(RNPs) by electroporation, then cultured for 48 hours with IL-2 before analysis by flow 
cytometry. 
Nucleofection of Thy1 Cas9 RNPs resulted in the loss of CD90 surface protein in both CD8+ and 
CD4+ T cells (Figure 5.2A). Up to 31.2 % and 18.6 % of Thy1 RNP-nucleofected CD8+ and CD4+ T 
cells, respectively, did not express CD90 at 48 h post-nucleofection, indicating homozygous 
knockout due to biallelic disruption of the Thy1 gene. Flow cytometry also revealed an increase 
in the proportion of cells expressing low levels of CD90 after Thy1 RNP nucleofection (Figure 
5.2B), which may reflect heterozygous knock out due to monoallelic gene disruption, or 





Figure 5.2 Successful knock out of CD90 in primary activated murine CD8+ and CD4+ T cells 
via Cas9 RNP nucleofection.  
A. CD90 cell-surface expression assessed by flow cytometry in control (non-electroporated (WT), 
electroporated (EP), and electroporated with gRNA only (EP+gRNA)) and Thy1 Cas9 RNP-
nucleofected CD8+ and CD4+ activated T cells 48 h post-nucleofection. Cas9 was complexed with 
one of two gRNAs targeting Thy1 (gRNA 1 or gRNA 2) or equimolar amounts of both guides (gRNA 
1+2), in the ratio 36.6:27 pmol Cas9:gRNA. 0.5  106 cells were electroporated for each condition, 
or rested in nucleofection buffer for WT. Flow plots indicate the percentage of live CD8+ and CD4+ 
cells falling within the CD90- gate, drawn according to isotype control-stained cells.  
B. Histograms of CD90 cell-surface staining assessed by flow cytometry, with cell counts 
normalised to the mode, corresponding to the same samples shown in A.  
C. Cell viability assessed by flow cytometry, expressed as the percentage of live single cells at 48 
h post-nucleofection, corresponding to the same samples shown in A and B. Data are from one 
experiment performed in duplicate with one technical replicate shown.  
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Cas9 RNPs complexed with Thy1 gRNA 2 achieved greater CD90 knock out efficiency than those 
complexed with Thy1 gRNA 1. The simultaneous use of both Thy1 gRNAs was also tested, as this 
approach has been shown to increase the efficiency of gene disruption due to deletion of the 
exonic sequence between the two Cas9 cleavage sites (Mandal et al, 2014; Hendel et al, 2015). 
In this experiment, use of both Thy1 gRNAs in combination generated lower CD90 knock out 
frequency compared to Thy1 gRNA 2 alone, suggesting low efficiency sequence disruption at the 
Thy1 gRNA 1 target site. 
The viability of cells at 48 hours post-electroporation was also assessed by flow cytometry 
(Figure 5.2C). The proportion of live cells following RNP-nucleofection was, on average, only 3 
% lower than for non-electroporated cells (WT), and similar to cells that had been 
electroporated with or without gRNA alone. This indicates that neither RNP delivery nor gene 
editing were considerably cytotoxic to activated T cells. 
The successful ablation of CD90 expression demonstrated that CRISPR/Cas9 gene editing via 
RNP nucleofection was a viable method to generate knock out CD8+ and CD4+ cells from primary 
activated murine total T cells in vitro. 
 
5.2.2 Optimisation of CRISPR/Cas9 gene editing via RNP nucleofection in 
primary activated murine T cells 
While successful knock out of CD90 was achieved using RNP delivery, the proportion of CD90- 
cells generated was low, at 20 - 30 %. Therefore, the RNP nucleofection protocol was 
optimised to increase the efficiency of gene knock out.  
The efficiency of DNA cleavage at target sites is limited by the amount of Cas9:gRNA complex 
present in the nucleus (Osakabe et al, 2016). While increasing the amount of Cas9 protein 
nucleofected may increase cutting frequency, introducing excessive amounts of exogenous 
protein into lymphocytes would likely increase cytotoxicity and thus reduce cell viability. 
Furthermore, Cas9 quantity cannot be varied independently of gRNA amount. Cas9 is expected 
to form a 1:1 molar complex with gRNA within the RNP complex, yet the ratio used to assemble 
RNPs in vitro is usually higher, with gRNA in excess (Hendel et al, 2015; Seki & Rutz, 2018, 
Kornete et al, 2018). The optimal ratio has not been empirically determined, and may vary 
depending on experimental conditions. Use of chemically synthesised gRNAs, as in this study, 
does not trigger an innate immune response and associated cytotoxicity in human CD4+ T cells, 
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unlike in vitro transcribed sgRNA (Kim et al, 2018). Nevertheless, introducing excessive synthetic 
RNA could reduce cell viability. The optimal amount of Cas9 and gRNA used for each RNP 
nucleofection was thus investigated, to increased gene editing efficiency while maintaining cell 
viability. A third factor to be considered was the number of cells subjected to nucleofection; an 
optimal concentration of cells within the electroporation mixture would allow a maximum 
number of cells to receive RNP complexes while remaining viable under the applied voltage. 
The most appropriate way to optimise these three interdependent factors was to model their 
combined contributions to knock out efficiency and cell viability. This was achieved by 
performing a set of 17 Thy1 RNP nucleofections that were designed to use specific combinations 
of Cas9 amount, gRNA amount and cell number, within defined practical limits (Table 5.1). The 
outcomes would allow efficiency and viability to be modelled as functions of the three variables, 
using response surface methodology, and thus optimal values could be determined. The 17 
nucleofections were performed and analysed in parallel. Knock out efficiency at 48 hours-post 
nucleofection was measured as the frequency of insertions and deletions (indels) generated at 
the Cas9:gRNA target site within Thy1. This was determined using TIDE (Tracking of Indels by 
Decomposition) analysis (Brinkman et al, 2014), by deconvolution of Sanger sequencing traces 
of PCR amplicons spanning the Thy1 gRNA target site, with comparison to control sequences of 
the same region from wild type cells (Figure 5.3A). The cutting efficiency reported by TIDE 
indicates the percentage of indels present within the total cell population at the Cas9 cleavage 
sites. In parallel, cell viability and CD90 surface expression were analysed by flow cytometry at 
48 hours post-nucleofection. It was clear simply by examining the variation in knock out 
efficiency across each of the 17 populations that the amount of Cas9 and gRNA nucleofected, 
along with the number of cells electroporated, had a considerable impact on efficiency and 
viability (Table 5.1). Cutting efficiency and CD90 expression measured in cells from 
nucleofections 17 and 15 are shown in Figure 5.3 as representative examples of low and high 




Table 5.1 Experimental design for optimisation of CRISPR/Cas9 gene editing via RNP 
nucleofection. 
Design-Expert software was used to design 17 nucleofection conditions to enable optimisation of 
RNP-mediated gene editing by response surface methodology. Three factors (cell number, Cas9 
amount, and gRNA amount) were varied between defined limits (0.5 – 2.5  106, 1 – 10 μg and 25 
– 125 pmol, respectively) according to Box-Behnken design. The 17 nucleofections were 
performed in parallel and responses were measured at 48 h post-nucleofection. Cutting Efficiency 
indicates the percentage of indels present within the total cell population at the Cas9 cleavage 
sites in Thy1 exon 2, as determined by TIDE analysis of Sanger sequencing traces of PCR amplicons 
spanning this region. Protein KO (% CD8+CD90- live cells) and Viability (% live cells) were 
determined by flow cytometry and represent the average of duplicate samples. *gRNA was an 
equimolar mixture of Thy1 gRNA 1 and gRNA 2. †Could not obtain quality Sanger sequence reads 





Figure 5.3 Optimisation of CRISPR/Cas9 gene editing via RNP nucleofection in primary 
activated murine T cells.  
A and B. Representative examples of low efficiency (NF 17) and high efficiency (NF 15) Thy1 
disruption from the 17 nucleofections detailed in Table 5.1. Cas9 was complexed with equimolar 
amounts of Thy1 gRNA 1 and gRNA 2, in the ratio 1 μg:75 pmol (NF 17) or 10 μg:75 pmol (NF 15) 
Cas9:gRNA. 2.5  106 cells were electroporated for each condition.  
A. TIDE graphs showing the aberrant sequence signal at the Thy1 target site at 48 h post-
nucleofection in Thy1 RNP-nucleofected total T cells (NF 17, left, and NF 15, right; ‘test’, in green), 
compared to wild type total T cells (‘control’; in black). Plots show the expected Cas9 cleavage 
sites (blue lines), the region used for decomposition (grey line) and the region used for sequence 
alignment with control (purple line). Decomposition of the sequence by TIDE determines the 
percentage of indels present in the total population, as indicated on the graphs.  
B. CD90 cell-surface expression, assessed by flow cytometry in CD8+ and CD4+ T blasts 
nucleofected with Thy1 Cas9 RNP, at 48 h, 72 h and 5 days (5 d) post-nucleofection. Flow plots 
indicate the percentage of live CD8+ or CD4+ cells falling within the CD90- gate, drawn according 
to isotype control-stained cells. Data are from one flow cytometry experiment performed in 
duplicate, with one technical replicate shown.  
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In addition to these analyses performed at 48 hours, Thy1-edited cells were expanded further 
and found to be viable at 5 days post-nucleofection (Figure 5.3B). It was also observed that the 
proportion of CD90- cells within the population increased from 48 to 72 hours for both CD8+ and 
CD4+ cells, indicating that CD90 protein turnover from the cell surface required longer than 48 
hours following Thy1 gene disruption. This may also explain the discrepancy between the 
estimated gene cutting efficiency and protein knock out efficiency observed at 48 hours in some 
cases (Table 5.1). Although, the frequency of editing was not expected to equal the proportion 
of CD90-knock out cells, as indel frequency does not distinguish between heterozygous and 
homozygous knock out. Nevertheless, in the majority of nucleofections, these percentages were 
similar, suggesting that there was a high proportion of biallelic gene editing in these samples. 
Regardless, these results indicated that protein loss should be analysed from 72 hours post-
nucleofection. The proportion of CD90- cells within the CD8+ and CD4+ populations did not 
change considerably from 72 to 5 days, indicating that there was no survival or proliferative 
defect, or advantage, in Thy1-edited cells. The CD8+ population exhibited a consistently higher 
proportion of CD90- knock out cells compared with the CD4+ population at 48 h, 72 h and 5 days 
post-nucleofection, suggesting that this was due to a difference in Thy1 editing frequency rather 
than protein turnover.  
The generation of 50 % Thy1-edited cells from several of the tested nucleofection conditions 
indicated that the RNP nucleofection protocol could be improved. To this end, response surface 
methodology was used to model cutting efficiency, protein knock out and cell viability as 
quadratic functions of the three variable factors (Cas9 amount, gRNA amount and cell number). 
Optimal values for each factor that were within the experimental space tested were determined 
using the Design-Expert software package, with the aim to maximise cutting efficiency and 
protein knock out while targeting high viability. These values (2.16  106 cells; 10 μg Cas9; 94 
pmol gRNA) were used in subsequent RNP nucleofections. Notably, the fact that the maximum 
quantity of Cas9 tested (10 μg) was calculated as an optimum suggests that the ‘true’ optimum 
for Cas9 amount may lie outside of the experimental space tested. Thus, it was predicted that 
the maximum Thy1 editing efficiency that could be achieved with these values would be similar 
to the highest observed in these experiments; approximately 50 %.   
This optimised protocol for RNP nucleofection in primary murine T blasts, and strategy for the 
analysis of knock out efficiency, was subsequently used for CRISPR/Cas9-mediated knock out of 
TCR-PI3K-associated proteins.  
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5.2.3 CRISPR/Cas9-mediated knock out of TCR-PI3K signalling proteins in 
primary activated T cells 
Proteins that had been identified by AP-MS as p110δ-interactors in primary activated T cells 
were the intended targets for CRISPR/Cas9-mediated knock out. To be able to examine the 
effect of their loss on TCR-induced PI3K signalling, p110δ-deficient T blasts were required as a 
positive control for disrupted PI3K signalling. Therefore, the first gene chosen for CRISPR/Cas9-
mediated editing was Pik3cd, which encodes the PI3K catalytic isoform p110δ.  
Two guide crRNA sequences were designed to uniquely target Pik3cd exon 2, with their Cas9 
cleavage sites separated by 31 bp. To enable the selection and analysis of p110δ-deficient cells 
by flow cytometry, in the absence of a detectable marker for successful knock out, a multiplex 
gene editing strategy with simultaneous targeting of Thy1 was used. To this end, recombinant 
Cas9 protein was complexed with equimolar amounts of Pik3cd gRNA 1 or 2 and Thy1 gRNA 2, 
or equimolar amounts of both Pik3cd gRNAs without Thy1 gRNA. Total T cells that had been 
activated for 48 hours were nucleofected with RNP complexes and then cultured for 5 days with 
IL-2. The efficiency of indel formation at the Pik3cd and Thy1 target sites was assessed at 72 
hours and 5 days post-nucleofection by Sanger sequencing and TIDE analysis (Figure 5.4).  
Across two independent experiments, Thy1 editing efficiency was consistently 50 % at both 72 
h and 5 days post-nucleofection. RNPs complexed with Pik3cd gRNA 1 or Pik3cd gRNA 2 
generated low Pik3cd editing efficiencies of up to 9 and 15 %, respectively, as estimated by 
TIDE analysis. In contrast, efficient Pik3cd editing was achieved with delivery of both Pik3cd RNP 
complexes combined, generating 57.6 % indel frequency within the population in one 
experiment. Notably, there was no clear depletion or enrichment of Pik3cd-edited cells from 72 
h to 5 days post-nucleofection. 
In parallel, TCR-PI3K signalling was investigated in Pik3cd-edited T blasts at day 5 post-
nucleofection and compared with wild type cells that had been electroporated with gRNA alone. 
For this, total T cells were subjected to acute TCR stimulation for 2 minutes and cell lysates were 
analysed by immunoblotting for phosphorylated AKT (pAKT T308) (Figure 5.4). The pAKT signal 
detected was then quantified and normalised to AKT1 to allow comparison between samples 
(Figure 5.5). Across two independent experiments, there was a trend for reduced pAKT upon 
stimulation in Pik3cd RNP-nucleofected cells, compared with wild type, which correlated with 
increased frequency of Pik3cd disruption within the cell population (Figure 5.5A and 5.5B). Thus, 
the small reduction in induced pAKT in Pik3cd-edited cells could be explained by the low 
100 
 
frequency of Pik3cd disruption, and therefore the low proportion of heterozygous and 
homozygous p110δ knock out cells within the total cell population. Nevertheless, the cell 
population with 57.6 % Pik3cd indel frequency exhibited only 57 % of the pAKT signal induced in 
wild type cells, which indicates loss of p110δ within the population.  
 
Figure 5.4 PI3K-AKT signalling and gene editing efficiency in Pik3cd Cas9 RNP-nucleofected 
T blasts.  
Activated total T cells were nucleofected with Cas9 RNPs complexed with equimolar amounts of 
Pik3cd gRNA (g1 or g2) and Thy1 gRNA (g2), or equimolar amounts of Pik3cd gRNA g1 and gRNA 
g2. Control (EP + gRNA) cells were electroporated with gRNA alone. At day 5 post-nucleofection, 
4 million cells were stimulated with 4 μg/ml CD3+CD4+CD8 plus 13 μg/ml crosslinking 
antibody for 2 minutes at 37°C, in the presence of 200 nM DMSO (-) or CAL101 (+), or left 
unstimulated in the presence of 200 nM DMSO. Cells were lysed and one-half of lysates were 
separated by SDS-PAGE and immunoblotted simultaneously for pAKT (T308) and total AKT1. 
Editing efficiency (indicated below immunoblots) was determined at 72 h and 5 days post-
nucleofection. Editing % indicates the percentage of indels present within the total cell population 
at the Cas9 cleavage sites in Pik3cd and Thy1, as determined by TIDE analysis of Sanger sequencing 
traces of PCR amplicons spanning the targeted regions. Blots shown are from two independent 





Figure 5.5 Pik3cd-edited T blasts exhibit reduced pAKT and p110-independent pAKT upon 
TCR stimulation. 
A. Quantification of pAKT signal intensity detected by immunoblotting in Figure 5.4, normalised 
to AKT1, expressed relative to that in stimulated EP+gRNA cells, set as 1. Data are from two 
independent experiments. Bars represent the mean, with error bars +SEM. 
B. The same data as in A but from ‘stimulated + DMSO’ cells only, showing individual values from 
two independent experiments as scatter points, relative to that in stimulated EP+gRNA cells in 
each experiment. Bars represent the mean for each genotype. 
C. Quantified pAKT, normalised to AKT1, in stimulated cells treated with 200 nM CAL101, relative 
to that in stimulated cells treated with 200 nM DMSO. Data are from two independent 
experiments. Bars represent the mean, with individual values shown as scatter points.  
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Interestingly, there was also a trend for increased residual pAKT in Pik3cd-edited cells upon 
stimulation in the presence of the p110δ-specific inhibitor CAL101 (Figure 5.5A). This was better 
examined by comparing the level of pAKT induced in the presence of CAL101 with that induced 
in DMSO-treated cells for each genotype (Figure 5.5C). In wild type cells treated with CAL101, 
the level of pAKT induced upon stimulation was only 10 % of that induced in DMSO-treated 
cells, demonstrating that the majority of AKT phosphorylation was p110δ-dependent. In 
contrast, 48 % of the pAKT level induced in DMSO-treated cells could be detected in CAL101-
treated Pik3cd-edited cells that had 57.6 % indel frequency. Notably, the proportion of p110δ-
independent pAKT upon stimulation positively correlated with the level of Pik3cd disruption 
within the cell population. This indicated that p110δ-independent phosphorylation of pAKT 
occurred in p110δ-deficient cells upon TCR stimulation.  
Following successful CRISPR/Cas9-mediated knock out of Pik3cd, two guide crRNA sequences 
were designed to target exon 4 of Pik3ap1, which encodes BCAP. This exon is present in all 
Pik3ap1 transcripts; thus, its disruption would enable knock out of all BCAP protein isoforms. 
The Cas9 cleavage sites of Pik3ap1 gRNA 1 and gRNA 2 were separated by 47 bp to allow both 
guides to be combined for editing. As before, a multiplex strategy with simultaneous targeting 
of Thy1 was also used. Activated total T cells were nucleofected with RNP complexes and indel 
frequency at both the Pik3ap1 and Thy1 target sites was assessed at 72 h and 5 days post-
nucleofection (Figure 5.6). 
RNP-nucleofection with either Pik3ap1 guide RNA generated efficient indel formation at the 
Pik3ap1 target site, with gRNA 1 achieving consistently higher editing frequencies of 37.7 - 54.1 
%, compared with 9.3 - 21.8 % for gRNA 2. Interestingly, the combination of both guides 
targeting the same exon did not generate greater cutting efficiency than when gRNA 1 was used 
alone, indicating that cleavage at the gRNA 2 target site may have been a limiting factor. 
Notably, the frequency of Pik3ap1 editing did not vary from 72 h to 5 days post-nucleofection in 
any case, indicating that there was no enrichment or depletion of BCAP-knock out cells. Thy1 
editing efficiency in multiplex nucleofections was also consistent at 50 - 60 % at both 72 h and 
5 days. 
PI3K-AKT signalling was also examined in Pik3ap1-edited T blasts upon acute TCR stimulation at 
day 5 post-nucleofection (Figure 5.6). Phosphorylated AKT detected by immunoblotting was 
then quantified, normalised to AKT1 and compared with wild type (WT) non-electroporated cells 
(Figure 5.7A). This revealed a small but consistent trend for reduced pAKT upon TCR stimulation 
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in Pik3ap1-edited T blasts. By comparing the detected pAKT signal to the level of Pik3ap1 
disruption within each cell population, it was revealed that the greatest reduction in pAKT was 
associated with a higher frequency of Pik3ap1 knockout (Figure 5.7B). In two independent 
experiments with 54.1 % and 44.2 % Pik3ap1-editing within the cell population, the pAKT signal 
upon stimulation was 30 % and 35 % lower than in WT cells, respectively. However, this 
association was not consistent at lower levels of editing; samples with 37.7 % and 17 % Pik3ap1 
disruption exhibited a 7 % and 35 % reduction in pAKT, respectively. This may reflect the fact 
that the measure of indel frequency does not distinguish between the proportion of 
heterozygous and homozygous knock out cells. In addition, a more appropriate control for 
multiplex edited Pik3ap1 + Thy1 knock out cells in this experiment would be Thy1-edited T 
blasts. Nevertheless, the observed defect in TCR-PI3K signalling in Pik3ap1-edited cells 




Figure 5.6 PI3K-AKT signalling and gene editing efficiency in Pik3ap1 Cas9 RNP-
nucleofected T blasts. 
Activated total T cells were nucleofected with Cas9 RNPs complexed with equimolar amounts of 
Pik3ap1 gRNA (g1 or g2) and Thy1 gRNA (g2), or equimolar amounts of Pik3ap1 gRNA g1 and gRNA 
g2. Control wild type (WT) cells were not electroporated. At day 5 post-nucleofection, 4 million 
cells were stimulated with 4 μg/ml CD3+CD4+CD8 plus 13 μg/ml crosslinking antibody for 2 
minutes at 37°C, in the presence of 200 nM DMSO (-) or CAL101 (+), or left unstimulated in the 
presence of 200 nM DMSO. Cells were lysed and one-half of lysates were separated by SDS-PAGE 
and immunoblotted simultaneously for pAKT (T308) and total AKT1. Editing efficiency (indicated 
below immunoblots) was determined at 72 h and 5 days post-nucleofection. Editing % indicates 
the percentage of indels present within the total cell population at the Cas9 cleavage sites in 
Pik3ap1 and Thy1, as determined by TIDE analysis of Sanger sequencing traces of PCR amplicons 
spanning the targeted regions. Blots shown are from three independent experiments (Expt1, 




Figure 5.7 Reduced pAKT upon TCR-stimulation in Pik3ap1-edited T blasts. 
A. Quantification of pAKT signal intensity as detected by immunoblotting in Figure 5.6, normalised 
to AKT1, expressed relative to that in stimulated WT cells, set as 1. Data are from three (for WT 
and Pik3ap1 g1 + Thy1) or two (for Pik3ap1 g2 + Thy1 and Pik3ap1 g1 + Pik3ap1 g2) independent 
experiments. Bars represent the mean, with error bars +SEM. 
B. The same data as in A but for ‘stimulated + DMSO’ cells only, indicating the individual pAKT 
values from two or three independent experiments as scatter points, relative to that in stimulated 
WT cells in each experiment. Bars represent the mean for each genotype.  
 
ICOS was chosen as a third target for CRISPR/Cas9-mediated knock out from the proteins 
identified by AP-MS as TCR stimulation-dependent p110δ-interactors. Two guide crRNA 
sequences were designed to target ICOS exon 2, with Cas9 cleavage sites separated by 44 bp. 
RNP nucleofections of activated T cells were performed to test each guide in combination with 
Thy1 gRNA, as well as both guides together without Thy1 gRNA. The efficiency of indel 
formation at each target site was then assessed at 72 h and 5 days post-nucleofection (Figure 
5.8A). 
RNP complexes with either ICOS gRNA generated efficient editing of the ICOS target site, with 
gRNA 1 achieving marginally higher indel frequency than gRNA 2, of up to 54.4 % within the cell 
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population. In contrast, using a combination of both ICOS guides led to only 20 % ICOS-editing. 
One explanation for this could be that Cas9 cleavage was sterically hindered by the presence of 
adjacent Cas9 molecules, potentially due to the organisation of this exon. However, this 
observation was based on one experiment only. The frequency of ICOS indels within the 
population did not vary from 72 h to 5 days post-nucleofection, indicating that there was no 
enrichment or depletion of ICOS-knock out cells. Interestingly, one population that was edited 
with both ICOS gRNA 1 and Thy1 gRNA exhibited higher levels of Thy1 editing (79.4 %) than that 
seen in all other experiments.  
PI3K-AKT signalling upon acute TCR stimulation was also examined in ICOS-edited T blasts at day 
5 post-nucleofection (Figure 5.8A). Phosphorylation of AKT was compared with that in Thy1-
edited T blasts, for multiplex Thy1 + ICOS-edited cells, or wild type cells electroporated with 
gRNA alone, for ICOS-only edited cells (Figure 5.8B). Immunoblots from one experiment 
demonstrated that pAKT induction following TCR stimulation was slightly enhanced in ICOS-
edited cells, both with and without simultaneous knock out of Thy1, compared with that 
induced in Thy1-only-edited cells or wild type cells. However, additional replicate experiments 




Figure 5.8 PI3K-AKT signalling and gene editing efficiency in ICOS Cas9 RNP-nucleofected T 
blasts. 
Activated total T cells were nucleofected with Cas9 RNPs complexed with equimolar amounts of 
ICOS gRNA (g1 or g2) and Thy1 gRNA (g2), or equimolar amounts of ICOS gRNA g1 and gRNA g2, 
or Thy1 gRNA (g2) alone. Control (EP + gRNA) cells were electroporated with gRNA alone.  
A. At day 5 post-nucleofection, 4 million cells were stimulated with 4 μg/ml CD3+CD4+CD8 
plus 13 μg/ml crosslinking antibody for 2 minutes at 37°C, in the presence of 200 nM DMSO (-) or 
CAL101 (+), or left unstimulated in the presence of 200 nM DMSO. Cells were lysed and one-half 
of lysates were separated by SDS-PAGE and immunoblotted simultaneously for pAKT (T308) and 
total AKT1. Editing efficiency (indicated below immunoblots) was determined at 72 h and 5 days 
post-nucleofection. Editing % indicates the percentage of indels present within the total cell 
population at the Cas9 cleavage sites in ICOS and Thy1, as determined by TIDE analysis. 
B. Quantification of pAKT signal intensity as detected by immunoblotting in A, normalised to AKT1, 
presented relative to that in stimulated Thy1-edited cells, set as 1, (left), or relative to that in 
stimulated EP+gRNA cells, set as 1, (right). Data are from one experiment. 
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As a cell surface receptor, ICOS expression following gene disruption could, in theory, be 
analysed by flow cytometric analysis. However, specific antibody staining of cell surface ICOS in 
these experiments was not sufficiently higher than that of isotype control and did not allow 
separation of ICOS- and ICOS+ populations. Therefore, the multiplex editing approach, with dual 
targeting of Thy1 and ICOS, was used in subsequent experiments to be able to select ICOS knock 
out cells, in accord with the strategy used for p110δ and BCAP knock outs.  
Overall, these experiments demonstrated successful knock out of Pik3cd, Pik3ap1 and ICOS in 
primary mouse T blasts using CRISPR/Cas9 via RNP delivery. However, the efficiency of gene 
editing clearly varied depending on the gRNA used. Thus, the most efficient guides were chosen 
for subsequent experiments. Thy1 editing efficiency within the cell population was generally 
consistent at 50 - 60 % across independent experiments. In contrast, Pik3cd and Pik3ap1 editing 
sometimes varied between experiments, even when the same guide RNA sequences were used. 
Furthermore, based on the assumption that Cas9 editing generates a mixed population of 
heterozygous and homozygous knock out cells, the observed indel frequencies of 50 % within 
the population suggests that not all cells in the population were edited. The presence of 
unedited, wild type cells could mask the detection of a knock out phenotype when using whole-
population analyses such as immunoblotting. Therefore, a method for knock out-enrichment 
before acute TCR stimulation was required. 
 
5.2.4 Altered PI3K-AKT signalling in BCAP, ICOS and p110δ knock out T 
blasts upon TCR stimulation 
To improve the analysis of heterogenous knock out populations generated by the CRISPR/Cas9 
RNP approach, edited T blasts were enriched before acute TCR stimulation at day 5 post-
nucleofection. This was possible due to the multiplex editing strategy used, involving 
simultaneous targeting of Thy1 with Pik3cd, Pik3ap1 or ICOS. Based on the assumption that 
Thy1-knock out cells were also successfully edited at the second target locus, CD90- cells could 
be selected to analyse cells with knock out of Pik3cd, Pik3ap1 or ICOS. To this end, T blasts 
edited with Pik3cd-, Pik3ap1- or ICOS-targeted RNPs were enriched by depletion of CD90+ cells 
using anti-CD90-conjugated magnetic beads.  
CD90--enriched and CD90+-selected populations were then analysed for editing efficiency at 
both the Thy1 target site and the second targeted locus. Indel frequency estimated by TIDE 
revealed that the second target gene, Pik3cd, Pik3ap1 or ICOS, was edited at a much higher 
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frequency in CD90--enriched cells than in CD90+ cells (Table 5.2). Very low editing of these genes 
was detected in CD90+-selected cells. Moreover, across three independent experiments, the 
frequency of Pik3cd, Pik3ap1 or ICOS editing was higher in CD90--enriched cells than in the total 
T cell population, by 1.9-fold on average, which was in agreement with the average 2.2-fold 
enrichment of edited Thy1. Overall, this indicated that the CD90+-depletion strategy successfully 
enriched Pik3cd, Pik3ap1 or ICOS knock out cells within the population.  
Nevertheless, knock out efficiency varied depending on the target gene. Pik3ap1 knock out was 
by far the most efficient, with up to 48 % editing of this gene within the CD90--enriched 
population. Surprisingly, ICOS and Pik3cd editing was lower than the levels seen in previous 
experiments, even though the more efficient guides were used. The concurrent high efficiency 
editing of Thy1 within the same populations indicated that RNP-nucleofection had been 
successful, therefore suggesting that the low efficiency target gene editing was due to low 










Table 5.2 Gene editing efficiency in CD90--enriched, CD90+-selected and total T blasts 
following RNP nucleofection. 
Activated total T cells were nucleofected with Cas9 RNPs complexed with Thy1 gRNA 2 (CD90 KO), 
equimolar amounts of Pik3ap1 gRNA 1 and Thy1 gRNA g2 (BCAP KO), equimolar amounts of ICOS 
gRNA g1 and Thy1 gRNA g2 (ICOS KO), or equimolar amounts of Pik3cd gRNA 1, Pik3cd gRNA 2 
and Thy1 gRNA g2 (p110δ KO). At day 5 post-nucleofection, CD90+ cells were depleted from the 
total populations using anti-CD90-conjugated magnetic beads. CD90+ cells were recovered for 
DNA purification and CD90- cells were used for in vitro stimulation experiments.  
Editing efficiency was determined at 5 days post-nucleofection in total cells before bead 
depletion, and CD90--enriched and CD90+-selected cells after bead purification. Editing % 
indicates the percentage of indels present within the total cell population at the Cas9 cleavage 
sites in Thy1, Pik3ap1, ICOS or Pik3cd, as determined by TIDE analysis of Sanger sequencing traces 
of PCR amplicons spanning the targeted regions. KO fold enrichment values indicate the 
enrichment of Thy1 or target gene editing in CD90--enriched cells compared to Total Cells. 
Asterisks (*)  indicate samples for which good quality Sanger sequencing traces could not be 
obtained, therefore TIDE analysis of indel frequency at the indicated target genes within these 
populations could not be performed. Data are from three independent experiments (Expt1, Expt2 
and Expt3).  
 
 
CD90--enriched Pik3cd-, Pik3ap1-, and ICOS-edited cells were then subjected to acute TCR 
stimulation and cell lysates were analysed for pAKT by immunoblotting (Figure 5.9). The pAKT 
signals detected were quantified, normalised and compared to those in Thy1 knock out cells 




Figure 5.9 PI3K-AKT signalling and gene editing efficiency in Thy1, Pik3ap1, ICOS and Pik3cd 
CRISPR/Cas9-edited T blasts. 
Activated total T cells were nucleofected with Cas9 RNPs complexed with either Thy1 gRNA 2 
(Thy1), equimolar amounts of Pik3ap1 gRNA 1 and Thy1 gRNA g2 (Pik3ap1 + Thy1), equimolar 
amounts of ICOS gRNA g1 and Thy1 gRNA g2 (ICOS + Thy1), or equimolar amounts of Pik3cd gRNA 
1, Pik3cd gRNA 2 and Thy1 gRNA g2 (Pik3cd + Thy1). At day 5 post-nucleofection, CD90+ cells were 
depleted from the total population using anti-CD90-conjugated magnetic beads. Two million 
CD90--enriched cells of each genotype were then stimulated with 4 μg/ml CD3+CD4+CD8 plus 
13 μg/ml crosslinking antibody for 2 minutes at 37°C, in the presence of 200 nM DMSO (-) or 
CAL101 (+), or left unstimulated in the presence of 200 nM DMSO. Cells were lysed and one-half 
of the lysates were separated by SDS-PAGE, followed by immunoblotting simultaneously for pAKT 
(T308) and total AKT1. Editing efficiency in CD90--enriched cells (indicated below immunoblots) 
was determined at 5 days post-nucleofection. Editing % indicates the percentage of indels present 
within the total cell population at the Cas9 cleavage sites in Thy1, Pik3ap1, ICOS or Pik3cd, as 
determined by TIDE analysis. High quality Sanger sequencing traces could not be obtained of the 
ICOS target site for the asterisked (*) sample, therefore TIDE analysis of ICOS indel frequency 
within this population could not be performed. Immunoblots are from three independent 




Figure 5.10 Reduced pAKT upon TCR-stimulation in Pik3ap1-, ICOS- and Pik3cd-edited CD90-
-enriched T blasts. 
A. Quantification of pAKT signal intensity as detected by immunoblotting in Figure 5.9, normalised 
to AKT1 and presented relative to pAKT in stimulated Thy1-edited cells, set as 1. Data are from 
three independent experiments. Bars represent the mean, with error bars +SEM. 
B. The same data as in A but for ‘Stimulated + DMSO’ cells only, with the individual normalised 
pAKT values from three independent experiments represented as scatter points, relative to pAKT 
in stimulated Thy1-edited cells in each experiment. Bars represent the mean for each genotype.  
 
In Pik3ap1-edited T blasts there was a clear trend of reduced pAKT upon TCR stimulation (Figure 
5.10A and 5.10B). This stimulated pAKT signal was compared to that induced in control Thy1-
edited cells across three independent experiments but was not found to be significantly 
different (adjusted p value 0.1638; repeated measures one-way ANOVA with Dunnett’s multiple 
comparisons test). This was due to the variation in the observed pAKT signal across the three 
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experiments. Intriguingly, the level of reduction in pAKT correlated with the percentage of 
Pik3ap1 editing within the cell population. A 50 % reduction in pAKT was observed in two 
experiments where Pik3ap1 indel frequency reached 48.2 and 48.1 %. In contrast, only a 22 % 
reduction in pAKT was seen in cells with 23.4 % Pik3ap1 editing. These results strongly 
suggested that BCAP knock out impairs TCR-dependent PI3K-AKT signalling in activated T cells. 
Further experiments, using cells with a consistently high efficiency of BCAP knock out, would be 
required to test this hypothesis.  
A trend of slightly reduced pAKT upon TCR stimulation was also observed in ICOS-edited T blasts 
(Figure 5.10). In cells with 13.8 and 23.0 % ICOS editing within the population, a 11.6 and 24.5 % 
reduction in pAKT signal was observed, respectively, compared with control Thy1-edited cells. 
Signalling in ICOS-edited cells was not found to be significantly different to that in control cells 
due to this variation (adjusted p value 0.2592; repeated measures one-way ANOVA with 
Dunnett’s multiple comparisons test). Nevertheless, the observed trend indicates that ICOS may 
be important for TCR-induced activation of the PI3K-AKT pathway. Further experiments, using 
cells with a consistently high efficiency of ICOS knock out, would be required to test this 
hypothesis. 
Pik3cd-edited T blasts also exhibited reduced pAKT upon TCR engagement, as expected, but this 
reduction was again variable (Figure 5.10). Consequently, pAKT in stimulated Pik3cd-edited cells 
was not found to be significantly different to that in Thy1-edited cells (adjusted p value 0.3616; 
repeated measures one-way ANOVA with Dunnett’s multiple comparisons test). Nevertheless, in 
two independent experiments a 33.3 and 41.5 % reduction in the level of induced pAKT was 
observed, compared with control cells (Figure 5.10B). Interestingly, TIDE analysis of the 
sequenced Pik3cd target region estimated only low indel formation at this locus. While it cannot 
be excluded that these efficiencies were underestimated, this suggests that even partial loss of 
p110δ had a considerable impact on AKT activation. However, in one experiment, Pik3cd-edited 
cells exhibited pAKT levels equivalent to control, reflecting either low frequency knock out of 
p110δ within the population or that another PI3K subunit compensated for its loss. 
Moreover, as seen in earlier experiments, Pik3cd-edited cells exhibited increased residual pAKT 
upon TCR stimulation in the presence of the p110δ-specific inhibitor CAL101 (Figure 5.11). In 
Thy1-, Pik3ap1- and ICOS-edited cells treated with CAL101, the level of pAKT induced upon TCR 
stimulation was only 19 % of that induced in DMSO-treated cells, indicating that the majority 
of AKT phosphorylation was p110δ-dependent in these cells. In contrast, Pik3cd-edited CAL101-
114 
 
treated cells exhibited, on average, 50 % of the pAKT level induced in DMSO-treated cells. This 
was significantly different to the residual pAKT signal in CAL101-treated Thy1-edited cells 
(adjusted p value of 0.0018; one-way ANOVA with Dunnett’s multiple comparisons test). This 
strengthened the earlier conclusion that p110δ-deficient T blasts exhibit p110δ-independent 
activation of AKT upon TCR engagement.  
 
 
Figure 5.11 p110δ-independent PI3K-AKT signalling in Pik3cd-edited CD90--enriched T blasts 
upon TCR-stimulation. 
Quantification of pAKT signal intensity in CAL101-treated TCR-stimulated cells, as detected by 
immunoblotting in Figure 5.9, normalised to AKT1 and expressed as a percentage of the pAKT in 
DMSO-treated TCR-stimulated cells. Bars represent the means of three independent experiments, 
with individual values shown as scatter points. The means for each genotype were compared to 
the mean of Thy1-edited cells by one-way ANOVA with Dunnett’s multiple comparisons test. ** 
indicates statistically significant difference with a multiplicity adjusted p value of 0.0018. ns 
indicates no statistically significant difference.  
 
 
Taken together, the study of PI3K-AKT signalling in CD90--enriched Pik3ap1 and ICOS knock out 
cells provided evidence to support a positive regulatory role for BCAP and ICOS in the TCR-
induced activation of PI3K in activated T cells. Nevertheless, further experiments, using cells 





5.2.5 Interrogating cytokine production in BCAP-, p110δ- and ICOS- deficient 
T blasts upon TCR stimulation 
Biochemical analyses suggested that BCAP and ICOS positively regulate the PI3K-AKT pathway 
upon TCR engagement in activated T cells. This was reasoned to be mediated via the specific 
activation of p110δ, given that BCAP and ICOS were identified by MS as p110δ interactors and 
that phosphorylation of AKT upon TCR stimulation was p110δ-dependent in wild type T cells. 
Previous studies have shown that p110δ also regulates cytokine production in T cells 
(Okkenhaug et al, 2002; Liu et al, 2009; Gracias et al, 2016). TNFα and IFNγ production is 
reduced in mouse and human effector/memory T cells in the presence of a p110δ-specific 
inhibitor, indicating that p110δ activity is required for cytokine production in activated T cells 
(Soond et al, 2010). It was therefore hypothesised that, if BCAP and ICOS positively regulate 
p110δ activation, loss of BCAP or ICOS would impair cytokine production in T blasts upon TCR 
stimulation.  
To evaluate whether knock out of BCAP or ICOS impaired cytokine production in T blasts, 
Pik3ap1, ICOS and Pik3cd CRISPR/Cas9-edited cells were stimulated for 8 hours with plate-
bound anti-CD3, and intracellular TNFα production was then analysed by flow cytometry. These 
cells were generated from the same nucleofections as those studied in section 5.2.4. 
Due to the multiplex CRISPR/Cas9 editing approach used thus far, cells that were edited at the 
Pik3ap1, ICOS or Pik3cd target locus could be selected based on CD90 cell surface expression. 
Earlier sequencing and TIDE analysis of CD90--enriched and CD90+-selected cells confirmed that 
knock out of these target genes was enriched in CD90- cells. Therefore, CD90- cells could be 
selected following flow cytometry analysis to specifically study Pik3ap1-, ICOS- or Pik3cd-edited 
cells. However, it was unlikely that all CD90- cells would exhibit knock out of BCAP, ICOS or 
p110δ, based on the editing efficiencies within CD90--enriched populations that were estimated 
by TIDE analysis (Table 5.2). Nevertheless, by comparing CD90- and CD90+ cells it would be 
possible to analyse the effect of Pik3ap1, ICOS or Pik3cd gene disruption. Conveniently, as Thy1-
targeting did not result in a homogenous CD90-knock out population, CD90+ cells from the same 
populations could be used as internal ‘wild type’ control cells, given that the earlier sequencing 
analysis also demonstrated that CD90+ cells exhibited very low levels of target gene editing. 
Thus, this strategy was used to analyse intracellular TNFα production in BCAP, ICOS and p110δ 
knock out cells. 
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Production of TNFα upon TCR stimulation was first examined in CD4+ T blasts (Figure 5.12). TNFα 
mean fluorescence intensity (MFI), detected by flow cytometry, was compared in CD90-TNFα+ 
and CD90+TNFα+ CD4+ cells from each of the Pik3ap1, ICOS and Pik3cd multiplex-edited 
populations, as well as the control population that was only targeted for editing at the Thy1 
locus (Figure 5.12A). This analysis revealed that CD90- CD4+ cells exhibited slightly higher TNFα 
MFI than CD90+ CD4+ cells. Interestingly, this difference was reduced in each of the multiplex-
edited populations, such that Pik3cd-edited CD90- cells produced equivalent levels of TNFα as 
CD90+ cells in the same sample. Due to this difference between CD90- and CD90+ cells, it was 
also crucial to compare each of the multiplex-edited CD90- populations with Thy1-only edited 
CD90- cells, rather than CD90+ cells from the same sample. To this end, TNFα production in 
Pik3ap1-, ICOS- and Pik3cd-edited CD90- cells was compared to that in Thy1-only edited CD90- 
cells (Figure 5.12B). There was no significant difference in TNFα MFI in each of the genotypes 
compared with Thy1-only edited CD90- cells (tested by one-way ANOVA with Dunnett’s multiple 
comparisons test). This may have been due to variation across the three independent 
experiments owing to differences in gene editing efficiency. Nevertheless, Pik3cd-edited CD90- 
CD4+ cells exhibited slightly reduced TNFα production compared to CD90- cells. Unexpectedly, 
there was a very small trend for increased TNFα production in Pik3ap1- and ICOS-edited CD90- 
cells, but this was not significant. Overall, it was interesting that the increased TNFα production 
observed in CD90- cells, relative to CD90+ cells, was reduced upon simultaneous editing of 
Pik3ap1, ICOS or Pik3cd (Figure 5.12A). This suggests that loss of either BCAP, ICOS or p110δ 
causes a reduction in TCR-induced TNFα production in CD90-CD4+ T blasts. However, it could not 
be ruled out that low level Pik3ap1- and ICOS-editing in CD90+ cells led to increased TNFα 




Figure 5.12 TNFα production upon TCR stimulation in BCAP, ICOS and p110δ knock out CD4+ 
T blasts. 
Activated total T cells were nucleofected with Cas9 RNPs as detailed in Figure 5.9. At day 5 post-
nucleofection, 200,000 cells of each genotype in duplicate were stimulated on 96-well plates 
coated with anti-CD3 (0.2 μg per well) in the presence of brefeldin A for 8 hours at 37°C. Cells 
were then analysed by flow cytometry for intracellular TNFα.  
A. TNFα production in CD4+CD90- cells relative to CD4+CD90+ cells. The mean fluorescence 
intensity (MFI) of TNFα antibody staining in TNFα+CD90- cells is expressed as a ratio of the TNFα 
MFI detected in TNFα+CD90+ cells (CD90-/CD90+). Bars represent the means of three independent 
experiments, with individual values shown as scatter points. Each value represents the average 
of duplicate samples. The means for each genotype were compared to the mean for Thy1-edited 
cells by one-way ANOVA with Dunnett’s multiple comparisons test. Asterisks indicate statistically 
significant differences with multiplicity adjusted p values of 0.0153 (*) and 0.0004 (***). ns 
indicates no statistically significant difference (adjusted p value 0.1126). 
B. TNFα production in CD4+CD90+ and CD4+CD90- T blasts. Individual values for TNFα MFI in TNFα+ 
cells from three independent experiments are shown as scatter points. Each value represents the 
average of duplicate samples. Black error bars show the mean ± SD. The means for CD90- cells of 
each genotype were compared to the mean for CD90- Thy1-edited cells by one-way ANOVA with 
Dunnett’s multiple comparisons test. ns indicates no statistically significant difference.  
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TNFα production was also analysed in CD8+ T blasts following TCR stimulation (Figure 5.13). 
CD8+TNFα+ T blasts produced higher levels of TNFα than that seen in CD4+ cells. In contrast to 
CD4+ cells, CD90- CD8+ cells exhibited slightly lower TNFα MFI than CD90+ CD8+ cells. This 
difference was greater in Pik3ap1- and Pik3cd-edited CD90- CD8+ cells (Figure 5.13A). Therefore, 
it was again necessary to compare each of the multiplex-edited CD90- populations with Thy1-
only edited CD90- cells, rather than CD90+ cells. This revealed that there was no significant 
difference in TNFα MFI in each of the genotypes compared with Thy1-only edited CD90- cells 
(Figure 5.13B; tested by one-way ANOVA with Dunnett’s multiple comparisons test). There was, 
however, a trend for decreased TNFα production in Pik3cd-edited CD90- CD8+ cells, compared 
with Thy1-only edited CD90- CD8+ cells. Overall, it was interesting that the reduced TNFα 
production in CD90- CD8+ cells, relative to CD90+ CD8+ cells, was further decreased upon 
simultaneous editing of Pik3ap1 or Pik3cd (Figure 5.13A). This suggests that loss of either BCAP 





Figure 5.13 TNFα production upon TCR stimulation in BCAP, ICOS and p110δ knock out CD8+ T 
blasts. 
Activated total T cells were nucleofected with Cas9 RNPs as detailed in Figure 5.9. At day 5 post-
nucleofection, 200,000 cells of each genotype in duplicate were stimulated on 96-well plates coated 
with anti-CD3 (0.2 μg per well) in the presence of brefeldin A for 8 hours at 37°C. Cells were then 
analysed by flow cytometry for intracellular TNFα.  
A. TNFα production in CD8+CD90- cells relative to CD8+CD90+ cells. The mean fluorescence intensity 
(MFI) of TNFα antibody staining in TNFα+CD90- cells is expressed as a ratio of the TNFα MFI detected 
in TNFα+CD90+ cells (CD90-/CD90+). Bars represent the means of three independent experiments, with 
individual values shown as scatter points. Each value represents the average of duplicate samples. The 
means for each genotype were compared to the mean for Thy1-edited cells by one-way ANOVA with 
Dunnett’s multiple comparisons test. Asterisks indicate statistically significant differences with 
multiplicity adjusted p values of 0.0311 (*) and 0.0076 (**). ns indicates no statistically significant 
difference (adjusted p value 0.8237). 
B. TNFα production in CD8+CD90- and CD8+CD90+ T blasts. Individual values for TNFα MFI in TNFα+ cells 
from three independent experiments are shown as scatter points. Each value represents the average 
of duplicate samples. Black error bars show the mean ± SD. The means for CD90- cells of each genotype 
were compared to the mean for CD90- Thy1-edited cells by one-way ANOVA with Dunnett’s multiple 
comparisons test. ns indicates no statistically significant difference.  
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The effect of p110δ-inhibition on TCR-induced TNFα production was also examined in CD4+ and 
CD8+ knock out T blasts. To this end, TNFα MFI was compared in CAL101- and DMSO-treated 
cells of each genotype (Figure 5.14). There was no difference in CAL101 sensitivity between 
Thy1-only edited CD90- and CD90+ cells. This indicates that TNFα production is equally p110δ-
dependent in CD90- and CD90+ T blasts. It was also observed that TNFα production was reduced 
to a greater extent in CAL101-treated CD4+ cells than CD8+ cells. This suggests that TNFα 
production in CD4+ T blasts is more p110δ-dependent than in CD8+ T blasts. The effect of 
CAL101 on TNFα production in Pik3ap1-, ICOS- and Pik3cd-edited CD90- CD4+ cells was then 
compared with the effect on Thy1-only edited CD90- cells (Figure 5.14A). There was no 
significant difference in CAL101 sensitivity in Pik3ap1- or ICOS-edited CD90- CD4+ cells compared 
with Thy1-only edited CD90- CD4+ cells. In contrast, TNFα production in Pik3cd-edited CD90- 
CD4+ cells was significantly less sensitive to p110δ-inhibition than in Thy1-only edited CD90- 
CD4+ cells (adjusted p value of 0.0102; one-way ANOVA with Dunnett’s multiple comparisons 
test). This suggests that a higher proportion of TNFα production in the Pik3cd-edited CD90- 
population was p110δ-independent, possibly corresponding to p110δ-deficient CD4+ cells. This 
phenotype was similar to that seen in earlier biochemical analyses of PI3K-AKT signalling in 
Pik3cd-edited CD90--enriched total T blasts.  
The effect of CAL101 on TNFα production in Pik3ap1-, ICOS- and Pik3cd-edited CD90- CD8+ cells 
was then analysed, with comparison to Thy1-only edited CD90- CD8+ cells (Figure 5.14B). There 
was no significant difference in CAL101 sensitivity in any of the multiplex-edited CD90- CD8+ cells 
compared with Thy1-only edited CD90- CD8+ cells. However, ICOS- and Pik3cd-edited CD90- CD8+ 
T blasts demonstrated slightly less CAL101 sensitivity with respect to TNFα production, 





Figure 5.14 The effect of p110δ-inhibition on TNFα production upon TCR stimulation in BCAP, 
ICOS and p110δ knock out T blasts. 
Activated total T cells were nucleofected with Cas9 RNPs as detailed in Figure 5.9. At day 5 post-
nucleofection, 200,000 cells of each genotype in duplicate were stimulated on 96-well plates coated 
with anti-CD3 (0.2 μg per well) in the presence of brefeldin A and either 200 nM CAL101 or 200 nM 
DMSO for 8 hours at 37°C. Cells were then analysed by flow cytometry for intracellular TNFα. The 
mean fluorescence intensity (MFI) of TNFα antibody staining in CAL101-treated TNFα+CD90- (red) and 
TNFα+CD90+ (blue) cells is expressed as a ratio of the TNFα MFI detected in the equivalent DMSO-
treated cells (CAL101/DMSO). Individual values from three independent experiments are shown as 
scatter points. Each value represents the average of duplicate samples. Black error bars show the 
mean ± SD. The means for CD90- cells of each genotype were compared to the mean of CD90- Thy1-
edited cells by one-way ANOVA with Dunnett’s multiple comparisons test.  
A. TNFα production in CAL101-treated CD4+ T blasts, relative to DMSO treated cells. * indicates a 
statistically significant difference with a multiplicity adjusted p value of 0.0102. ns indicates no 
statistically significant difference.  
B. TNFα production in CAL101-treated CD8+ T blasts, relative to DMSO treated cells. ns indicates no 




In addition to investigating TNFα production in knock out T blasts, the proportion of TNFα-IFNγ 
double cytokine producing cells upon TCR stimulation was considered. IFNγ production in 
effector/memory T cells is also regulated by p110δ (Soond et al, 2010), and TNFα-IFNγ double 
producing T cells represent those that have differentiated upon antigenic stimulation to a stage 
of enhanced effector function (Seder et al, 2008). Examination of TNFα+IFNγ+ CD90- and CD90+ 
cells within CD4+ and CD8+ populations from all knock out genotypes revealed that the 
percentage of these cells generated upon TCR stimulation followed the same trends observed 
for TNFα production in Thy1-, Pik3ap1-, ICOS- and Pik3cd-edited T blasts (Figure 5.15). In 
summary, a slightly higher proportion of CD4+ CD90- cells were double producers than CD4+ 
CD90+ cells (Figure 5.15A). Interestingly, this difference was reduced slightly upon simultaneous 
editing of Pik3ap1 or ICOS, and significantly upon editing of Pik3cd. Each CD4+ CD90- genotype 
was also compared with Thy1-only edited CD90- cells (Figure 5.15B). This revealed no significant 
difference in the proportion of double producers in Pik3ap1- or Pik3cd-edited CD90- T blasts 
compared to the control. There was, however, a small significant increase in double producers 
in ICOS-edited CD90- CD4+cells. In the CD8+ populations, a slightly lower proportion of CD90- 
cells were double producers than CD90+ cells (Figure 5.15C). This difference was not significantly 
increased upon simultaneous editing of Pik3ap1, ICOS or Pik3cd, although there was some 
indication that Pik3ap1-editing had a small effect. Each CD8+ CD90- genotype was then 
compared with Thy1-only edited CD90- cells (Figure 5.15D). This revealed no significant 
difference in the proportion of double producers in Pik3ap1-, ICOS- or Pik3cd-edited CD90- T 




Figure 5.15 The proportion of TNFα-IFNγ-producing cells upon TCR stimulation in BCAP, ICOS 
and p110δ knock out T blasts. 
Activated total T cells were nucleofected with Cas9 RNPs as detailed in Figure 5.9. At day 5 post-
nucleofection, 200,000 cells of each genotype in duplicate were stimulated on 96-well plates 
coated with anti-CD3 (0.2 μg per well) in the presence of brefeldin A for 8 hours at 37°C. Cells 
were then analysed by flow cytometry for intracellular TNFα and IFNγ.  
A and C. Percentage of TNFα+IFNγ+ CD90- cells relative to TNFα+IFNγ+ CD90+ cells. The percentage 
of TNFα+IFNγ+CD90- cells is expressed as a ratio of the percentage of TNFα+IFNγ+CD90+ cells (CD90-
/CD90+). Bars represent the means of three independent experiments, with individual values 
shown as scatter points. Each value represents the average of duplicate samples. The means for 
each genotype were compared to the mean for Thy1-edited cells by one-way ANOVA with 
Dunnett’s multiple comparisons test. In A, * indicates a statistically significant difference with a 
multiplicity adjusted p value of 0.0340. ns indicates no statistically significant difference.  
B and D. Percentage of TNFα+IFNγ+ CD90- cells and TNFα+IFNγ+ CD90+ cells. Individual percentages 
of TNFα+IFNγ+ CD90- and CD90+ cells from three independent experiments are shown as scatter 
points. Each value represents the average of duplicate samples. Black error bars show the mean 
± SD. The means for CD90- cells of each genotype were compared to the mean for CD90- Thy1-
edited cells by one-way ANOVA with Dunnett’s multiple comparisons test. ns indicates no 
statistically significant difference. In B, * indicates a statistically significant difference with a 
multiplicity adjusted p value of 0.0372. ns indicates no statistically significant difference.  
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Taken together, the study of cytokine production upon TCR stimulation revealed only small 
differences in Pik3ap1-, ICOS- and Pik3cd-edited T blasts compared with Thy1-edited cells. In 
CD8+ T blasts, there was a slight decrease in cytokine production upon Pik3ap1 or Pik3cd knock 
out. In CD4+ T blasts, there was a slight decrease in cytokine production upon Pik3cd knock out 
in CD90- cells. Pik3ap1 or ICOS knock out reduced the phenotype of increased cytokine 
production in CD90- CD4+ cells compared with CD90+ CD4+ cells. These experiments suggest that 
BCAP and ICOS play a role in regulating cytokine production in T blasts, but this may differ in 
CD8+ and CD4+ cells. However, the small differences observed, and the potential interplay with 
loss of CD90 expression, confounds the interpretation of these results. Furthermore, the 
differences in editing efficiency across the three independent experiments possibly contributed 
to the variability in cytokine production within each genotype, thus reducing the confidence in 
the observed differences. Further experiments, achieving a consistently high efficiency of target 
knock out, would be required to investigate these phenotypes. Nevertheless, one observed 
phenotype was in accord with earlier biochemical analyses of PI3K-AKT signalling in Pik3cd-
edited CD90--enriched total T blasts. TNFα production in the Pik3cd-edited CD4+ CD90- 
population was less p110δ-dependent than in Thy1-edited CD4+ CD90- cells, and this trend was 
also noticeable in CD8+ Pik3cd-edited cells and ICOS-edited CD4+ and CD8+ cells. This CAL101-
resistant TNFα production may have originated from p110δ- and ICOS-deficient cells, thus 
suggesting that another PI3K isoform or pathway was compensating for their loss. However, 
further experiments would be required to investigate these small phenotypic differences. 
 
5.3 Discussion 
This body of work set out to develop a CRISPR/Cas9-mediated gene editing approach to knock 
out proteins of interest in primary mouse activated T cells. The results of this work have 
demonstrated that ribonucleoprotein (RNP) nucleofection is a viable and effective method for 
delivering Cas9 protein and guide RNA to primary mouse T cells. Using this approach, it was 
possible to successfully knock out genes encoding CD90, BCAP, ICOS and p110δ in vitro in both 
CD4+ and CD8+ T blasts. This enabled the subsequent study of the role of BCAP and ICOS in PI3K 
signalling in the same physiological setting in which they were identified by mass spectrometry 
as p110δ-interacting proteins.   
As part of this study, the conditions for RNP nucleofection of primary activated mouse T cells 
were optimised, with respect to the amount of Cas9, gRNA and cells used. This process was 
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successful, achieving a substantial improvement in knock out efficiency from only 20 - 30 % to 
over 60 %. Despite this improvement, it was noted that the highest amount of Cas9 that was 
tested in optimisation experiments was also calculated as the optimal quantity for high 
efficiency knock out. This indicated that the experimental space tested did not cover the ‘true’ 
optimum. Hence, the maximum efficiency that could be achieved with the optimised protocol 
was predicted to equal the highest that was observed in the optimisation experiment, which 
was approximately 50 %. Indeed, in subsequent experiments, the frequency of indel formation 
at the Thy1 locus was usually 50 - 60%. Therefore, it is possible that greater editing efficiency 
could be achieved using increased amounts of Cas9. Future work will include another set of 
optimisation experiments that test higher Cas9 protein amounts. The results from this should 
nevertheless take into account the resources available and the level of knock out efficiency 
required for downstream assays. Using flow cytometry-based single-cell analysis, 50 % knock 
out within a population is generally acceptable if the edited cells can be selected using a cell 
surface or intracellular marker. In addition, the presence of unedited cells provides a useful 
internal control for phenotypic analysis. However, in the absence of a marker for successful 
knock out, or for whole-population analyses such as immunoblotting, high efficiency editing in 
the majority of the population would be required. 
While the RNP nucleofection protocol is a focal point for improvement, the experiments in this 
study have shown that the guide crRNA sequence used has a significant impact on the editing 
efficiency achieved, as does the targeted locus itself. Consistently lower editing of ICOS and 
Pik3cd was observed compared to Pik3ap1 and Thy1, as estimated by TIDE analysis. Thus, knock 
out efficiency for these targets may be improved in future experiments by designing new guide 
crRNAs. However, it is also likely that some genomic sequences are simply more resistant to 
editing than others (Wu et al, 2014; Liu et al, 2016). Alternatively, faithful repair of double 
strand breaks, without indel formation, may be more efficient at some genomic sites. Therefore, 
achieving equivalent knock out efficiency when targeting multiple genes may require gene-by-
gene optimisation for future experiments.  
Another interesting observation made in this study was the apparent higher efficiency of protein 
knock out in CD8+ T blasts compared to CD4+ cells. This did not appear to be due to slower 
protein turnover or a survival disadvantage in CD4+CD90- T cells, thus suggesting that the extent 
of gene editing differed in these two subsets. This could be because CD8+ cells are more 
proliferative than CD4+ cells in response to IL-2 and enter the S phase of the cell cycle sooner 
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(Smith et al, 2017). By completing more rounds of cell division than CD4+ cells in the presence of 
Cas9 RNPs, the CD8+ population could accumulate a higher frequency of Cas9 cleavage-induced 
indels. 
In the current study, knock out of the intracellular proteins p110δ and BCAP presented the 
challenge of how to select successfully edited cells in downstream analyses. This is a widely 
recognised difficulty in the implementation of CRISPR/Cas9-editing in primary human and 
mouse cells (Schumann et al, 2015). For cell surface targets, flow cytometry allows the 
separation of knock out cells upon analysis, and can also be used for flow cytometry-assisted cell 
sorting before biochemical analyses. In the current work, a multiplex editing strategy was used 
to solve the selection issue. This involved simultaneous Cas9-mediated disruption of Thy1 with 
target genes, leading to the loss of CD90 surface expression on knock out cells. This study also 
confirmed by sequencing and TIDE analysis the assumption that CD90 knock out correlated with 
editing at the second target locus, thus demonstrating the validity of this selection method. 
Thus, this strategy allowed for the enrichment of CD90- knock out cells for biochemical analysis 
using anti-CD90-conjugated magnetic bead-mediated depletion of CD90+ cells. It also enabled 
selection of CD90- cells, and comparison with CD90+ cells, following flow cytometric analysis. 
There were, however, two caveats associated with this approach. Firstly, sequencing and TIDE 
analysis of CD90--enriched cells revealed that the extent of target gene disruption within this 
population did not reach the same frequency as Thy1 editing. The maximum observed editing of 
Pik3ap1, for example, was 50 % within CD90--enriched cell populations. While this could, at 
most, reflect a 100 % heterozygous BCAP knock out population, it is more likely that the 
population was heterogenous, with homozygous and heterozygous knock out cells. Thus, in the 
experiments presented in this study, selection or enrichment of CD90- cells did not necessarily 
equate to selection of BCAP, ICOS or p110δ knock out cells. Therefore, knockout phenotypes 
could have been masked by the presence of unedited or heterozygous cells within the CD90- 
population. In this respect, it is remarkable that functional impacts were observed in ICOS- and 
Pik3cd-edited CD90- cells in experiments where the editing efficiencies at the ICOS and Pik3cd 
loci, respectively, were estimated to be relatively low. There are two possible explanations for 
this: either, sequencing combined with TIDE analysis underestimated the extent of editing, or, 
even a partial deficiency in p110δ or ICOS has a detectable effect on T cell signalling. TIDE 
analysis has been shown to estimate indels similarly to next generation sequencing (Sentmanat 
et al, 2018) and is limited mainly by the quality of Sanger sequencing traces that can be 
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obtained for the target locus. Thus, the latter explanation may be likely. Further optimisation to 
the RNP nucleofection protocol in future experiments may lead to higher editing efficiency of 
ICOS, Pik3ap1, Pik3cd and Thy1, and this may bring the editing frequency of each target to 
equivalent levels. In this scenario, CD90- cells would represent a homogenous population of 
double knock outs and knock out phenotypes would not be diluted. Ideally, a highly efficient 
level of editing would remove the need for a method of selection. 
The second caveat associated with the Thy1 multiplex editing approach was only revealed upon 
the analysis of cytokine production in T blasts by flow cytometry. In these experiments, CD90- 
cells demonstrated slightly different levels of cytokine production than CD90+ cells. Intriguingly, 
compared with CD90+ cells, TNFα production and the proportion of TNFα-IFNγ double producers 
was higher in CD90- CD4+ populations, but lower in CD90- CD8+ populations. This suggests that 
loss of CD90 influences cytokine production in an inverse manner in CD4+ and CD8+ T cells. CD90 
is a GPI-anchored protein highly expressed on the T cell surface, with a somewhat enigmatic role 
in cell adhesion and signalling. Its inherent lateral mobility between plasma membrane lipid 
domains has led to the hypothesis that it may influence the localisation of membrane-
associated proteins (Barker & Hagood, 2009). In this respect, loss of CD90 could impair or 
augment TCR signalling by altering the trafficking or partitioning of molecules such as the TCR 
itself, or SFKs via their palmitoylated residues (Shenoy-Scaria et al, 1993). In any case, the 
observed effect of CD90 knock out in the experiments presented herein necessitated that 
multiplex-edited CD90- cells be compared with Thy1-only knock out CD90- cells as a control.  
Biochemical analysis of PI3K-AKT signalling upon TCR stimulation in the knock out T blasts 
generated in this work revealed trends for reduced AKT phosphorylation upon loss of BCAP, 
ICOS or p110δ. Phosphorylation of AKT was reduced by up to 50 % in total T blast populations 
exhibiting 50 % knock out of Pik3ap1, encoding BCAP. Phosphorylation of AKT was reduced by 
up to 25 % in total T blast populations exhibiting lower editing frequency of ICOS. In populations 
with seemingly low editing of Pik3cd, encoding p110δ, up to a 40 % reduction in AKT 
phosphorylation was observed. Due to variable CRISPR/Cas9 editing efficiency, it was necessary 
to correlate observed phenotypes with the extent of target gene disruption in the population of 
cells analysed. It was generally consistent that higher gene disruption led to greater reduction in 
PI3K-AKT signalling, which adds confidence to the interpretation of the phenotypes as being 
resultant of loss-of-function editing of the specific target. It also supports the conclusion that 
BCAP and ICOS are positive regulators of PI3K signalling. Thus, BCAP may play an analogous role 
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to that in B cells, serving as a PI3K adaptor recruiting p110δ to the TCR in activated T cells. ICOS 
may also act as a PI3K adaptor in the absence of ICOS ligation, upon TCR and CD4/CD8 
crosslinking.  
Analysis of PI3K-AKT signalling in the presence of p110δ-specific pharmacological inhibition 
revealed an interesting adaptation in Pik3cd knock out T blasts. TCR stimulation induced p110δ-
independent phosphorylation of AKT in these cells, which accounted for 50 % of the pAKT 
induced. This suggests that another PI3K isoform, possibly p110α, substituted for p110δ in 
Pik3cd-edited T blasts. Interestingly, a similar phenotype was observed when investigating 
cytokine production upon TCR stimulation. Pik3cd knock out CD4+ cells, and to an extent CD8+ 
cells, exhibited a higher proportion of p110δ-independent TNFα production, suggesting that 
another isoform may have compensated for its loss. It was also clear from these experiments 
that TNFα production in T blasts is not completely sensitive to p110δ inhibition. The p110δ-
specific inhibitor CAL101 reduced TNFα production by approximately 20 % and 40 % in CD8+ and 
CD4+ cells, respectively. This suggests that measuring cytokine production is perhaps not a 
robust assay to study the effect of protein knock out on p110δ-mediated signalling in activated T 
cells. Indeed, the effects of Pik3ap1, ICOS or Pik3cd knock out on cytokine production that were 
observed in this study were very small. This would have been exacerbated by the extent of gene 
editing, and consequently the proportion of knock out cells, within the populations studied. 
Thus, robust conclusions could not be drawn from the results. Nevertheless, there was evidence 
to suggest that BCAP and ICOS play a role in regulating cytokine production in T blasts, but this 
may differ in CD8+ and CD4+ cells. This would correspond with their proposed function as 
adaptor proteins for PI3K at the TCR signalosome. Further experiments are required to test this 
hypothesis.  
To conclude, this body of work has developed a CRISPR/Cas9-mediated gene editing approach 
using RNP nucleofection to disrupt proteins of interest in primary mouse activated T cells. Knock 
out of genes encoding BCAP, ICOS and p110δ allowed interrogation of their functions by 
biochemical and flow cytometry analyses. The results of these assays, in combination with 
analyses of CRISPR/Cas9 editing efficiency, strongly suggest that improvements to knock out 
efficiency will reveal robust knock out phenotypes in future experiments. Optimising gene 
editing efficiency would also likely remove the need for a selection marker for knock out cells, 
and thus abrogate the associated caveats. Nevertheless, this study has demonstrated that 
multiplex CRISPR-editing can be used to remove a surface marker on edited cells, which can 
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subsequently enable enrichment or selection for whole-population or single-cell analysis 
methods, respectively. This CRISPR/Cas9 approach has been used thus far to study the function 
of BCAP and ICOS in TCR-PI3K signalling in primary T blasts. Following further optimisation, it can 









A key aim of this study was to identify proteins involved in the recruitment and activation of 
p110δ upon engagement of the TCR. Using a combination of proteomic, biochemical and gene 
editing approaches, this work has identified proteins that associate with p110δ in activated CD4+ 
T cells before and after TCR stimulation and interrogated the roles of two proposed regulators 
of PI3K activity, BCAP and ICOS.  
The physiological relevance of this work is evidenced by its investigation of endogenous proteins 
in primary murine T lymphocytes throughout. Previous studies of TCR and PI3K signalling using 
immortalised T cell lines have yielded conflicting results with respect to T cell activation and co-
stimulation, in part because they exhibit constitutive PI3K activation (Astoul et al, 2001). This 
can be attributed to the fact that Jurkat T cell lines lack expression of a number of key proteins, 
including PTEN and SHIP-1 (Gioia et al, 2018). Thus, the results of the proteomic analysis herein 
provide a valuable insight into the molecular events of T cell activation proximal to the TCR. 
They also shed light on the mechanisms of PI3K activation via the TCR and identify new players 
in this pathway. 
An important aspect of this study was the optimisation of the AviTag affinity purification 
approach, specifically for the isolation of p110 isoforms from primary lymphocytes following 
TCR stimulation. This was with the aim to improve the recovery of transient stimulation-
dependent PI3K complexes. The technique was subsequently coupled with a quantitative 
proteomic analysis for the unbiased identification of proteins associated with p110δ in primary 
CD4+ T cells. Analyses of the proteins identified by mass spectrometry led to the selection of 24 
proteins of interest that specifically associated with p110δ. Strikingly, 11 of these proteins were 
distinctly associated with p110δ in a TCR stimulation-dependent manner, indicating that they 
may be involved in the regulation of PI3K activity upon TCR engagement. Notably, the successful 
isolation and identification of such interactors highlights the efficacy of the optimised 





6.1 The p110δ interactome in activated CD4+ T cells 
The majority of the 24 p110δ-associated proteins identified in this study are known to play a 
role in TCR signal transduction. Moreover, the molecular mechanisms of their recruitment to the 
TCR signalosome are well studied, albeit not necessarily resolved. Remarkably, many have been 
found to interact directly with p85 in previous studies, either in primary lymphocytes, Jurkat T 
cells or in vitro, as reviewed in Chapter 3. Thus, it is possible to speculate on the molecular 
organisation and regulation of the p110δ interactome that was identified herein. The 
constitutive or TCR stimulation-dependent nature of each association provides invaluable 
context to the models proposed. 
Collectively, the proteomic analysis suggests that p110δ associates with several interconnected 
protein complexes at the TCR signalosome. One such complex may involve the Gab-family 
adaptors, GAB2 and GAB3, which are recruited to tyrosine phosphorylated LAT via GRB2 and 
associate with PIP3 in the plasma membrane (Yamasaki et al, 2003). Binding to the GAB YxxM 
motifs is one plausible mechanism by which PI3K may be simultaneously recruited to the TCR 
signalosome and activated. The inclusion of the tyrosine phosphatase SHP-2 in this complex, 
through binding to GAB2, could provide a means to downregulate PI3K activity by disrupting 
these phosphotyrosine-dependent interactions; this is speculative based on a similar 
mechanism observed for GAB1:SHP-2 in other cell types (Koncz et al, 2001; Zhang et al, 2002), 
but warrants further investigation. Interestingly, GAB2-deficient naïve T cells exhibit increased 
proliferation in response to anti-CD3 or anti-CD3+anti-CD28 co-stimulation, indicating that GAB2 
plays an inhibitory role in TCR stimulation in naïve cells. Further interrogation of the PI3K-AKT 
pathway in GAB2-deficient activated T cells is required to investigate its role in PI3K regulation. 
The p110δ interactome comprised several proteins that interact with CBL, including CBL itself, 
and thus it is possible that PI3K also forms a complex with CBL upon TCR stimulation. Indeed, 
CBL is tyrosine phosphorylated at a YxxM motif upon TCR stimulation (Hunter et al, 1999). 
Aside from its E3 ubiquitin ligase activity, the multidomain architecture of CBL suggests that it 
could act as a scaffolding protein. In this respect, it is intriguing that p110δ was found to be 
constitutively associated with the CBL interactors CRK, CRKL, CD2AP and SH3KBP1. These 
proteins could therefore facilitate the association of PI3K with CBL upon TCR stimulation. A 
further addition to this model is based on the identification of the co-receptor CD5 as a 
stimulation-dependent p110δ interactor. It has been demonstrated that CBL associates with 




Thus, the proposed CBL:PI3K complex could be localised to the plasma membrane via CD5. 
Alternatively, CBL:PI3K may be localised to the TCR via the TCR stimulation-dependent 
CD3ζ:ZAP-70:CBL complex that has been observed in Jurkat T cells (Wang et al, 2001). An 
obvious question is whether the proposed association of p85 with CBL leads to the 
ubiquitination of PI3K, as observed in other cell types (Dufour et al, 2008; Bulut et al, 2013). 
This would indicate another level of regulation of PI3K activity in T cells. Experiments 
examining the ubiquitination status of p85 and p110δ upon TCR stimulation would be 
required to investigate this further. Nevertheless, it is interesting that CBL-deficient mature 
CD4+ T cells exhibit reduced proliferation and ERK activation in response to anti-CD3 
stimulation (Naramura et al, 2002). It could be that the adaptor function of CBL mediates a 
positive regulatory role upon TCR stimulation in mature T cells, involving the recruitment and 
activation of p110δ. 
An interesting link between the proposed GAB:PI3K and CBL:PI3K complexes are the proteins 
CRK and CRKL; the Crk-family SH2 domain can bind to phosphorylated YxxP motifs present in 
both CBL and GAB2, as well as the tyrosine phosphorylated CD3ζ chain (Reedquist et al, 1996; 
Sármay et al, 2006; Dong et al, 2017). Moreover, the Crk-family proteins are thought to stabilise 
the binding of p85 to CBL (Gelkop et al, 2001). CRK and CRKL were both constitutively associated 
with p110δ in the present study, and thus could represent key adaptors that allow recruitment 
of PI3K to the TCR signalosome upon tyrosine phosphorylation of CBL, GAB2 and CD3ζ. 
Proteomic analysis also revealed that p110δ associated with the co-stimulatory receptors ICOS 
and CD28 upon TCR stimulation, both of which contain YxxM motifs in their cytoplasmic tails. It 
is intriguing that this association with ICOS and CD28 occurred upon CD3+CD4 crosslinking 
alone, in the absence of professional antigen-presenting cells that express their natural ligands 
ICOS-L and B7-1/B7.2, respectively. This suggests that ICOS and CD28 may act as adaptors for 
PI3K recruitment to the plasma membrane independently of ligation. In support of this, a recent 
report indicated that p85α associates with ICOS in primary mouse CD4+ T cells upon CD3 
crosslinking alone (Pedros et al, 2016). One explanation for the apparent ‘in trans’ TCR-induced 
recruitment of PI3K to ICOS and CD28 is that, following the clustering of CD3 and CD4 at the cell 
surface, ICOS and CD28 co-receptors are also co-localised with the TCR and are tyrosine 
phosphorylated at their YxxM motifs, allowing p85 to bind. This may serve to amplify or sustain 




production of PIP3 and phosphorylation of AKT over time following CD3+CD4 crosslinking in 
ICOS-deficient and CD28-deficient CD4+ T blasts. 
One limitation of the proteomic analysis performed herein is that it only provides a snapshot of 
the p110δ interactome at the 1 minute timepoint following TCR stimulation. An indication of 
how these proteins regulate PI3K recruitment and activation following TCR stimulation could be 
obtained via a time-resolved AP-MS analysis. This would uncover the sequence of protein 
interactions with p110δ and transient patterns of binding, thus revealing the temporal 
organisation of the p110δ protein network. It would be interesting to see whether tyrosine 
phosphorylated components of the proposed PI3K:CBL and PI3K:GAB complexes show similar 
kinetics of assembly with, and disassembly from, p110δ. Furthermore, it was noteworthy that 
several negative regulatory proteins were found to be associated with p110δ, including CBL and 
the phosphatases STS-2 and SHP-2. Uncovering the dynamics of their interaction with p110δ 
could provide an interesting perspective to the membrane proximal events leading to TCR 
downregulation. Therefore, as part of the present study, p110δ affinity purifications have been 
performed at several timepoints following TCR stimulation of CD4+ T blasts and, at the time of 
writing, await analysis by mass spectrometry.  
 
6.2 BCAP as an adaptor for PI3K in activated T cells 
Perhaps the most surprising adaptor identified as a p110δ-specific interactor in this study was 
BCAP, due to the fact that it was not previously known to be expressed in T lymphocytes. 
Further work has demonstrated that BCAP is upregulated in activated CD4+ T cells and is rapidly 
tyrosine phosphorylated upon TCR stimulation, and this appears to correlate with its association 
with p85. Thus, BCAP appears to be a key component of the TCR signalling pathway in activated 
T cells. Based on these results, and the proposed role for BCAP as a PI3K adaptor in B cells 
(Okada et al, 2000; Castello et al, 2013), it is likely that BCAP acts as an adaptor for PI3K in 
activated T cells.  
To investigate this hypothesis, this study used a CRISPR/Cas9 gene editing approach to knock 
out BCAP (Pik3ap1) in primary activated murine T cells. Interrogation of PI3K-AKT signalling in 
Pik3ap1-edited cells provided evidence to support the hypothesis that BCAP plays a positive 
regulatory role in the TCR-induced activation of PI3K in activated T cells. Notably, T blasts with a 




AKT upon TCR stimulation. However, as discussed previously, further experiments studying T 
blasts with a consistently high efficiency of BCAP knock out are required to robustly test this 
hypothesis. Interestingly, at the time of writing, a report was published demonstrating a role for 
BCAP in the clonal expansion and differentiation of effector and memory CD8+ T cells (Singh et 
al, 2018). Furthermore, Pik3ap1−/− activated CD8+ T cells demonstrated reduced phosphorylation 
of AKT upon stimulation with anti-CD3. This supports the observations and conclusions from the 
present study that BCAP acts as an adaptor for the recruitment and activation of PI3K in 
activated T cells upon TCR stimulation. 
Nevertheless, the mechanism by which BCAP may recruit p110δ to the TCR signalosome is 
unclear. Intriguingly, the adaptor NCK1 was identified in the present study as a constitutively-
associated p110δ interactor. In B cells, NCK proteins bind to a proline-rich region in BCAP via 
their SH3 domains and are thought to recruit BCAP to the phosphorylated Igα chain of the BCR 
upon stimulation (Castello et al, 2013). In T cells, NCK is recruited to both the CD3ɛ chain and 
SLP-76 upon TCR stimulation (Gil et al, 2002; Koretzky et al, 2006). Furthermore, NCK-deficient T 
cells exhibit greatly reduced TCR-induced proliferation (Roy et al, 2010). Therefore, this study 
proposes that NCK1, constitutively associated with PI3K, may facilitate the interaction between 
p85 and BCAP and subsequently recruit this complex to the CD3ɛ chain or SLP-76 upon TCR 
stimulation. Further experiments are required to test this hypothesis. In the first instance, co-
immunoprecipitation studies in primary CD4+ T cells could investigate whether these proteins 
form a complex upon TCR stimulation. Notably, BCAP also contains consensus binding motifs for 
the SH2 domains of GRB2 (YxNx) and SHP-2 (YxxV) (Songyang et al, 1993, 1994). As GRB2 and 
SHP-2 were also identified in the present p110δ AP-MS study, it would be interesting to examine 
whether BCAP forms a complex with these proteins upon TCR stimulation. 
BCAP is thought to interact with p85 via three phosphorylated YxxM motifs (Okada et al, 2000; 
Inabe & Kurosaki, 2002). BCAP also contains three proline-rich regions, and it is not known if 
these interact with the SH3 domain of p85. It would be interesting to examine if the BCAP YxxM 
motifs are tyrosine phosphorylated upon TCR stimulation in activated T cells. Thus, a 
phosphoproteomic analysis is planned in subsequent work to identify the phosphorylation sites 
within endogenous BCAP isolated from primary CD4+ T blasts following TCR stimulation. To 
further elucidate the regulation of BCAP in T cells, it would be necessary to investigate the 
tyrosine kinases responsible for the rapid tyrosine phosphorylation of BCAP downstream of the 




phosphorylation in the presence Src-family- and ZAP-70-selective kinase inhibitors could be 
performed for this purpose.  
 
6.3 TCR-PI3K signalling in activated T cells 
It is noteworthy that two of the TCR stimulation-induced p110δ interactors identified in this 
study, BCAP and ICOS, are only expressed in activated T cells. ICOS is not expressed on resting T 
cells but is rapidly induced in activated T cells following TCR crosslinking (Hutloff et al, 1999). 
Similarly, the present study revealed that BCAP is not expressed in naïve CD4+ T cells but is 
upregulated in activated CD4+ and CD8+ T cells. This intriguing observation suggests that there 
may be a rewiring of TCR-induced signalling upon differentiation of effector T cells, which 
specifically alters the regulation of PI3K activity. Interestingly, ICOS appears to be responsible for 
the recruitment of the p50α PI3K regulatory subunit to the immune synapse in activated cells; 
the p50α isoform does not appear to be recruited to the immune synapse in resting cells (Fos et 
al, 2008). p50α has been associated with higher p110 lipid kinase activity than other p85 
isoforms (Inukai et al, 2001). Nevertheless, ICOS also recruits p85α (Gigoux et al, 2009; Pedros et 
al, 2016). Thus, ICOS expression in activated T cells may serve to induce a higher level of PI3K 
activity upon TCR stimulation. In light of the results of the present proteomic study, this could 
occur independently of ICOS ligation. The consequence of BCAP upregulation in activated T cells 
is unclear. It may simply serve to provide an additional means of PI3K recruitment to the TCR. 
Collectively, this rewiring of the TCR-PI3K pathway may be responsible for the lower threshold 
of activation exhibited by activated T cells, by reducing the number of TCRs required to be 
engaged by peptide-MHC for PI3K-AKT pathway activation (Chandok & Farber, 2004). 
The pertinent question, therefore, is whether p110δ is recruited to the TCR in naïve T cells via 
the same complexes and mechanisms proposed here in activated T cells. To answer this, it 
would be necessary to investigate the p110δ interactome downstream of the TCR in naïve T 
cells. To this end, the AviTag AP-MS approach used in this work to study p110δ in CD4+ T blasts 
has been applied to the isolation and identification of p110δ complexes from naïve CD4+ T cells. 
At the time of writing, this experiment requires further analysis. The results of this investigation 
will provide further invaluable insight into the p110δ interactome, as well as the regulation of 
PI3K activity upon TCR stimulation in naïve T cells. Moreover, comparison with the p110δ 
interactome in CD4+ T blasts may uncover changes in the mechanisms of TCR-PI3K signalling 




Taken as a whole, the proteomic analysis performed herein suggests that, in activated T cells, no 
single adaptor is essential for PI3K recruitment and activation. Instead, it is possible that the 
adaptors identified perform redundant roles. Physiologically, this would provide a means for 
both the amplification and maintenance of TCR-induced PI3K signalling; several YxxM motif-
containing proteins could recruit multiple p110δ heterodimers to its substrate PIP2 and 
collectively sustain PI3K localisation and activation at the membrane. This would allow 
previously activated effector T cells to initiate a rapid and robust response to antigen 
recognition via the TCR. 
Intrinsic to this model is that loss of only one adaptor at the TCR signalosome may not affect the 
recruitment or activation of PI3K. This presents a difficulty for the investigation of the functional 
importance the p110δ-associated proteins identified in this study. Nevertheless, it is important 
to systematically assess the contribution of each protein to PI3K signalling in primary CD4+ T 
cells. In addition, since several of their reported interactions with p85 have only been 
demonstrated in vitro or in Jurkat T cells, it would be important to validate these in primary 
cells, in the context of CD3+CD4 crosslinking. To this end, this study used a CRISPR/Cas9-
mediated gene editing approach to knock out the p110δ-asscociated proteins BCAP and ICOS in 
primary T blasts and interrogate their role in PI3K-AKT signalling. A CRISPR/Cas9 approach was 
chosen for several reasons, including the number of target proteins to be investigated and the 
availability of relevant knock out mouse models. In relation to the latter, studying the 
consequences of constitutive gene deletion in mice also has clear limitations, as cellular 
mechanisms are likely to adapt and compensate for the absence of the gene product. 
Furthermore, the loss of a protein that is important for TCR-PI3K signalling could block the 
development of mature lymphocytes or alter the expression of proteins during development 
that subsequently impacts the signalling pathways in mature cells (Saveliev & Tybulewicz, 2009). 
Conditional deletion of the genes in mature T cells would alleviate some of these limitations. 
CRISPR/Cas9 editing via RNP nucleofection goes a step further as it allows for the study of 
protein loss at a specific stage of T cell activation or differentiation. In the present study, wild 
type cells were activated for two days prior to gene knock out, thus allowing the interrogation of 
TCR-induced PI3K signalling in the absence of BCAP or ICOS specifically in activated T cells. This 
was a highly appropriate model, as these proteins are expressed only in activated T cells.  
Nevertheless, as previously discussed, it would be desirable to study the interactome of PI3K in 




naïve cells would require either conditional deletion in mature T cells or application of 
CRISPR/Cas9 gene editing to non-activated naïve T cells. However, primary murine naïve T cells 
die within 48 hours in the absence of TCR stimulation in vitro, within the time that would be 
required for Cas9 editing (Vella et al, 1997). Interestingly, CRISPR/Cas9-mediated gene knock 
out has recently been achieved in non-activated naïve murine T cells that were maintained in 
the presence of the cytokine IL-7 (Seki & Rutz, 2018). This approach could be applied in future 
studies interrogating the recruitment and activation of p110δ downstream of the TCR in naïve T 
cells.  
This study has shown that CRISPR/Cas9 can be used successfully for multiplex gene editing in 
primary T cells. In this case, it was used to incorporate a selection marker via simultaneous 
knock out of CD90. The real power of multiplex editing, however, lies in the capability to knock 
out multiple genes of interest. Proteomic analysis of the p110δ interactome suggests that 
several adaptor proteins may perform redundant roles in the recruitment and activation of 
p110δ upon TCR stimulation. Thus, it would be interesting to knock out several p110δ-
associated adaptors and examine the effect on the PI3K-AKT pathway. For example, combined 
loss of NCK1 and BCAP, or CRK and GAB2, may reveal the key complexes that are required for 
p110δ regulation.  
 
6.4 The role of p110α in mature T cells  
The work presented herein has led to the identification of proteins that may regulate p110δ 
recruitment and activation upon TCR engagement. However, it remains poorly understood why 
p110δ is the dominant class IA isoform activated downstream of the TCR. Phosphorylation of 
AKT and production of PIP3 following TCR stimulation are dependent on the kinase activity of 
p110δ (Okkenhaug et al, 2002; Stark et al, 2018). This is despite the fact that p110α 
heterodimers are also present in T cells, as shown in this study. Furthermore, p110α possesses a 
higher intrinsic specific activity than p110δ (Meier et al, 2004). One hypothesis that could 
explain the dominance of p110δ in mature T cells is that p110δ is preferentially recruited or 
activated by the TCR signalosome. To test this, it would be necessary to identify the proteins 
associated with p110α in T cells upon TCR stimulation. This could reveal whether p110α is also 
recruited to the TCR or if it is sequestered elsewhere in the cell. In support of the latter, p110α 
was not identified with p110δ complexes in the proteomic analysis carried out in this study. 




lymphocytes using the AviTag AP approach. Thus, it would be possible to perform a quantitative 
proteomic analysis of the p110α interactome in primary T cells. Furthermore, the 10-plex nature 
of the TMT-labelling approach would allow for a high-throughput quantitative comparison of 
p110δ and p110α affinity purifications, thus enabling the identification of isoform-specific 
interaction partners.  
An interesting observation was made during this study following the CRISPR/Cas9-mediated 
disruption of Pik3cd, encoding p110δ, in activated T cells. Pik3cd-edited cell populations 
exhibited p110δ-independent phosphorylation of AKT upon TCR stimulation, whereas 
phosphorylation of AKT was almost completely p110δ-dependent in Pik3cd-unedited cells. 
Given that the efficiency of Pik3cd knock out was low, it was assumed that a heterogenous 
population of wild type and p110δ-deficient cells were present within the cell populations 
stimulated. Therefore, in the presence of a p110δ-selective inhibitor, it was likely that the 
p110δ-deficient cells were the source of the phosphorylated AKT detected. These experiments 
suggest that another PI3K p110 isoform is able to compensate for the loss of p110δ in activated 
T cells. To test this hypothesis, isoform-selective inhibitors targeting p110α, p110β and p110γ 
could be used to examine the isoform-dependency of PI3K-AKT signalling in Pik3cd-edited cells. 
Importantly, these experiments should be performed on homogenous Pik3cd knock out cell 
populations. 
 
6.5 CRISPR/Cas9 gene editing in primary murine T lymphocytes 
To interrogate the TCR-PI3K signalling pathway in primary T cells, this study developed a 
CRISPR/Cas9-mediated gene editing approach to knock out proteins of interest in primary 
mouse activated T cells. This work demonstrated that RNP nucleofection is a viable delivery 
method to introduce Cas9 protein and gRNA into activated T cells and allows for efficient target 
gene disruption. Of note, this is the first demonstration of successful RNP nucleofection and 
editing of total non-purified activated murine T cells. The application of this approach to the 
targeted knock out of BCAP, ICOS and p110δ revealed both the power of the technique and the 
associated caveats, as discussed in Chapter 5. Overall, there are three main aspects of the 
strategy that require further optimisation: efficiency, selection, and the phenotypic assay.  
The efficiency of CRISPR/Cas9 gene editing will likely be improved via further optimisation of the 




within a cell population, such that the requirement for a method of selection is eliminated. 
However, if high efficiency editing cannot be reached for a particular intracellular target it would 
be necessary to select for knock out cells. This study has demonstrated that simultaneous knock 
out of a cell surface marker enables the enrichment or selection of edited cells for whole-
population or single-cell analysis, respectively. Although, as observed following knock out of 
CD90, loss of the marker can generate a phenotypic effect. Alternative strategies for knock out 
selection include the use of fluorescently-labelled tracrRNA that can be detected by flow 
cytometry (Kornete et al, 2018). However, there are two main disadvantages to this method. 
First, cells may incorporate tracrRNA independently of Cas9. Second, selection of tracrRNA-
positive cells would be required within the half-life of the RNA. This would involve cell sorting 
shortly after electroporation, which may reduce cell viability by subjecting cells to additional 
stress before expansion.  
An alternative selection approach makes use of Cas9-transgenic mice, which also overcomes the 
requirement of Cas9 protein delivery by electroporation (Platt et al, 2014; Chu et al, 2016). 
Inducible Cas9-transgenic mice are a valuable development as they reduce the risk of off-target 
gene editing that is associated with constitutive Cas9 expression (Katigbak et al, 2018). In this 
system, expression of Cas9 and GFP from the same genetic locus can be temporally controlled in 
primary cells in vitro by administration of doxycycline. Primary T cells expressing Cas9 and GFP 
would likely exhibit a higher efficiency of gene editing, due to consistent levels of Cas9 protein in 
all cells, and also provide a means of knock out selection, contingent upon efficient gRNA 
delivery (Harrison et al, 2014; Chu et al, 2016). The disadvantage is the exposure of primary T 
cells to the cytotoxicity of doxycycline, and the requirement for transgenic animals (Ermak et al, 
2003). Nevertheless, primary T cells from inducible Cas9-mice could be considered for future 
CRISPR/Cas9 knock out experiments. 
Due to variable CRISPR/Cas9 editing efficiency achieved in this study, it was necessary to 
correlate observed knock out phenotypes with the extent of target gene disruption in the 
population of cells analysed. While this provided meaningful insight, it illustrated the fact that 
heterogenous knock out populations are not compatible with whole-population analyses such 
as immunoblotting. It would be more appropriate to measure phosphorylated AKT (pAKT) in a 
heterogenous population using a quantitative single-cell approach, such as intracellular flow 
cytometry. Indeed, this was tested as part of this study. However, only weak fluorescence 




detect differences between genotypes. This could be due to a combination of factors, including 
loss of phosphorylation or fluorescence during processing, non-specific binding of the 
fluorescently-conjugated pAKT antibody, and the higher autofluorescence of blasted T cells. 
Thus, this technique requires further optimisation to enable the analysis of edited T blasts. 
Nevertheless, the detection of pAKT by immunoblotting is a sensitive, specific and reliable assay, 
and a robust approach to indirectly measure p110δ activity. Thus, it could be used in future 
experiments to interrogate TCR-PI3K signalling in homogenous knock out populations.  
 
6.6 Conclusion  
This work has optimised the AviTag AP system for the isolation of endogenous p110 isoforms 
from primary murine lymphocytes and subsequently employed a quantitative mass 
spectrometry-based proteomics approach to identify endogenous proteins that interact with 
p110δ in primary activated CD4+ T cells. This analysis has identified multiple adaptor proteins 
and co-stimulatory receptors that may regulate p110δ activity at the TCR signalosome, including 
the adaptor BCAP. Biochemical analyses revealed that BCAP is upregulated in activated T cells 
and rapidly tyrosine phosphorylated upon TCR stimulation. Collectively, this work suggests that 
BCAP is a key adaptor for PI3K downstream of the TCR, specifically in activated T cells. 
This study has also developed a CRISPR/Cas9-mediated gene editing approach to disrupt targets 
of interest in primary murine activated T cells via ribonucleoprotein (RNP) nucleofection. This 
system was used to investigate the roles of BCAP and ICOS in TCR-induced PI3K signalling and 
cytokine production in activated T cells. Collectively, this work has demonstrated that AP-MS 
coupled with CRISPR/Cas9 is a powerful system for the identification and interrogation of 
signalling pathway components in primary T lymphocytes.  
Using this approach, this work has shed light on the previously ambiguous mechanisms of p110δ 
recruitment and activation downstream of the TCR. The p110δ-associated proteins that have 
been identified require further biochemical and genetic analysis to uncover the molecular 






Chapter 7        
 
Materials and methods 
 
7.1 Mice 
p110δAvi/Avi, BirA+/+ and p110αAvi/WTBirA+/- C57BL/6J mice were a generous gift from T Chessa, L 
Stephens and P Hawkins (Inositol Laboratory, Babraham Institute). These mice were housed 
under specific pathogen-free conditions within the Babraham Institute Biological Services Unit 
and genotyping was performed by Transnetyx (Cordova, TN). Wild type C57BL/6J mice used for 
experiments in Chapter 5 were purchased from The Jackson Laboratory and housed at the 
Cancer Research UK Cambridge Institute Biological Resources Unit. All transgenic mice and wild 
type mice were culled when aged 8 - 12 weeks according to Schedule 1 procedures.  
7.2 Purification of naïve T cells 
Axillary, brachial, mesenteric and inguinal lymph nodes were isolated from mice and 
homogenised in ice-cold MACS buffer (MB; calcium and magnesium free 1X PBS (in-house), 0.5 
% BSA (Sigma #A7906), 2 mM EDTA (Invitrogen #AM9261) by passing through 40 µm cell 
strainers (BD Biosciences) using a syringe plunge. Cells were washed once by centrifugation at 
400 × g for 5 minutes at 4°C and counted using the CASY cell counter (Scharfe Systems). Cells 
were resuspended in 1 ml of a FITC-conjugated antibody cocktail (anti-MHCII I-Ab, anti-CD25, 
anti-CD19, anti-CD49b, anti-CD69, anti-B220 and anti-CD11b, with addition of anti-CD8a for the 
purification of CD4+ cells; all at 1:500 dilution in MB; see Table 7.1 for antibody details) per 108 
cells and incubated on ice for 30 minutes in the dark. Cells were washed in ice-cold MB and 
resuspended in 90 μl MB and 10 μl anti-FITC microbeads (Miltenyi Biotec #130-048-701) per 107 
cells followed by incubation at 4°C for 15 minutes. Cells were washed in ice-cold MB and naïve T 
cells were isolated by negative selection using LS magnetic columns (Miltenyi Biotec #130-042-
401) according to the manufacturer’s instructions and collected in ice-cold MB. Purity of the 






Specificity  Clone Supplier Catalogue Number 
MHCII I-Ab  AF6-120.1 BD Biosciences 553551 
CD25  PC61 BioLegend 102006 
CD19  6D5 BioLegend 115506 
CD49b  DX5 BioLegend 108906 
CD69 H1.2F3 BioLegend 104506 
B220 RA3-6B2 BioLegend 103206 
CD11b  M1/70 BioLegend 101205 
CD8a  53-6.7 BioLegend 100706 
 
Table 7.1 Antibodies used for T cell purification  
 
7.3 Activation and expansion of primary T cells in vitro 
Axillary, brachial, mesenteric and inguinal lymph nodes were isolated from mice and 
homogenised in ice-cold MB by passing through 40 µm cell strainers (BD Biosciences) using a 
syringe plunge. Cells were washed once by centrifugation at 400 × g for 5 minutes at 4°C and 
counted using the CASY cell counter (Scharfe Systems). Cells were resuspended at 5 × 106 
cells/ml in 5 % RPMI media (RMPI 1640 + L-glutamine (Life Technologies #21875-034), 5 % heat 
inactivated FBS (Labtech #FBS-SA-10454/500), 100 U/ml penicillin-streptomycin (Life 
Technologies #15140-122), 50 μM β-mercaptoethanol (Life Technologies #31350-010)) 
containing 1 ug/ml anti-CD3 (145-2C11; in-house) and incubated in 6-well plates (Thermo 
Scientific #140685) at 37°C and 5 % CO2 for 48 hours. Cells were then pooled, collected by 
centrifugation at 400 × g for 5 minutes at 37°C and resuspended at 0.5 × 106 cells/ml in 5 % 
RPMI media containing 20 ng/ml recombinant human IL-2 (rhIL-2; PeproTech #200-02). Cells 
were incubated in upright 75 or 175 cm2 flasks (Thermo Scientific #156499, #159910) at 37°C 
and 5 % CO2 for 5 days, with supplementation of rhIL-2 and media every 2 days to maintain a 
cell concentration of 1 × 106 cells/ml.  
7.4 Purification of activated T cells (T blasts) 
T blasts from in vitro culture were pooled in 50 ml falcons by centrifugation at 400 × g for 5 
minutes, resuspended in 5 % RPMI and counted using the CASY cell counter (Scharfe Systems). 
Cells were pelleted once more and resuspended in 1 ml of a FITC-conjugated antibody cocktail 
(anti-I-Ab (MHCII), anti-CD19 and anti-CD49b, with addition of anti-CD8a for the purification of 
CD4+ cells; all at 1:500 dilution in MB; see Table 7.1) per 108 cells and incubated on ice for 30 
minutes in the dark. Cells were washed in ice-cold MB and then resuspended in 90 μl MB and 10 
μl anti-FITC microbeads (Miltenyi Biotec #130-048-701) per 107 cells followed by incubation at 
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4°C for 15 minutes. Cells were washed in ice-cold MB and T blasts were isolated by negative 
selection using LS magnetic columns (Miltenyi Biotec #130-042-401) according to the 
manufacturer’s instructions and collected in ice-cold MB.  
To enrich for CD90- cells following CRISPR/Cas9 gene editing, T blasts at day 5 post-
nucleofection were pooled in 15 ml falcons and counted. Cells were pelleted by centrifugation 
at 400 × g for 5 minutes and resuspended in 90 μl MB and 10 μl anti-CD90.2 microbeads 
(Miltenyi Biotec #130-049-101) per 107 cells followed by incubation at 4°C for 15 minutes. Cells 
were washed in ice-cold MB and then passed through MS magnetic columns (Miltenyi Biotec 
#130-042-201) according to the manufacturer’s instructions, and CD90--enriched cells were 
collected in ice-cold MB. The CD90+ fraction was collected by plunging the magnetic columns 
with 1 ml ice-cold MB.  
7.5 TCR stimulation in vitro 
Following purification of naïve T cells or T blasts, cells were resuspended at 4 x 106 cells/ml in 
0.5 % RPMI (RMPI 1640 + L-glutamine, 0.5 % heat inactivated FBS, 100 U/ml penicillin-
streptomycin, 50 μM β-mercaptoethanol) and rested for 75 minutes at 37°C. For experiments 
involving pharmacological inhibition of p110δ, the media was supplemented with 200 nM DMSO 
(Sigma #D8418) or CAL101 (AstraZeneca, in-house). Cells were collected by centrifugation at 400 
× g for 5 minutes and then incubated at 2 × 107 cells/ml in 0.5 % RPMI containing 4 µg/ml anti‐
CD3 (145-2C11; BioLegend #100314) and 4 µg/ml anti‐CD4 (RM4.5; BioLegend #100520) for 30 
minutes on ice. For some experiments, anti-CD28 (37.51; BioLegend #102112) or anti-CD8a (53-
6.7; BioLegend #100716), and DMSO or CAL101, were also included, as indicated in 
accompanying figure legends. Cells were then washed by centrifugation at 400 × g and 
resuspended in ice-cold 0.5 % RPMI at 2 × 107 cells/ml. T cells were incubated at 37°C for 2 
minutes before addition of 13 µg/ml goat anti-Armenian Hamster IgG (Jackson ImmunoResearch 
#127-005-099) and further incubation at 37°C for 1 minute, or the times indicated in 
accompanying figure legends. Cells were immediately centrifuged at 800 × g for 2 minutes at 4°C 
and then resuspended in ice-cold lysis buffer. 
7.6 Purification of naïve splenic B cells 
Mouse spleens were homogenised in ice-cold MB by passing through 40 µm cell strainers (BD 
Biosciences) using a syringe plunge. Cells were washed once by centrifugation at 400 × g for 5 
minutes at 4°C and red blood cells (RBC) were lysed by incubation with 1 ml RBC lysis buffer 
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(Sigma-Aldrich #R77570) per spleen for 5 minutes at room temperature. Lysis was quenched 
with ice-cold MB and cells were collected by centrifugation and counted using the CASY cell 
counter (Scharfe Systems). Naïve B cells were isolated using a mouse B cell Isolation Kit (Miltenyi 
Biotec #130-090-862). Briefly, cells were resuspended in 40 μl MB and 10 μl biotin-conjugated 
antibody cocktail per 107 cells and incubated at 4°C for 5 minutes, followed by addition of 30 μl 
MB and 20 μl anti-biotin microbeads per 107 cells and further incubation at 4°C for 10 minutes. 
Naïve B cells were isolated by negative selection using LS magnetic columns (Miltenyi Biotec 
#130-042-401) according to the manufacturer’s instructions and collected in ice-cold MB.  
7.7 BCR stimulation in vitro 
Following purification of naïve B cells, cells were resuspended at 4 x 106 cells/ml in 0.5 % RPMI 
(RMPI 1640 + L-glutamine, 0.5 % heat inactivated FBS, 100 U/ml penicillin-streptomycin, 50 μM 
β-mercaptoethanol) and rested for 75 minutes at 37°C. Cells were collected by centrifugation at 
400 × g for 5 minutes and then incubated at 2 × 107 cells/ml in 0.5 % RPMI containing 50 µg/mL 
goat anti-mouse IgM (F(ab’)2 fragment; Jackson ImmunoResearch #115-036-075) for 30 minutes 
on ice. B cells were stimulated by incubation at 37°C for 2.5 minutes, or the times indicated in 
accompanying figure legends. Cells were immediately centrifuged at 800 × g for 2 minutes at 4°C 
and then resuspended in ice-cold lysis buffer. 
7.8 Lysis buffers and cell lysis 
For experiments shown in Figures 2.2 – 2.6, lymphocytes were lysed in ‘standard’ recipe lysis 
buffer, comprising 1 % IGEPAL CA-630 (Sigma #I8896), 50 mM HEPES, 150 mM NaCl, 5 mM 
EDTA, 10 mM NaF, 10 mM Iodoacetamide and 5 mM Proteoloc Protease Inhibitor Cocktail 
(Expedeon Ltd). Protease inhibitor cocktail was added to the lysis buffer immediately before 
use. Cells were resuspended in 50 μl (Figure 2.2) or 500 μl (Figures 2.3 – 2.6) ice-cold lysis buffer 
and lysed on ice for 10 minutes. Insoluble material was cleared by centrifugation at 17,000 × g 
for 10 minutes at 4°C. 
For all other experiments, lymphocytes were lysed in a ‘modified’ lysis buffer, comprising 1 % 
IGEPAL CA-630, 50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 25 mM NaF, 10 mM 
Iodoacetamide, 2.5 mM sodium pyrophosphate, 5 mM β-glycerophosphate, 5 mM sodium 
orthovandate and 5 mM Proteoloc Protease Inhibitor Cocktail (Expedeon Ltd). To prepare 
activated sodium orthovanadate, a 200 mM solution was adjusted to pH 10 and boiled 3 - 5 
times until the solution remained colourless and stabilised at pH 10. Aliquots were then frozen 
145 
 
at -20°C until use. Protease inhibitor and sodium orthovanadate was added to the lysis buffer 
immediately before use.  
For affinity purification experiments, cells were resuspended in 600 μl ice-cold lysis buffer per 
108 cells, lysed on ice for 10 minutes and insoluble material was cleared by ultracentrifugation at 
96,416 × g for 5 minutes at 4°C. For immunoprecipitation or immunoblotting experiments, cells 
were resuspended in 100 μl ice-cold lysis buffer per 107 cells, lysed on ice for 10 minutes and 
cleared by centrifugation at 20,000 × g for 10 minutes at 4°C. 
The protein concentration of cell lysates was determined using the Pierce 660 nm Protein Assay 
Kit (Thermo Scientific #22662) according to the manufacturer’s Microplate Procedure 
instructions. Briefly, 10 μl of lysate and pre-diluted BSA Protein Assay Standards were incubated 
with 150 μl of Protein Assay reagent for 5 minutes at room temperature and the absorbance 
was measured at 660 nm using a FLUOstar Omega plate reader (BMG Labtech). Protein 
concentration was determined using a standard curve of the blank-corrected absorbances for 
each BSA standard.  
7.9 Affinity purification  
Streptavidin-conjugated paramagnetic beads (Dynabeads M-280 Streptavidin; Invitrogen 
#11205D) were prepared by washing three times in ice-cold lysis buffer using the DynaMag-2 
magnetic rack (Invitrogen) and then resuspended in an equal volume of lysis buffer on ice. 
Fresh lysates from 1 × 108 cells were immediately incubated with 60 μl streptavidin-conjugated 
beads for 30 minutes on a rotating wheel at 4°C. Beads were then separated using the magnetic 
rack and ‘post’ lysates were retrieved. Beads were washed three times with 1 ml ice-cold lysis 
buffer, each time with five rotations at 4°C and separation using the magnetic rack on ice. 
Washed beads were then resuspended in 60 μl 1X NuPAGE LDS Sample Buffer (Invitrogen 
#NP0007) and boiled at 95°C for 5 minutes. Beads were allowed to return to room temperature 
and were then separated by using the magnetic rack. Eluates were retrieved to low-protein 
binding Eppendorf microcentrifuge tubes (Sigma #Z666505) and snap frozen in liquid nitrogen.  
7.10 Immunoprecipitation  
To prepare 50 % protein-A-sepharose bead slurry for immunoprecipitation, 0.2 g lyophilised 
beads (Sigma #P3391) were hydrated in 10 ml 1X PBS for 1.5 hours at room temperature with 
agitation. Beads were washed once in 10 ml PBS and resuspended in an equal volume of PBS 
with 0.1 % sodium azide (Sigma #S2002) and stored at 4°C for up to 1 week. Immediately before 
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use, beads were washed three times in lysis buffer and resuspended in an equal volume of lysis 
buffer. 
Lysates from 1 × 107 cells were incubated with 2 μl rabbit polyclonal anti-mouse-BCAP (a kind 
gift from T. Kurosaki) or 10 μl normal rabbit IgG (Cell Signaling Technology #2729) for 45 minutes 
at 4°C with rotation, followed by addition of 50 μl of 50 % protein-A-sepharose bead slurry and 
further incubation for 30 minutes at 4°C with rotation. Beads were then washed three times 
with 450 μl lysis buffer by centrifugation at 12,000 × g for 30 seconds at 4°C. Beads were 
resuspended in 25 μl 2X NuPage LDS sample buffer (Invitrogen) with 20 mM DTT and proteins 
were eluted from the beads by boiling at 95 C for 5 minutes, followed by centrifugation at 
13,000 × g for 2 minutes at room temperature. This protocol was scaled appropriately for 
immunoprecipitation from 2 × 107 cells. 
7.11 Immunoblotting via enhanced chemiluminescence (ECL) 
detection 
Immunoblots presented in Figures 2.2 and 2.3 were produced via the ECL method, as follows. 
Cell lysates were boiled at 70°C for 10 minutes in 1X NuPAGE LDS Sample Buffer (Invitrogen 
#NP0007) supplemented with 20 mM DTT. NuPAGE 4-12% Bis-Tris Gels (Invitrogen 
#NP0322BOX) were loaded with 25 μl of each sample and 15 μl of Novex Sharp Pre-stained 
Protein Standard (Invitrogen #LC5800) and run for 1 hour at 200 V in NuPAGE SDS MOPS 
Running Buffer (Invitrogen #NP0001) using the XCell SureLock Mini-Cell Electrophoresis System 
(Invitrogen). Proteins were transferred onto PVDF membranes (Millipore #IPVH00010) in 1X 
NuPAGE Transfer Buffer (Invitrogen #NP0006-1) containing 20 % methanol and 0.1 % NuPAGE 
Antioxidant (Invitrogen #NP0005) using the XCell II Blot Module (Invitrogen) for 1 hour at 30 V. 
Membranes were blocked for 1 hour with shaking at room temperature in 5 % (w/v) milk in 
TBST (0.1 % Tween-20, 150 mM NaCl, 50 mM Tris-HCl, pH 7.6). Membranes were rinsed in TBST 
and incubated with primary antibody according to Table 7.2. Membranes were washed three 
times with TBST for 10 minutes each and then incubated for 1 hour at room temperature with 
shaking with either 1:25,000 HRP-conjugated polyclonal goat anti-rabbit IgG (Dako #P0448) or 
1:10,000 HRP-conjugated polyclonal goat anti-mouse IgG (Dako #P0448) in 5 % milk in TBST. 
Membranes were washed three times for 10 minutes each then incubated for 5 minutes in the 
dark with Immobilon Western Chemiluminescent HRP substrate (Millipore #WBKLS0500) 
according to the manufacturer’s instructions. Membranes were exposed to Amersham 
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Hyperfilm ECL (GE Healthcare #28-9068-40) and films were developed using a Compact X4 
developer (Xograph). 
7.12 Immunoblotting via near-infrared (NIR) fluorescence detection  
Immunoblots, except those in Chapter 2 Figure 2.2 and 2.3, were produced via NIR fluorescence 
detection, as follows. Cell lysate samples were denatured and reduced in 1X NuPAGE LDS 
Sample Buffer (Invitrogen #NP0007) with 20 mM DTT at 70C for 10 minutes. Lysate, AP and IP 
Samples were subjected to SDS-PAGE, alongside 3 μl Chameleon Duo pre-stained protein ladder 
(LI-COR #928-60000), on NuPAGE 4-12% Bis-Tris Gels (Invitrogen) at 200 V for 45 – 75 minutes 
using the XCell SureLock Mini-Cell Electrophoresis System (Invitrogen) with NuPAGE SDS MOPS 
Running Buffer (Invitrogen #NP0001). Proteins were transferred onto Immobilon-FL PVDF 
membrane (Millipore #IPFL00010) at 30 V for 65 minutes in 1X NuPAGE Transfer Buffer 
(Invitrogen #NP0006-1) containing 20 % methanol and 0.1 % NuPAGE Antioxidant (Invitrogen 
#NP0005) using the XCell II Blot Module (Invitrogen).  
Membranes were blocked in 5% BSA (w/v) TBST for 1 hour at room temperature with shaking 
and then incubated with primary antibody (Table 7.2) in 5% BSA TBST with 0.05 % NaN3 
overnight at 4C. For detection of pAKT and AKT1, membranes were incubated with both 
primary antibodies simultaneously. Membranes were washed four times over 30 mins in TBST 
and then incubated with secondary antibody goat anti-rabbit IRDye® 680RD (1:10,000; LI-COR 
#926-68071) or goat anti-mouse IRDye® 800CW (1:10,000; LI-COR #926-68070) in 5% BSA TBST 
for 1 hour in the dark at room temperature. For detection of pAKT and AKT1, membranes were 
incubated with both secondary antibodies simultaneously. Membranes were then washed as 
before and allowed to dry in the dark at room temperature for 1 hour between Whatman paper. 
Dry membranes were imaged using an Odyssey® CLx Imaging System (LI-COR) in the 700 nm and 
800 nm channels. Membranes were reactivated in 100 % methanol for 10 seconds before 








Table 7.2 Antibodies used for immunoblotting.  
mAb, monoclonal; pAb, polyclonal; RT, room temperature; O/N, overnight; h, hour.  
 
7.13 Immunoblot quantification  
The signal intensity for pAKT, AKT, p85 and p110δ detected by NIR fluorescence immunoblotting 
was quantified using Image Studio Lite Version 5.2 software (LI-COR). Rectangles were 
positioned to encompass each band and the signal was calculated as the total signal less the 
product of the background and area. The background was computed as the median intensity of 
pixels above and below the rectangles with a border size of 1 pixel. The pAKT signal was 
normalised by dividing by the signal for AKT, or β-actin for p85 and p110δ signals, in the same 
lane. Graphical and statistical analyses were performed in GraphPad Prism version 7 (GraphPad 
Software, Inc), as detailed in figure legends and the text. 
7.14 Preparation of peptide samples for mass spectrometry 
analyses 
For the targeted mass spectrometry (MS) analysis of a 115 kDa protein, 35 μl (one-half) of each 
denatured affinity purification sample was subjected to SDS-PAGE on a 10-well NuPAGE 4-12% 
Bis-Tris Gel (Invitrogen #NP0335BOX) alongside 5 μl Chameleon Duo pre-stained protein ladder 
(LI-COR #928-60000). The gel was run at 200 V for 1 hour in NuPAGE SDS MOPS Running Buffer 
(Invitrogen #NP0001) and then proteins were visualised with InstantBlue Coomassie Protein 
Stain (Expedeon #ISB1L). The region encompassing 110 – 120 kDa was excised from the gel using 
the 100 kDa marker and p110δ protein band as reference. 
The following steps were performed by Katarzyna Wojdyla at the Babraham Institute MS facility. 
Specificity Raised in Supplier Catalogue no. Diluent Dilution Incubation 
AviTag Rabbit pAb GenScript  A00674 5% BSA- PBST 1:1000 RT 1.5 h 
β-actin Mouse mAb Santa Cruz  sc-47778 5% milk-TBST 1:400 RT 1 h 
GRB2 Mouse mAb BD Biosciences  610112 5% BSA-TBST 1:1000 4°C O/N 
NCK1 Rabbit mAb Cell Signaling Technology  2319S 5% milk-TBST 1:1000 4°C O/N 
p110α Rabbit mAb Cell Signaling Technology  4249 5% milk-TBST 1:2000 4°C O/N 
p110δ Rabbit pAb Santa Cruz  sc-7176 5% BSA-TBST 1:200 4°C O/N 
Pan-p85 Rabbit pAb Millipore  06-195 5% BSA-TBST 1:2000 4°C O/N 
pAKT (T308) Rabbit mAb Cell Signaling Technology  4056 5% BSA-TBST 1:1000 4°C O/N 
AKT1 Mouse mAb Cell Signaling Technology  2967 5% BSA-TBST 1:1000 4°C O/N 
pTyr  Mouse mAb Millipore  05-321 5% BSA-TBST 1:1000 4°C O/N 
BCAP Rabbit pAb Gift from T. Kurosaki  5% BSA-TBST 1:2000 4°C O/N 
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For quantitative TMT-based MS analysis, denatured affinity purification samples were subjected 
to SDS-PAGE on Bolt 10% Bis-Tris Plus Gels (Invitrogen) and run at 160 V in NuPAGE MES SDS 
running buffer (Invitrogen # NP0002) until samples fully entered the gel. Gels were washed 
briefly with miliQ water and proteins were visualised with Coomassie dye (Imperial Protein 
Stain, ThermoFisher Scientific) and excised. 
Gel slices for all MS experiments were cut into 1 x 1 mm cubes and transferred to Eppendorf 
LoBind Protein tubes (Sigma-Aldrich/Merck). Coomassie dye was removed by sequential washes 
in 150 µl 12.5 mM ammonium bicarbonate (AMBI) and 50 % acetonitrile (ACN) with 20 minutes 
sonication, repeated until gel pieces turned transparent. Samples were then dehydrated with 
150 µl 100 % ACN for 10 minutes with sonication. After removing ACN, gel pieces were 
rehydrated in reduction buffer (10 mM DTT in 25 mM AMBI) and incubated for 60 minutes at 
50°C. Reduction buffer was removed and gel pieces were incubated with an equal volume of 
alkylation buffer (50 mM iodoacetamide in 25 mM AMBI) for 60 min at room temperature with 
shaking in the dark. Reduced and alkylated samples were washed with 150 µl 25 mM AMBI 
followed by dehydration with 150 µl 100 % ACN and 10 minutes sonication, repeated twice. ACN 
was then removed and samples dried in a vacuum centrifuge. Finally, gel pieces were 
rehydrated for 15 - 20 min at room temperature with trypsin solution (10 ng/µl trypsin in 50 
mM triethylammonium bicarbonate (TEAB) with 0.1% octylglucoside) before addition of further 
TEAB to a total volume of 50 µl for overnight digestion at 30°C.  
For in-gel tandem mass tag (TMT) labelling, TMT-10 plex tags (ThermoFisher Scientific #90110) 
were brought to room temperature and each 0.2 mg TMT aliquot was resuspended in 20 µl 100 
% ACN and added to individual digested samples. Peptides were labelled for 1 hour at room 
temperature with sonication and vortexing every 15 minutes. Labelling was quenched with 0.3 % 
hydroxylamine for 30 minutes at room temperature with sonication. TMT-labelled peptides were 
extracted from gel pieces with 100 % ACN in a series of 3 washes consisting of 25 µl 100 % ACN 
and 10 minutes sonication per wash. Final extracts from all samples were combined in 1:1 ratio 
and dried in a vacuum centrifuge. The dried sample (containing 10 TMT-labelled samples) was 
resuspended in 16 µl 0.2 % NH3 for high pH reverse phase fractionation on the UltiMate 3000 
system (ThermoFisher Scientific). An in-house made microcolumn (0.53 x 200 mm packed with 
ReproSil-Pur C18-AQ resin, 3 µm particle size (Dr. Maisch, Germany) was used for peptide 
separation at 20 µl/min using linear gradient 0 - 40% ACN over 30 minutes. Eluted peptides were 
manually collected into 1-minute fractions and stored at -80°C until further use.  
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7.15 nLC-MS/MS analysis of TMT-labelled samples  
The following analyses were performed by Katarzyna Wojdyla and David Oxley at the Babraham 
Institute MS facility. 
Peptide-enriched fractions were analysed by nano-liquid chromatography-tandem mass 
spectrometry (nLC-MS/MS) using an EASY-nLC System (ThermoFisher Scientific) interfaced via a 
nano-electrospray ion source onto a Q Exactive Plus hybrid Quadrupole-Orbitrap mass 
spectrometer (ThermoFisher Scientific). An in-house made pre-column (100 µm ID fritted fused 
silica packed with POROS 20 R2 reversed-phase resin) and analytical column (75 µm ID x 15 cm 
fused silica capillary with integrated emitter (New Objective) packed with ReproSil-Pur C18-AQ 
resin (2.1 µm; Dr. Maisch, Germany)) were used for peptide separation. Half of each fraction 
was used. Samples were loaded onto the pre-column in solvent A (0.1 % formic acid) at a flow 
rate corresponding to 60 bar. Peptides were then separated over the analytical column at a flow 
rate of 300 nl/min using a linear gradient from 5 – 35 % solvent B (100 % ACN) over 60 - 90 
minutes. Eluted peptides were ionised by applying a 1.6 - 1.7 kV voltage and introduced to the 
mass spectrometer as gas-phase ions. MS1 scans were only triggered when a threshold of 3e6 
ions or 50 ms was reached and were acquired in the Orbitrap mass analyser with a mass 
resolution of 70,000 and a scan range of m/z 350-1800. The 12 most intense ions from each MS1 
spectrum were isolated in the quadrupole mass analyser using a 1.2 m/z window and 
fragmented using higher-energy collisional dissociation (HCD) with normalised collision energy 
(NCE) of 30 and 35. MS2 scans of fragment ions were only triggered when a threshold of 5e4 
ions or 500 ms was reached and were acquired in the Orbitrap mass analyser with a mass 
resolution of 35,000 and mass range starting at 100 m/z. Fragmented ions were excluded from 
repeated analysis for 30 seconds. MS and MS2 spectra were recorded in Xcalibur 3.0 
(ThermoFisher Scientific). 
Raw MS data were processed in Proteome Discoverer 2.1 (ThermoFisher Scientific). First, raw data 
from all the fractions were combined and searched against the mouse UniProt database (52026 
entries) and Global Proteome Machine database of common contaminants (57 entries) using 
Mascot search engine. Trypsin was set as the specific protease with a maximum of two missed 
cleavage sites allowed. Peptide mass tolerance was set to 10 ppm and fragment mass tolerance 
was set to 20 mmu. Carbamidomethylation of cysteine and TMT modification of the peptide N-
terminus and lysine side chains were set as fixed modifications. Oxidation of methionine was set 
as a variable modification. Only high confidence peptides were used, with a 0.01 target peptide 
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FDR, and a minimum of 1 unique peptide was required for successful protein identification. 
Reporter ion intensities were extracted from MS2 spectra that exceeded an average reporter 
signal-to-noise threshold of 10 with a co-isolation interference lower than 50%. Reporter ion 
intensities were normalised to the total peptide amount per channel within Proteome Discoverer 
2.1. 
7.16 nLC-MS/MS analysis of gel slice samples 
The following analyses were performed by Katarzyna Wojdyla and David Oxley at the Babraham 
Institute MS facility. 
Peptides extracted from the 110 – 120 kDa gel slice were analysed by nano-liquid 
chromatography-tandem mass spectrometry (nLC-MS/MS) using the UltiMate 3000 liquid 
chromatography system system (ThermoFisher Scientific) interfaced via a nano-electrospray ion 
source onto a Q Exactive Plus hybrid Quadrupole-Orbitrap mass spectrometer (ThermoFisher 
Scientific). An in-house made pre-column (100 µm ID fritted fused silica packed with POROS 20 
R2 reversed-phase resin) and analytical column (75 µm ID x 15 cm fused silica capillary with 
integrated emitter (New Objective) packed with ReproSil-Pur C18-AQ resin (2.1 µm; Dr. Maisch, 
Germany)) were used for peptide separation. Samples were loaded onto the pre-column in 
solvent A (0.1 % formic acid) at a flow rate of 6 µl/min and then separated over the analytical 
column at a flow rate of 250 nl/min using a linear gradient from 0 – 40 % solvent B (100 % ACN) 
over 30 minutes. Eluted peptides were ionised by applying a 1.8 kV voltage and introduced to 
the mass spectrometer as gas-phase ions. MS1 scans were only triggered when a threshold of 
3e6 ions or 100 ms was reached and were acquired in the Orbitrap mass analyser with a mass 
resolution of 70,000 and a scan range of m/z 350-1800. The 10 most intense ions from each MS1 
spectrum were isolated in the quadrupole mass analyser using a 1.2 m/z window and 
fragmented using higher-energy collisional dissociation (HCD) with normalised collision energy 
(NCE) of 27. MS2 scans of fragment ions were only triggered when a threshold of 1e5 ions or 
300 ms was reached and were acquired in the Orbitrap mass analyser with a mass resolution of 
17,500 and mass range starting at 100 m/z. Fragmented ions were excluded from repeated 
analysis for 10 seconds. MS and MS2 spectra were recorded in Xcalibur 3.0 (ThermoFisher 
Scientific). 
Raw MS data were processed in Proteome Discoverer 1.4 (ThermoFisher Scientific). Spectra were 
searched against the mouse UniProt database (74290 entries) and Global Proteome Machine 
database of common contaminants (247 entries) using Mascot. Trypsin was set as the specific 
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protease with a maximum of three missed cleavage sites allowed. Peptide mass tolerance was set 
to 10 ppm and fragment mass tolerance was set to 20 mmu. Carbamidomethylation of cysteine 
was set as a fixed modification. Oxidation of methionine and phosphorylation of serine, threonine 
and tyrosine were set as variable modifications. Only high confidence peptides were used, with a 
0.01 target peptide FDR, and a minimum of 1 unique peptide was required for successful protein 
identification. Precursor ions area detector node was used for label-free protein quantitation 
within Proteome Discoverer 1.4 
7.17 Proteomics data analysis in Perseus 
Quantified proteomics data was analysed in Perseus Version 1.6.2.2. Abundance values for 3473 
proteins quantified in all stimulated control purifications and all stimulated p110δ purifications 
were loaded into Perseus and log2 transformed. Biological triplicates were grouped by 
categorical annotation of rows. A ‘Two sample T-test’ was performed on the two groups and 
corrected for multiple hypothesis testing using a permutation-based false discovery rate (FDR) 
with a threshold of either 0.05 or 0.20 and an S0 of 0. The values for -Log(P-value) and Student’s 
T-test Difference were exported to GraphPad Prism version 7 (GraphPad Software, Inc) to create 
a volcano scatter plot.  
To generate a heatmap visualising the relative abundance of selected proteins of interest across 
all nine samples using Perseus, protein abundance values were first normalised using Z-score 
transformation. Unsupervised hierarchical clustering was then performed on rows using 
Euclidean distance and average linkage. 
7.18 Preparation of samples for RNA sequencing 
The following experiments were performed by Hicham Bouabe.  
Naïve (CD44-CD62Lhi) CD8+ T cells were purified by flow cytometry-assisted cell sorting from 
splenic cells isolated from wild type mice. Wild type mice were infected intravenously with 2 × 
106 colony forming units of ΔActA-Lm-Ova and spleens were isolated on day 7 post-infection. 
Effector (CD44+CD62LloH-2Kb-SIINFEKL+ antigen-specific) CD8+ T cells were purified by flow 
cytometry-assisted cell sorting from splenic cells. Cells were then frozen at -80°C. RNA was 
isolated from cell samples using a modified protocol based on reagents from RNAqueous-Micro 
Total RNA Isolation Kit (ThermoFisher Scientific) and Pellet Paint Co-Precipitant (Novagen) RNA 
precipitation procedure. DNA was removed by treatment with DNaseI from the RNAqueous-
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Micro Kit. cDNA libraries for sequencing were prepared from 150 ng total RNA using TruSeq 
Stranded Total RNA Library Prep Kit with Ribo-Zero Gold (Illumina #RS-122-2301).  
7.19 CRISPR oligonucleotides and Cas9 protein 
Two CRISPR RNA (crRNA) guide sequences were designed per target gene using the CRISPR3 
web-based tool (AstraZeneca, proprietary software). Pairs of guides were only chosen if their 
base pair separation was a non-multiple of 3 and if they targeted all transcripts of a gene. 
Preference was given to guides targeting early exons. Guides with a predicted efficacy score 
greater than 0.500 and a low probability of off-targets in a coding region (pCoding < 0.500) were 
selected. Guides predicted to have off-targets with only one mismatch were not acceptable.  
crRNA sequences, as shown in Table 7.3, were purchased from Integrated DNA Technologies 
(IDT) in the Alt-R® CRISPR-Cas9 format. Universal trans-activating crRNA (tracrRNA) was also 
purchased from IDT in the Alt-R® CRISPR-Cas9 tracrRNA format. Carrier DNA was purchased 
from IDT as a PAGE Ultramer® DNA Oligo with the following sequence: 
CCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCC
GCCCTGAGCAAAGACCCCAACGAGA.  
Oligonucleotides were resuspended in Nuclease-Free IDTE Buffer (IDT) to a concentration of 100 
μM and stored at -80°C. Recombinant S. pyogenes Cas9 (AstraZeneca, in-house) was stored at -
80°C in 20 mM HEPES pH 7.4, 150 mM KCl, 1 mM TCEP and 10 % (v/v) glycerol.  
crRNA Targeted exon Sequence (5’ – 3’) 
Thy1 gRNA 1 Exon 2 GCGGGAGCGGTACGTGTGCT 
Thy1 gRNA 2  Exon 2  TCAGCCTGACCCGAGAGAAG 
Pik3cd gRNA 1 Exon 2 AGTTAATGAGCTTCTTCACG 
Pik3cd gRNA 2  Exon 2 TCGGGCCACGAGGCGCAGCA 
Pik3ap1 gRNA 1  Exon 4 CAGTGTGCCTTCCACCCGGA 
Pik3ap1 gRNA 2  Exon 4 ACGGTCTCTGTGAAAGCACC 
ICOS gRNA 1  Exon 2 GCAGAAGTAATAGCTTCCCT 
ICOS gRNA 2 Exon 2 AGGTTCCTTTCTTGAAAAGG 
 
Table 7.3 CRISPR RNA (crRNA) sequences used for CRISPR/Cas9 gene editing  
 
 
7.20 RNP nucleofection of primary mouse T blasts 
crRNA:tracrRNA duplexes (gRNA) and Cas9 ribonucleoproteins (RNPs) were prepared fresh for 
each RNP experiment. tracrRNA and crRNA were mixed in equimolar amounts and annealed at 
95C for 5 min, then cooled to room temperature to a final duplex concentration of 50 uM. 
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Recombinant Cas9 protein was mixed with gRNA in the amounts and combinations indicated in 
the figure legends, or in the optimised ratio 10 μg:94 pmol (Cas9:gRNA), to a total volume of 7 μl 
per nucleofection in Neon Buffer R (Invitrogen #MPK1096T). Cas9:gRNA complexes were then 
incubated at room temperature for 30 minutes to generate Cas9 RNPs.  
Activated T cells were pooled following 48-hour stimulation with 1 μg/ml anti-CD3 (as detailed 
in section 7.3) and centrifuged at 350 × g for 5 minutes at 22°C. Cells were resuspended in warm 
5 % RPMI and counted using the EVE™ Automated Cell Counter (NanoEntek). Cells were washed 
once in sterile 1X PBS (Life Technologies #10010-015) and resuspended in Neon Buffer R at a 
concentration of 2.16 × 106 cells per 5 µl. Cells were immediately added to RNP complexes along 
with 0.2 μg carrier DNA to a final volume of 12 μl per nucleofection, which was then 
electroporated in 10 μl Neon tips (Invitrogen #MPK1096T) using the Neon transfection system 
programme #24 (voltage: 1600 V, width: 10 ms, pulses: 3; Invitrogen). Each nucleofection 
mixture was then dispensed into 940 μl pre-warmed 5 % RPMI containing 20 ng/ml rhIL-2 in 12-
well plates and incubated at 37°C. After 2 hours, cells were split across three wells and then 
expanded for 5 days, with supplementation of rhIL-2 and media at 48 and 72 hours post-
nucleofection to maintain a cell concentration of 1 – 2 × 106 cells/ml. Cell aliquots of 100 μl were 
taken at 48 and 72 hours and cell pellets were stored at -20°C for later DNA extraction and 
sequencing analysis.  
7.21 DNA extraction, PCR and Sanger sequencing 
To extract genomic DNA for sequencing analysis, cell pellets were resuspended in 50 μl 
DirectPCR Cell Lysis Reagent (Viagen Biotech #301-C) with 0.8 μg/μl proteinase K (Invitrogen 
#100005393) and incubated at 85°C for 45 minutes. Lysates were then used directly for PCR 
amplification of a 1000 bp region spanning each Cas9 cleavage site, using the Phusion Flash 
High-Fidelity PCR Master Mix (Thermo Scientific #F-548L), as follows: 
Cell lysate         1 µl 
2X Phusion Flash PCR Master Mix     25 µl 
Forward primer   0.25 µl 
Reverse primer   0.25 µl 
H2O     23.5 µl 
 
Primers as detailed in Table 7.4 were purchased from Eurogentec (Seraing, Belgium) as 
lyophilised oligonucleotides, resuspended in TE buffer (pH 8; in-house), and used at a final 
concentration of 0.5 μM. The PCR cycling conditions used are listed in Table 7.5. PCR products 
were purified for sequencing using the illustra GFX PCR DNA and Gel Band Purification Kit (GE 
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Healthcare #28903470) according to the manufacturer’s instructions, with elution of the DNA in 
20 μl H2O. Sanger sequencing of purified PCR amplicons was carried out by GATC (Eurofins 
Genomics, Germany) using the Supremerun Tube service and the relevant forward primer, as 
listed in Table 7.4. 
















Reverse  TACAAATGTGACTAATAGGTGGTGC 
 
Table 7.4 Primer sequences for PCR  
 
 
Cycle step Temperature (°C) Time Cycles 


















Table 7.5 PCR thermocycling conditions  
 
 
7.22 Tracking of Indels by Decomposition (TIDE) analysis 
To estimate insertion-deletion (indel) frequencies, Sanger sequencing chromatograms of PCR 
amplicons were analysed using TIDE version 1.1.2, AZ version v03 (AstraZeneca, proprietary 
software based on https://tide.deskgen.com/). Chromatograms were input as .ab1 files along 
with the sequences of the gRNAs used for editing. Analyses were performed using a reference 
sequence from unedited wild type cells. The aberrant sequence signal across the sequenced 
length was examined to exclude regions of poor sequence quality from the alignment window 
(the sequence used to align the control and test sample) and decomposition window (the 
sequence segment used for decomposition). The maximum size of insertions and deletions 
modelled in decomposition was adjusted to achieve R2 values close to or greater than 0.9 to 
indicate good algorithm performance. 
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7.23 Cell surface staining and flow cytometry  
For the analysis of extracellular surface markers at 48 and 72 hours post-nucleofection, T blasts 
from culture were pelleted by centrifugation at 400 × g for 5 minutes, resuspended in 1X PBS 
(Life Technologies #10270-106) and transferred to V-bottom 96-well plates (Greiner #651201). 
Cells were centrifuged at 400 × g for 5 minutes at 4°C and resuspended in 50 µl/well 1X PBS 
containing Live/Dead Fixable Blue Stain (1:400 dilution; Invitrogen #L23105) followed by 
incubation for 30 minutes at 4°C in the dark. Cells were then washed once in FACS buffer (FB; 
1% BSA (Sigma #A7906), 1X PBS (Life Technologies #10270-106), 2 mM EDTA) and resuspended 
in 50 μl/well of 1:1 FB:Brilliant violet staining buffer (FB:BV; BD Biosciences #563794) containing 
antibodies for extracellular markers or isotype controls (Table 7.6). Cells were incubated for 30 
minutes at 4°C in the dark, washed once in FB and then fixed for 15 minutes at room 
temperature in the dark with 100 μl Fixation Buffer (BioLegend #420801). Cells were washed 
twice in FB and finally resuspended in 100 μl FB before analysis using a BD LSRFortessa flow 
cytometer (BD Biosciences). Data obtained by flow cytometry was analysed using FlowJo version 
10.4.1 (FlowJo, LLC). Graphical and statistical analyses were performed in GraphPad Prism 
version 7 (GraphPad Software, Inc), as detailed in figure legends and the text. 
7.24 Antibody stimulation of T blasts in culture 
Flat-bottom 96-well plates (Sigma #CLS3595-50EA) were coated overnight at 37°C with 100 μl 
PBS per well containing 2 μg/ml anti-CD3 (145-2C11; BioLegend #100314). T blasts at day 5 post-
nucleofection were pooled by centrifugation at 300 × g for 5 minutes and resuspended in fresh 
5% RPMI (RMPI 1640 + L-glutamine, 5 % heat inactivated FBS, 100 U/ml penicillin-streptomycin, 
50 μM β-mercaptoethanol). Cells were then plated at 200,000 per well and supplemented with 
200 nM CAL101 or 200 nM DMSO. After 1 hour incubation at 37 C, cells were incubated for a 
further 7 hours in the presence of brefeldin A (BD GolgiPlug™ Protein Transport Inhibitor, 
1:1000 dilution; BD Biosciences #555029).  
7.25 Intracellular flow cytometry  
For the analysis of intracellular cytokines following 8-hour antibody stimulation, cells were 
transferred from flat-bottom 96-well plates to V-bottom 96-well plates (Greiner #651201) on ice 
and pelleted by centrifugation at 400 × g for 5 minutes at 4°C. Cells were washed once in FACS 
buffer (FB) and then resuspended in 50 μl/well FB:BV buffer containing antibodies for 
extracellular markers or isotype controls (Table 7.6) and Fixable Viability Dye eFluor 780 (1:5,000 
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dilution; Invitrogen #65-0865-14). Cells were incubated for 30 minutes at 4°C in the dark, 
washed once in FB and then fixed for 15 minutes on ice in the dark with 100 μl 
fixation/permeabilization solution (BD Cytofix/Cytoperm kit; BD Biosciences #554714). Cells 
were washed twice in FB and stored overnight at 4°C in the dark. Cells were then centrifuged at 
720 × g for 3 minutes at 4°C, resuspended in 1X BD Perm/Wash Buffer (BD Biosciences #554714) 
and again centrifuged at 720 × g, before resuspension in 50 µl/well Perm/Wash Buffer 
containing antibodies for intracellular cytokines or isotype controls (Table 7.6). Cells were 
incubated for 30 minutes at 4°C in the dark and then washed twice, first in Perm/Wash Buffer 
and then FB. Cells were finally resuspended in 100 μl FB before analysis using a BD LSRFortessa 
flow cytometer (BD Biosciences).  
 
Table 7.6 Antibodies used for flow cytometry  
 
7.26 Optimisation of experimental parameters  
To optimise the RNP nucleofection protocol by response surface methodology, Design-Expert 
Version 6.0.9 (Stat-Ease, Inc.) software was used to design experimental runs using Box-Behnken 
design with the following parameters: 0.5 × 106 ≤ cell number ≤ 2.5 × 106; 1 μg ≤ Cas9 amount ≤ 
10 μg; 25 pmol ≤ gRNA amount ≤ 125 pmol. Responses for cutting efficiency %, protein KO % 
and cell viability % from 17 experimental runs were input and Design-Expert developed 
quadratic models for each response that were found to be significant by analysis of variance 
(ANOVA). Optimisation parameters were set to maximise cutting efficiency and protein KO, 
Specificity Clone Conjugation Dilution Supplier Catalogue No. 
TCRb H57-597 PerCP/Cy5.5 1:400 BioLegend 109228 
CD4 RM4-5 BV711 1:800 BioLegend 100557 
CD8a 53-6.7 FITC 1:600 BioLegend 100706 
CD44 1M7 BUV737 1:200 BD Biosciences 564392 
CD62L MEL14 PE-CF594 1:200 BD Biosciences 562404 
CD90.2 53-2.1 BV605 1:200 BioLegend 140317 
ICOS 7E.17G9 APC 1:200 eBioscience 17-9942-82 
IFNγ XMG1.2 PE/Cy7 1:200 BioLegend 505826 
TNFα MD6-XT 22 Pacific Blue 1:200 BioLegend 506318 
CD16/32 (Fc block) 93 Unconjugated 1:100 eBioscience 14-0161-86 
Rat IgG1 κ RTK2071 PE/Cy7 1:200 BioLegend 400416 
Rat IgG1 κ RTK2071 Pacific Blue 1:200 BioLegend 400419 
Rat IgG2b κ  RTK4530 APC 1:200 BioLegend  400611  
Rat IgG2a κ RTK2758 BV605 1:200 BioLegend 400540 
Armenian hamster IgG HTK888 PerCP/Cy5.5 1:400 BioLegend 400931 
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within the limits 30 – 100 %, and to target cell viability of 43.5 % (the maximum observed) and 
response surface analysis calculated the optimum values for each factor. 
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